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ABSTRACT 
 
The purpose of the present study was to evaluate the potential usefulness of tubulin 
inhibitors when complexed with hydroxypropyl-β-cyclodextrin (ΗPβCD) against a 
range of protozoan parasites.  This approach involved investigations into the 
complexation of these drugs with ΗPβCD, and subsequent investigations of these drugs 
and their complexes in regard to cytotoxicity, pharmacokinetics, in vitro efficacy 
against Giardia, Cryptosporidium and rodent malaria (Plasmodium chabaudi), and their 
in vivo efficacy against Giardia and malaria. 
 
Albendazole (ABZ) is a benzimidazole carbamate with a broad anti-parasite spectrum, 
while the dinitroanilines trifluralin (TF) and oryzalin (OZ) have recently been found to 
exhibit activity against certain parasites.  All three compounds are microtubule 
antagonists in either nematodes or weeds and have poor aqueous solubility, with the 
solubility of ABZ and OZ dependent on pH.  Cyclodextrins (CD) have a hydrophobic 
cavity that allows them to form inclusion complexes with hydrophobic drugs, resulting 
in increased drug aqueous solubility, and often, improved drug dissolution and 
bioavailability.  Thus the complexation of these drugs with ΗPβCD was investigated.  
All three compounds exhibited type AL phase solubility diagrams with ΗPβCD 
complexation, with additional increases in ABZ and OZ solubility achieved through the 
manipulation of temperature and pH.  OZ displayed a stronger interaction with ΗPβCD 
when ionised over its neutral form. However, insufficient concentrations of the 
TF/ΗPβCD complex were achieved for drug efficacy studies.   
 
The cytotoxicity of the drugs and their complexes was assessed using the assay kit 
Cytotox 96 with human carcinoma cells.  This is a colourimetric assay that measures 
lactate dehydrogenase release as a consequence of compromised cellular and membrane 
integrity.  Both ABZ and OZ are cytotoxic to rapidly proliferating and differentiating 
cells but are not cytotoxic to cells in the stationary phase.  Complexation did not affect 
drug cytotoxicity.  In pharmacokinetic studies, complexation improved ABZ (and 
metabolites) bioavailability, but had no significant affect on OZ bioavailability. In vitro 
drug assessment studies found ABZ to be highly effective against Giardia, and effective  
  v
against  Cryptosporidium and malaria.  OZ on the other hand exhibited no activity 
against Giardia, but was effective against Cryptosporidium and malaria. Complexation 
did not improve the antiprotozoal efficacy of either ABZ or OZ.  In particular, excess 
ΗPβCD decreased the antigiardial effects of ABZ, possibly due to competitive complex 
formation.  In addition, complexation did not improve the antiprotozoal effects of ABZ 
in vivo.  However, the cytotoxic effect of the ABZ/ΗPβCD complex was more evident 
in the treatment of malaria in vivo, resulting in increased anaemia and suppression in 
weight gain, due to the improved bioavailability of ABZ and metabolites. 
 
ΗPβCD alone was found to be cytotoxic at greater than 2.5%, and inhibited Giardia 
both in vitro and in vivo at greater than 1% and 2% respectively.  This was attributed to 
membrane disruption caused by the dissolution and removal of membrane components.  
In comparison, malaria grew better in the presence of ΗPβCD  in vitro, with no 
detrimental effect observed at up to 8% ΗPβCD.  This was attributed to either the 
increased solubilization of a necessary media component, or the complexation and 
removal of an inhibitory compound from the cultivation medium.   
 
Therefore  ΗPβCD complexation did not improve the antiprotozoal activity of the 
tubulin antagonists ABZ and OZ.  However, the results of the pharmacokinetic studies 
suggest that anthelmintic activity of ABZ, particularly against systemic infections, may 
be improved with oral administration of the ABZ/ΗPβCD complex.  In addition, the 
antiparasitic activity of ΗPβCD alone may be promising, especially against intestinal 
infections.  Finally, the improved in vitro cultivation of P. chabaudi in the presence of 
ΗPβCD presents a promising approach to its potential long term cultivation. 
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1.1. THE NEED FOR IMPROVED DRUG DELIVERY SYSTEMS 
 
Parasitic diseases account for millions of deaths each year and impose a significant 
burden on Third World countries by reducing the productive potential of its people and 
animals (Gero et al., 1991; Smith, 2001). In addition, the mobility of human populations 
has resulted in many of these parasites being imported into developed countries (Gero et 
al., 1991; World Health Organization (WHO), 1997).  Half of humanity is exposed to 
the risk of parasitic infections, with the most significant being Ascaris, malaria, 
Schistosoma, Filaria, hookworm, Trichuris, Amoeba, Trypanosoma,  Leishmania and 
Strongyloides (Smith, 2001; Gero et al., 1991).  The helminths alone infect more than 
one quarter of the world’s population (de Silva et al., 1997). The three groups of 
helminths that parasitise humanity are the nematodes (roundworms), trematodes (flukes) 
and cestodes (tapeworms), with the most common being Ascaris, Trichuris, hookworm, 
filariasis,  Onchocerca and Schistosoma.  Virtually all of the important helminth 
infections can be treated by one of five anthelmintics currently in use, ABZ, MBZ, 
diethylcarbamazine, ivermectin and praziquantel (de Silva et al., 1997).  However the 
control of parasitic diseases has not been as successful as hoped, largely due to the 
increased numbers of individuals who are immunocompromised (Gero et al., 1991). 
Traditionally important parasitic diseases like malaria and schistosomiasis are at least as 
significant in many places as they were in the past, and many rare parasitic infections 
such as Pneumocystis, Toxoplasma, Cryptosporidium, Isospora and Sarcocystis are now 
more commonly encountered.  More information concerning the prevalence and 
treatment of the parasites Giardia, Cryptosporidium, and Plasmodium can be found in 
chapters 5, 6 and 7 respectively.  
 
Resistance to antiparasitic drugs is also a serious setback in attempts to control many 
parasitic diseases. Parasitic resistance is a global problem, both in humans and in many 
animal industries, with resistant pathogens emerging and spreading more rapidly than in 
previous decades (Gero et al., 1991; Sangster & Gill, 1999). In particular, drug 
resistance in malaria has become a major problem, with drug resistance to newly 
developed drugs increasing, along with the problem of providing adequate protection to 
non-immune travellers (see review in chapter 7) (Gero et al., 1991).  The development 
of parasite drug resistance, especially in the animal industries, has been exacerbated by CHAPTER 1 
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treatment techniques such as mass treatments, frequent use of antiparasitic drugs, use of 
the same class of drugs over long periods of time, and underdosing. These specifically 
have resulted in widespread anthelmintic resistance of nematodes in various sheep 
populations across the world (Waller, 1990; Geerts et al., 1997; Hennessy, 1997).   
Alternative treatment strategies include vaccines, biological control, and, in the animal 
industry, breeding of parasite resistant animals (Hennessy, 1997).  However, these are 
unlikely to be widely available in the near future, and even then they will be integrated 
with chemotherapy (Hennessy, 1997).   
 
The treatment of resistant parasites is increasingly hampered by either the lack of 
effective antiparasitic agents, or the significant cost of drug research to develop new 
drugs (Hennessy, 1997; WHO, 1997).  To compound the problem, there appears to be 
no new chemical classes of antiparasitic agents on the horizon (Hennessy, 1997; 
Williams, 1997).  Therefore existing actives must be preserved and utilized 
appropriately if parasite control is to be maintained.  Currently, drug development often 
results in the simplest formulation being developed, with little thought to maximising 
drug bioavailability at the host-parasite interface (Hennessy, 1997).  Thus a promising 
approach to maintaining drug efficacy is the development of modified formulations 
and/or delivery systems using chemical or physical drug carriers.  Such systems not 
only increase the efficacy of older compounds, but are also instrumental in prolonging 
the useful life of newer drugs (Hennessy, 1997).  In addition, research on new 
formulations of current drugs is less expensive than developing new drugs, and can 
result in preparations that are more stable, thus improving drug bioavailability and 
increasing their antiparasitic effect.   
 
Chapter one reviews CDs and the formulation of inclusion complexes.  Please go to the 
individual chapters for reviews on specific parasites. 
  
1.1.1. Formulation design 
 
Almost all orally active drugs are marketed as tablets, capsules or both. Initially 
however, in order to guarantee precise drug and dose disposition, they are formulated as 
injections for toxicity, metabolic, bioavailability and clinical studies (Wells & Aulton, CHAPTER 1 
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1988).  A common problem experienced in the early development of drug formulations, 
especially those intended for parenteral administration, is the solubilization of a slightly 
soluble, or water insoluble active ingredient (Sweetana & Akers, 1996).  The inability to 
generate water-soluble or stable parenteral formulations has limited the application and 
development of many drug substances.  This is particularly apparent in intravenous 
dosage forms as successful systems must be non-toxic and stable (Brewster, 1992). 
Drugs are almost always administered in some kind of formulation.  While some are 
formulated in simple aqueous solutions, more often, however, formulations are complex 
mixtures containing the drug compound, or a derivative of the drug compound, together 
with excipients, diluents, stabilisers, or preservatives (Jonkman-de Vries et al., 1996).   
 
The development of a drug delivery system is dependent upon the physicochemical and 
biological properties of the drug, intended dose, and patient/disease factors (Jonkman-de 
Vries et al., 1996). The most important properties of the drug to be considered are the 
aqueous solubility, stability, disassociation constant (pKa), and the rate of dissolution 
(Wells & Aulton, 1988; Jonkman-de Vries et al., 1996; Sweetana & Akers, 1996).   
Usually the first approach used to increase the solubility of an insoluble drug in water is 
to form water soluble salts.  If salt formation is not possible due to drug instability or 
insufficient aqueous solubility, a series of formulation approaches may be investigated.  
These include pH adjustment, the formation of prodrugs, lyophilised formulations, 
surfactant systems, cosolvent systems, complex formation and colloidal systems (such 
as liposomes, microencapsulation systems, emulsions or lipoproteins). These techniques 
have been used to modify drug absorption or metabolism, and to specifically direct large 
quantities of drug, over an extended or pre-determined period, to the target sites 
(Jonkman-de Vries et al., 1996; Sweetana & Akers, 1996; Hennessy, 1997). 
 
The safety of the formulation is also very important.  Since any component of the 
formulation may contribute to or modify the toxicity, it is important to keep the 
formulation as simple as possible (Jonkman-de Vries et al., 1996). The safety of a drug 
carrier system must be evaluated from two standpoints: the toxicity of the carrier itself, 
and the risk of the novel, drug induced toxicities arising from differences in disposition, 
pharmacokinetics, and metabolism of carrier associated drug as compared with 
conventional drug formulations (Jonkman-de Vries et al., 1996). CHAPTER 1 
__________________________________________________________________________________________________________ 
  5
 
1.1.1.1. Complexation 
 
Complexation of water insoluble drugs generally involves the incorporation of the drug 
within an inner core of complexing agent/s, so that the outer hydrophilic groups of the 
complexing agent interact with the water, rendering the complex soluble (Jonkman-de 
Vries et al., 1996; Sweetana & Akers, 1996).  Complexation is a reversible association 
of a substrate molecule with molecules of a ligand to form a new species, and is carried 
out to alter the physicochemical properties of a drug so that the solubility and stability 
of the complex is higher than the parent compound (Jonkman-de Vries et al., 1996).  
However, caution should be taken to ensure that the change in physicochemical 
characteristics does not alter drug activity or mechanism of action.  Selection of a 
complexing agent is dependent on the structure of the drug, as the complexing agent 
must be able to interact with the drug in a structurally specific manner (Yalkowsky, 
1999).  Examples of complexing agents would be CDs and hydrotropic compounds such 
as salicylates, sodium salts, several benzoic acids, and fatty acids.  In particular, interest 
in drug/CD complexes is increasing, with the aim of designing newer and more 
effective drug delivery systems (Szejtli, 1991a).  
 
1.2. CYCLODEXTRINS 
 
1.2.1. Structure and physiochemical properties 
 
Cyclodextrins (CD) are cyclic oligosaccharides of α-D-glucose joined through 1-4 
bonds.  The three major natural CDs are α-CD, β-CD and γ-CD, which are built up 
from 6, 7 and 8 glucopyranose units respectively (Figure 1.1). CDs with less than 6 
glucopyranose units cannot be formed for steric reasons (too strained to exist), while 
those with greater than 8 are difficult to isolate in crystalline form due to their high 
solubility resulting from higher flexibility.  They are also thought to have low 
complexing ability and therefore of little practical value (Szejtli, 1988; Connors, 1997).  
The general physiochemical properties of the CDs (Table 1.1) can be obtained from the 
numerous review articles and books, such as Szejtli, (1988) and Connors, (1997). 
 CHAPTER 1 
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Figure 1.1: Chemical structure of α-CD, β-CD and γ-CD.  Arrows indicate the 2-, 3- 
(secondary) and 6- (primary) hydroxyls of a glucopyranose unit (Szejtli, 1988; 
Thompson, 1997). 
 
Table 1.1: Characteristics of α-CD, β-CD and γ-CDs (Szejtli, 1988; Connors, 1997). 
Property  α  β  γ 
No. of glucose  6  7  8 
Empirical formula  C36H60O30 C 42H70O35 C 48H80O40 
Molecular weight  972.85  1134.99  1297.14 
Aqueous solubility % (M)  14.5 (0.1211)  1.85 (0.0163)  23.2 (0.168) 
Melting point °C  275  280  275 
Cavity diameter Å  4.7-5.3  6-6.5  7.5-8.3 
Height of torus Å  7.9±0.1  7.9±0.1  7.9±0.1 
Periphery diameter Å  14.6±0.4  15.4±0.4  17.5±0.4 
Approx. cavity vol. per g CD (mL)  0.1  0.14  0.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Functional schematic of β-cyclodextrin.  The secondary hydroxyls at the 2- 
and 3- positions exist on the secondary face of the structure, and the primary hydroxyls 
at the 6- position exist on the primary face (Szejtli, 1988; Thompson, 1997). 
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CDs are not perfectly cylindrical, but are instead shaped like a truncated cone.  All 
secondary hydroxyls line one end of ring, while the primary hydroxyls line the other 
end of ring (Figure 1.2 (above)).  The free rotation of the primary hydroxyls at one end 
of the molecule reduces its effective diameter (Szejtli, 1988).   The interior of the cavity 
is free of hydrogen bonding groups, and lined with non-polar methylene groups and 
non-polar ether oxygens (Yalkowsky, 1999). In addition, the C2-OH of one 
glucopyranose unit can form a hydrogen bond with the C3-OH of its adjacent 
glucopyranose unit, resulting in the formation of a secondary belt, making it a rigid 
structure (Szejtli, 1988).  This secondary hydrogen belt is incomplete in α-CD as one of 
the glucopyranose units is distorted.  With the CD exterior relatively hydrophilic, and 
the interior lipophilic, CDs resemble micelles.  However, unlike micelles, whose size is 
fluid and can therefore adjust to a wide variety of sizes and shapes, the CD interior is 
fixed in size and shape (Yalkowsky, 1999). 
 
The natural CDs, particularly β-CD, have limited aqueous solubility. The lower 
solubility of β-CD is attributed to the stable formation of the secondary hydrogen belt 
and its ability to form a more stable lattice, which limits its interaction with water 
(Szejtli, 1988; Connors, 1997).  This secondary hydrogen belt is incomplete in the other 
natural CDs, and so allows more favorable interactions between the CD and water 
molecules.  In addition, γ-CD has a more flexible structure and therefore the most 
soluble of the three.  The aqueous solubility of the CDs increases with temperature, 
approximately doubling with every 20°C increase in temperature (Duchêne et al., 1987; 
Yalkowsky, 1999). CD’s are susceptible to acid hydrolysis, particularly at high 
temperatures. However, the intact ring is more stable than acyclic dextrins, as splitting 
of the first glucosidic bond is slower than the hydrolysis of a terminal glucose unit, 
which CD does not have (Szejtli, 1982).  The low aqueous solubility of the naturally 
occurring CDs as a class causes them to crystallize and produce toxic effects when they 
become concentrated in the kidney (Section 1.2.3) (Yalkowsky, 1999).   
 
1.2.2. Synthesis and degradation 
 
Cyclodextrin glycosyltransferase (CGT: EC 2.4.1.19) is produced by various 
microorganisms and is responsible for the degradation of starch to CD  (Szejtli, 1988). CHAPTER 1 
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While CD can be produced synthetically, CD can only be produced on an industrial 
scale by the enzymatic conversion of starch utilizing the CGT enzyme.  Therefore 
extensive studies have been carried out on CGT enzyme kinetics.  More specific and 
detailed information on enzyme properties, sources of enzyme, enzyme activity etc. may 
be obtained from Szejtli, (1988) and Horikoshi, (1999).  Generally the CGT enzyme 
produces all three CDs, with their ratios dependent of the conversion time and the 
applied enzyme.  Most CGT’s produce α-CD first, with the rate of larger CD formation 
much slower.  However, as β-CD production is rarely reversed, it accumulates at the 
expense of α-CD due to secondary transfer reactions.  Therefore only the incubation 
time determines which CD is obtained as the main product. Improved production has 
been achieved through the use of debranching enzymes, as 1,6-bonds of the amylopectin 
branches block CGT action, and immobilized CGT, therefore allowing the same 
enzyme to be used for several conversion cycles. Isolation of the desired CD is 
accomplished through either insoluble specific complex formation or dialysis.  However 
the use of complexants has to be carefully controlled to ensure residual content is at 
acceptable levels.   
The preparation of CDs involves: 
-  Cultivation of a microorganism which produces CGT 
-  Separation, concentration and purification of CGT  
-  Enzymatic conversion of starch to a mixture of cyclic and acyclic dextrins and 
-  Separation, purification and crystallization of the desired CD (Szejtli, 1988). 
 
Cyclomaltodextrinase (EC 3.2.1.54) is an enzyme that hydrolyses cyclic dextrins and 
linear maltodextrins, but has little or no activity for polysaccharides such as starch and 
glycogen.  It is produced by a number of microbes, including some of those found 
among the human colon microflora (Antenucci & Palmer, 1984).  Other enzymes are 
also capable of degrading CDs, but at a slower rate (Section 1.2.3.1). For a review, see 
Saha & Zeikus, (1992).   
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1.2.3. Biological effects 
 
1.2.3.1. Oral administration 
 
α-CD and β-CD are very resistant to enzymatic digestion by the usual starch 
hydrolyzing enzymes (Szejtli, 1988).  They are completely resistant to β-amylases as 
they do not contain end groups susceptible to the attack of this enzyme.  α-amylases 
however do not require end groups and are therefore capable of hydrolyzing CDs, 
although at a slow rate.  γ-CD on the other hand can be digested in the upper 
gastrointestinal tract by pancreatic enzymes (Antlsperger & Schmid, 1996).   
Insignificant amounts of orally administered CD are absorbed intact through the 
gastrointestinal tract. Approximately 2% α-CD and  <1−10%  β-CD are absorbed intact 
in the upper intestine by passive transport (Szabó et al., 1981; Frijlink et al., 1990; 
Antlsperger & Schmid, 1996). α-CD absorption is thought to occur via the paracellular 
pathway (Irie et al., 1988), while γ-CD absorption is negligible due to its digestion 
(Antlsperger & Schmid, 1996).  The majority of orally administered  α-CD and  β-CD 
is metabolized in the large intestine by the colon microflora (Szabó et al., 1981; 
Antenucci & Palmer, 1984).  The primary metabolites (glucose and malto-
oligosaccharides) are then metabolized and absorbed in the same way as starch. The 
fundamental difference between the metabolism of starch and CD is that starch is 
metabolized in the small intestine while CD is metabolized in the colon, with 
corresponding maxima observed around 1-2 hours, and 6-8 hours after consumption 
respectively.  Not all the β-CD is digested, with some also excreted in the faeces 
(Gerlóczy et al., 1985). Ingestion of CDs by humans therefore leads to similar 
nutritional or physiological effects to starch, at least at low CD concentrations (Szejtli, 
1988; Shizuka et al., 1996).   
 
Oral administration of the natural CDs does not result in acute toxicity.  Defined oral 
LD50 values have been difficult to determine, as high doses do not result in mortality.  
The LD50 in rats was determined to be greater than 12.5, 18.8 and 8 g kg
-1 for α-CD, β-
CD, and γ-CD respectively (Szejtli & Sebestyén, 1979; Szejtli, 1987; 1988).  Poor 
digestion of both α-CD and β-CD however, have been attributed to retarded body CHAPTER 1 
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weight gain, caecal enlargement and reduced body fat disposition when animals have 
been administered high doses over extended time frames (Szejtli, 1988).  
 
CDs are capable of complexing with a wide range of compounds (Section 1.3).   Orally 
administered CDs can therefore potentially complex with a wide range of endogenous 
compounds in the gut, influencing their distribution from the gastrointestinal tract 
(Pitha, 1990).  This may result in secondary systemic effects where increased 
gastrointestinal elimination of certain nutrients, steroids and bile salts occurs, or in the 
solubilization and increased absorption of toxic contaminants of the ingested food 
(Gerlóczy et al., 1994; Pitha, 1994). However, orally administered CD is considered 
non-toxic if the daily dose does not exceed 600 mg kg
-1 or 1800 mg kg
-1 of the diet in 
rats and dogs respectively (Bellringer et al., 1995).   
 
1.2.3.2. Parenteral administration 
 
Parenterally administered α-CD and β-CD are not metabolized, but are concentrated in 
the kidneys.  As these CDs (particularly β-CD) have low solubility and are generally 
administered in high doses, they precipitate, resulting in severe nephrotoxicity (Frank et 
al., 1976; Gerlóczy et al., 1985). During elimination, CD is taken up in the renal tubules 
where they are concentrated in the vacuoles.  Initially the number of apical vacuoles 
increases and lysosomes become prominent.  The lysosomes enlarge and the peripheral 
membrane becomes distorted due to confinement of large embedded microcrystals, 
which are characteristic of CD nephrosis.  This is followed by the appearance of giant 
vacuoles and the degeneration of cell organelles, particularly the mitochondria (Frank et 
al., 1976; Serfözö et al., 1981).  These observations are comparable to injections of 
glucose, sucrose, dextran and mannitol, which cause some vacuolative change and 
lysosomal increase, but do not result in sustained injury as they are easily hydrolysed.  
Therefore CD nephrosis represents an exaggerated form of osmotic nephrosis resulting 
in irreversible injury (Frank et al., 1976; Yamamoto et al., 1990).  
 
The intravenous LD50 for α-CD and β-CD is 1008 mg kg
-1 and 788 mg kg
-1 respectively 
(Frank et al., 1976).  Similar results have been obtained for subcutaneous, 
intraperitoneal and intramuscular treatments (Brewster, 1992).  Therefore parenteral CHAPTER 1 
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applications of α-CD and β-CD are limited to rather low doses (Gerlóczy et al., 1985; 
Szejtli, 1988).  Of the natural CDs, γ-CD is the most appropriate for use as an injectable 
drug carrier due to its higher water solubility and its rapid enzymatic degradation. In 
addition, the natural CDs exhibit no mutagenicity or teratogenicity, and are not 
carcinogenic, although β-CD may enhance the occurrence of renal tumors in animals 
treated with carcinogens (Szejtli, 1988).   
 
Parenterally administered CDs also cause haemolysis of erythrocytes.  At low 
concentrations (<1mM for β-CD, 5mM for α-CD and 10mM for γ-CD), CDs protect 
erythrocytes from osmotic and heat induced haemolysis.  These protective effects have 
been attributed to membrane expansion and fluidization of membrane components, 
therefore altering the mechanical properties of the membrane lipids (Uekama et al., 
1981; Irie et al., 1982).  However, at higher concentrations (3mM for β-CD, 6mM for 
α-CD and 16mM for γ-CD) they sequester membrane components such as cholesterol, 
phospholipids and proteins from cell membranes, resulting in haemolysis (Irie et al., 
1982; Fridrich et al., 1990). The amount and type of extracted component varies with 
the CD, and is dependent on the cavity size of the CD (Irie et al., 1982).  Therefore CD-
induced haemolysis is a secondary event, resulting from the interaction between CD and 
membrane components. A more detailed review of the oral and parenteral toxicity of the 
CDs, their complexation of endogenous compounds, and their cytotoxicity can be found 
in Szejtli, (1988) and Thompson, (1997). 
 
1.3. CYCLODEXTRIN COMPLEXATION  
 
1.3.1. Solubilization 
 
Due to the hydroxy groups the CD exterior is relatively hydrophilic, while in 
comparison the interior is lipophilic.  Connors, (1997) determined the interior to have an 
effective polarity comparable to ethanol and dioxane (semi-polar). Therefore CDs can 
solubilize compounds into aqueous solutions through the formation of inclusion 
complexes (Gerlóczy et al., 1994; Stella & Rajewski, 1997) (Figure 1.3). Hydrophobic 
compounds have higher affinity for the cavity in aqueous solution, as it provides a 
microheterogenous hydrophobic matrix in such polar solvents.  On the other hand, CHAPTER 1 
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hydrophilic compounds can form inclusion compounds with CDs in solvents that are 
less polar than the CD cavity (Hirayama & Uekama, 1987).  It is generally observed that 
the lower the aqueous solubility of the pure drug, the greater the relative solubility 
enhancement obtained through complexation.  No covalent bonds are formed or broken 
during drug/CD complexation, and in aqueous solution the complexes readily dissociate 
(Loftsson & Brewster, 1996).  Complexation is dynamic with the kinetics of inclusion 
formation and dissociation very fast.  Therefore drug complexes should be viewed as an 
average of free drug, free CD and complex (Stella & Rajewski, 1997).     
 
CDs usually function as one-site ligands, with this site being the wider rim of the CD 
with the secondary hydroxyl groups (Connors, 1997).  In these inclusion complexes, 
suitably sized compounds are partially or wholly contained within the non-polar cavity 
of the cyclodextrin (Gerlóczy et al., 1994). The substrate possesses one or more binding 
sites, portions of the molecule sterically capable of insertion (shallow or deeply) into the 
CD cavity (Connors, 1997).   When a guest molecule is too large for the CD cavity, 
more that one CD molecule may be involved in inclusion. On the other hand, when the 
guest molecule is too small for the CD cavity, more that one guest may be included 
(Hirayama & Uekama, 1987).  While lipophiles do not have to fit completely into the 
cavity of the CDs, the extent of the mutual fit determines the efficiency of the 
solubilization (Pitha et al., 1988).  The structure of a complex is determined by an 
energetic balance between maximal inclusion of the non-polar surface, and optimal 
mutual orientation to permit interactions with polar portions of the guest with the CD or 
solvent (Connors, 1997).    
 
 
 
 
 
 
Figure 1.3: Scheme illustrating the association of free CD and drug to form a 
drug/cyclodextrin complex (Stella & Rajewski, 1997). 
 
host complex  guest 
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Within the motional limitations of the CD, there is still significant conformational 
mobility.  This lends itself to the accommodation of a wide variety of guests, provided 
they are of a size compatible with the CD cavity.   Of the three natural CDs, β-CD has a 
cavity size that is most appropriate for a wide range of drugs, in that it is able to 
accommodate aromatic groups (Szejtli, 1988).   Some functional groups that are 
included by β-CD are aromatic rings, alkyl groups and trifluoromethyl groups (Jones & 
Grant, 1984).  α-CD can only be used for small molecules or for the complexation of 
slim side chains, while γ-CD fits larger molecules (Szejtli, 1991a). While γ-CD interacts 
with many drugs, the current high cost of manufacture has made its extensive use 
unfavorable.  
 
Large drug molecules like peptides and proteins can also form CD complexes, as they 
contain hydrophobic aromatic moieties that can complex with CD.  The CDs attach to 
the amino acids exposed on the surface of the protein, creating a hydrate shell around 
the molecule.  CDs therefore modify protein hydration allowing it to deaggregate, 
solubilize, stabilize or even denature the dissolved protein molecule.  This results from 
either the disruption of certain hydrogen bonds and thus stabilizes the tertiary structure, 
or prevents the disorganization of structure-stabilizing hydrogen bonds by immobilizing 
certain moieties.  The latter can be seen as an increase in the denaturation temperature.  
Therefore CDs can reduce the loss of enzyme activity through improved formulation 
and storage, and solubilize proteins that usually undergo aggregation or precipitate in 
aqueous solution (Szejtli, 1991b; Loftsson & Brewster, 1996).  Therefore complexation 
often results in both enhanced chemical and physical stability of this type of drug.      
 
1.3.2. Stability 
 
CD complexation can be regarded as molecular encapsulation.  In forming inclusion 
complexes, the physical and chemical properties of both the guest and cyclodextrin can 
be altered (Duchêne et al., 1987; Szejtli, 1991a; Loftsson & Brewster, 1996).  For 
example, drug/CD complexation has been used extensively to improve the aqueous 
solubility and dissolution rate of numerous drugs.  However, inclusion of the chemically 
reactive centre of a drug molecule within the CD cavity will also stabilize the drug 
considerably (Jones & Grant, 1984). Therefore, complexation can be used to increase CHAPTER 1 
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the boiling point, evaporation temperature and melting point of a compound, or to 
increase the stability of drugs that would otherwise be sensitive to temperature, 
hydrolysis, autoxidation, photodegradation and other autocatalytic reactions (Duchêne 
et al., 1987; Szejtli, 1991a).  In addition, complexation can decrease volatility, steric 
arrangement, isomerisation, polymerization and even the enzymatic decomposition of a 
compound (Jones et al., 1984; Szejtli, 1991a).   
 
Formulation of compounds with CDs may also result in technological advantages (Jones 
et al., 1984; Szejtli, 1991a).  For example, complexation may be used to convert a liquid 
material into a solid product, to mask an unpleasant taste or odor of a compound, or to 
change the colour of a compound (as inclusion usually involves a change in spectrum of 
the molecule).  In addition, drug formulations may be improved by easier 
emulsification, avoiding incompatibilities of uncomplexed compound with other drugs 
or excipients in the formulation, and specific reactions (such as catalysis) can be made 
more selective by the inclusion of specific functional groups (Duchêne et al., 1987; 
Szejtli, 1991a). Alternatively, formulation of low dose drugs in CD complexes often 
allows improved uniformity in tablets (Jones et al., 1984).  These changes are often 
translated into biological advantages, such as the enhanced in vivo absorption, and 
hence bioavailability, of drugs by a number of administration routes, and reduced 
haemolysis, irritancy and toxicity of the drugs (Szejtli, 1991a; Stella & Rajewski, 1997). 
 
However favorable results are not always obtained. For example, drug/CD 
complexation may have no effect, or even accelerate drug degradation (Duchêne & 
Wouessidjewe, 1990b).  If increased drug stability is observed with the inclusion of the 
chemically reactive centre of a drug molecule in the CD cavity, the size of the cavity 
and the chemically reactive group must be compatible.  Therefore if the CD cavity was 
not sufficiently large to protect the reactive group, unchanged degradation rates or even 
accelerated drug degradation may be observed. The stabilization and sensitization of 
certain compounds by certain types of CD is to some extent predictable when the size of 
the reactive group is known (Jones & Grant, 1984). Other factors may also affect 
stabilization/destabilization, such as the stoichiometric ratio of drug to CD, the 
formation of solid drug complexes, and interactions of the CD with the degradation 
product (Jones & Grant, 1984; Duchêne et al., 1987; Loftsson & Brewster, 1996).  CHAPTER 1 
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1.3.3. Complex formation 
 
Several types of interactions between guest molecules and cyclodextrin may account for 
CD complex formation.  These include hydrophobic interaction, van der Waals 
interaction, hydrogen bonding, dipole-dipole and/or electric charge interaction 
(Connors, 1997).  Hydrophobic interaction is probably the most important in many CD 
complexations.  However, as it does not follow classical hydrophobic interaction 
theories, it is often rejected.  It has therefore been proposed that a non-classical 
hydrophobic interaction, a composite of the hydrophobic interaction and van der Waals 
effects, between semi-polar molecules occurs (Loftsson & Brewster, 1996; Connors, 
1997).  Overall however, hydrophobic interaction is supported by the repeated 
observation that the most non-polar portion of guest molecule is enclosed in the CD 
cavity.  In addition, significant complex stability has been observed in systems where 
classic hydrophobic interactions are unlikely (with very polar substrates) and indicates 
that other factors contribute to complex stability (Connors, 1997).  Therefore 
combinations of electrostatic interactions (dipole-dipole and hydrogen bonding), 
induction and dispersion forces with hydrophobic interactions can add to complex 
stability, depending on the nature of the enclosed guest (Szejtli, 1988; Connors, 1997).  
For molecules that are too large to be included in the CD cavity, hydrogen bonding is 
probably the main interaction on complexation and solubilization (Jones & Grant, 
1984).  Conformational strain relief, or the release of high-energy water from the CD 
cavity have also been proposed as types of interactions between guest molecules and 
cyclodextrin to account for CD complex formation, although they are not strongly 
supported by experimental evidence. Connors, (1997) found no support for the theory of 
conformational strain relief (induced fit) within the CD ring upon complexation, and did 
not consider release of high-energy water from the CD cavity, as a major driving force, 
as it neglects the energetics of the entire system, which is overall a destabilizing one.   
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1.4. CYCLODEXTRIN DERIVATIVES 
 
1.4.1. Characteristics 
 
Originally the production of derivatives was undertaken in an attempt to improve the 
safety of the natural CDs, especially β-CD, and to increase their aqueous solubility 
(Müller & Brauns, 1985; Szente & Strattan, 1992). β-CD is of appropriate size and 
shape to interact efficiently with numerous drug substances, but is soluble to only 
1.85% w/v in water. While complexes can be generated in an efficient manner with β-
CD, the absolute amount of the drug that can be solubilized is low (Brewster, 1992).  
Since the low aqueous solubility of the natural CDs is predominately due to 
intramolecular bonding, derivatization techniques that disrupt this process have been 
used.  CDs can be modified by substitution of the H-atom on any of the primary or 
secondary hydroxyls (to produce esters, ethers, glycosyl-CDs), or substitution of the 
primary or secondary hydroxyls (to produce deoxy-, halogeno- amino etc CD 
derivatives).  Alternatively, modification may be carried out by elimination of the H-
atom on the C5-CH2OH to produce C5-COOH, or splitting of the C2-C3 bonds (Szejtli, 
1988).  
 
The random replacement of hydroxy groups is technically more feasible, with 
substitution of any of the hydroxyl groups, even by hydrophobic moieties, resulting in a 
dramatic increase in water solubility (Müller & Brauns, 1985; Szejtli, 1991a).  This 
improvement results from the disruption of the secondary belt of hydrogen bonds 
formed between the secondary C2-OH and C3-OH of adjacent glucopyranose units 
(Szente & Strattan, 1992).  In addition, chemical manipulation frequently transforms the 
crystalline CD into amorphous mixtures of isomeric derivatives (Loftsson & Brewster, 
1996). The total solubility of a modified CD is the sum of the independent solubilities 
of its components. For example, there are many thousand possible hydroxypropyl 
derivatives of β-CD (three different positions on seven rings containing between 1 and 
21 hydroxypropyl groups). If each of these had identical solubility, and if the 
solubilities were independent of one another, the total solubility of a methylated-ß-
cyclodextrin derivative would be hundreds of times that of any single, pure isomer.  
However this difference is not often observed, as certain substitution patterns are not CHAPTER 1 
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likely to occur (Yalkowsky, 1999).  It is this tremendous diversity of molecular entities 
that accounts for the lack of crystallinity of chemically modified CDs, and provides a 
virtually infinite selection of interactive opportunities for molecular encapsulation 
(Szente & Strattan, 1992).  
 
The average degree of substitution (DS) is the most common measure to differentiate 
between different CD derivatives, and usually refers to the average number of 
chemically-modified groups (adducts) per CD molecule (Pitha et al., 1988; Szente & 
Strattan, 1992; Buvári-Barcza et al., 1996).  However, the DS does not differentiate 
between the different locations where these groups can occur within both the 
glucopyranose unit and the CD unit (Buvári-Barcza et al., 1996).  While the ratio of 
substituted-glucopyranose units can be maintained within a molecule, their location 
within the molecule may vary (Pitha, 1990). However there is a degree of positional 
(which hydroxyl groups) and regioselectivity (which glucopyranose units) possible. For 
example, preparation of hydroxypropyl CD at low alkalinity promotes substitution of 
the secondary hydroxy groups, while high alkalinity promotes substitution of the 
primary hydroxy groups and possibly oligomeric substitution (Pitha, 1990; Buvári-
Barcza et al., 1996) (See section 1.5).  The DS does not uniquely characterize a 
chemically-modified CD, with chemically-modified CDs of the same DS potentially 
being very different.  However, the methods used to determine the DS can produce 
spectrographs that can be used to assure that the same product is manufactured each 
time (Szente & Strattan, 1992). While it is possible to derivatize specific locations 
within the CD unit, this decreases amorphousness and hence solubility (Rao et al., 1990; 
Pitha, 1990).    The average molecular weights of the preparations can easily be 
calculated from the molecular weight of the natural CD (α 973, β 1135 and γ 1297), the 
molecular weight of the derivative group, and the DS (Pitha et al., 1988). For example: 
Avg. mw for hydroxyethyl CD = mw natural CD + (DS x 44), and  
Avg. mw for hydroxypropyl CD = mw natural CD + (DS x 58). 
 
CD derivatives are characterized by the nature of the substituent, the position of the 
substituent, and the DS (Szejtli, 1991a; Yalkowsky, 1999). There is a correlation 
between the hydrophobicity of a derivative and its solubilizing capacity, complex 
stability, tissue irritation, haemolytic effect and surface activity (Müller & Brauns, CHAPTER 1 
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1986b; Yoshida et al., 1988; Szejtli, 1991a).  Therefore the most hydrophobic 
derivatives show highest solubilizing power but also display the highest number of 
deleterious effects (Szejtli, 1991a).   In general, the DS also correlates with surface 
activity, with higher degrees of substitution resulting in increased surface activity 
(Müller & Brauns, 1986b; Yoshida et al., 1988).  In addition, the DS can influence CD 
solubility and drug solubilization (Müller & Brauns, 1986b; Backensfeld et al., 1990).  
An increased number of substituents improves the solubility of the CD derivative, but 
CD derivatives with lower degrees of substitution are better solubilizing agents, as 
increases in the number of bulky substituents on the CD ring result in steric blockage of 
the CD cavity (Müller & Brauns, 1986b; Backensfeld et al., 1990; Szejtli, 1991a). 
However, this is not a rule.  One exception to this is indomethacin, where higher 
substitution results in a longer CD cavity, which results in increased indomethacin 
protection (Backensfeld et al., 1990).    
 
Economic and quality control considerations also play a role is determining what CDs 
are pharmaceutically useful.  For a given modified CD to be commercially viable, its 
synthesis and purification must be relatively inexpensive and feasible.  Therefore 
modified CDs of pharmaceutical interest are likely to be complex mixtures (Stella & 
Rajewski, 1997).  Since multi- component systems are considered, accurate 
characterization of batches is important to ensure content and reproducibility. Therefore 
production methods need to be characterized to ensure lot-to-lot reproducibility, 
including possible positional and regio-substitution (Brewster, 1992).  They must also 
be free of potentially reactive and toxic components, especially for parenteral 
formulations, and must be sterilizable either by heat or filtration (Rajewski & Stella, 
1996). 
 
1.4.2. Types of derivatives  
 
Although a large number of derivatives have been reported (Table 1.2), the most 
common derivatives of β-CD are the partially alkylated, e.g. dimethyl and trimethyl-β-
CD, the partially hydroxyalkylated, e.g. hydroxyethyl and hydroxypropyl-β-CD, and the 
branched β-CDs (Yalkowsky, 1999). In the pharmaceutical industry, five general types 
of CDs are of interest due to their potential in vivo use (Rajewski & Stella, 1996): CHAPTER 1 
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-  The alkylated CDs  
-  The hydroxyalkylated CDs 
-  The branched CDs 
-  The carboxymethyl CDs (Polymerised CDs) 
-  The sulphoalkylether CDs (ionic CDs) 
 
Table 1.2: Some currently available CDs obtained by substitution of the OH groups 
located in the edge of the CD ring (Loftsson & Brewster, 1996). 
CD Derivatives  α  β  γ 
Alkylated:  Methyl 
 
Butyl 
Methyl 
Ethyl 
Butyl 
Methyl 
 
Butyl 
Hydroxylalkylated:   
2-Hydroxypropyl 
 
Hydroxyethyl 
2-Hydroxypropyl 
2-Hydroxybutyl 
Hydroxyethyl 
2-Hydroxypropyl 
Esterified:  Acetyl 
 
 
Succinyl 
 
Acetyl 
Propionyl 
Butyryl 
Succinyl 
Benzoyl 
Palmityl 
Toluenesulfonyl 
Acetyl 
 
 
Succinyl 
 
Esterified and 
alkylated: 
 Acetyl  methyl 
Acetyl butyl 
 
Branched:  Glucosyl 
Maltosyl 
Glucosyl 
Maltosyl 
Glucosyl 
Maltosyl 
Polymerized:  Simple polymers 
Carboxymethyl 
Simple polymers 
Carboxymethyl 
Simple polymers 
Carboxymethyl 
Ionic:  Carboxymethyl ether 
 
Phosphate ester 
Carboxymethyl ether 
Carboxymethyl ethyl 
Phosphate ester 
3-Trimethylammonium-2-
hydroxypropyl ether 
Sulfobutyl ether 
Carboxymethyl ether 
 
Phosphate ester 
  
1.4.2.1. Alkylated cyclodextrin derivatives 
 
The most common examples of the alkylated (methylated) CDs are 2,6-dimethyl-β-CD 
(DMβCD), 2,3,6-trimethylmethyl-β-CD (TMβCD) and randomly methylated-β-CD 
(RMβCD).  The methylation of the secondary hydroxyl groups increases the solubility 
of β-CD many fold.  Methylation also extends the hydrophobic cavity of the CD and CHAPTER 1 
__________________________________________________________________________________________________________ 
  20
provides a greater surface area for complexation (Brewster et al., 1989). As a result, 
stability constants for drug/CD complexes are generally higher for DMβCD that for β-
CD (Brewster, 1992). Currently the methylated CDs appear to be the most powerful 
solubilizers. DMβCD in particular is one of the most effective drug solubilizers of all  
CD derivatives (Szejtli, 1991a).  The main drawback of the methylated CDs is that they 
have similar parenteral toxicity to β-CD. Parenterally administered DMβCD results in 
an increase in glutamate-pyruvate transaminase (GPT) and glutamate-oxaloacetate 
transaminase (GOT), indicating hepatic disorder (Yamamoto et al., 1990).   In addition, 
the methylated CDs also show marked surface tension reducing capacity and haemolytic 
activity due to their relatively high lipophicity compared to β-CD. They exert detergent-
like effects on biological membranes, where they are able to complex with, and extract, 
membrane components from erythrocytes at concentrations as low as 0.07% DMβCD 
(Yoshida et al., 1988).  The LD50 for DMβCD has been estimated at or below 200mg/kg 
(Müller & Brauns, 1985).  Another disadvantage is that DMβCD drug complexes 
precipitate upon heating, as DMβCD decreases in solubility with heating.  Therefore 
these complexes cannot be heat sterilized (Duchêne & Wouessidjewe, 1990b). While 
methylated β-CDs show great promise as complexing agents, they are too lipophilic for 
pharmaceutical use (Szente & Strattan, 1992).  
 
1.4.2.2. Hydroxyalkylated cyclodextrin derivatives 
 
An alternative chemical modification is hydroxy- or dihydroxyalkylation.  Examples of 
hydroxyalkylated CD derivatives are hydroxyethyl- (HECD), 2-hydroxypropyl- (2-
HPCD), and 3-hydroxypropyl-CDs (3-HPCD) (Brewster et al., 1989). This chemical 
reaction generates amorphous mixtures of literally thousands of geometric and optical 
CD isomers. They are highly water soluble, hydrophilic, and can rapidly be dissolved 
(Brewster et al., 1989).  The non-selective nature of these modifications generates many 
chemically distinct species whose solubility is independent of even close structural 
analogues. For example, the derivatized moiety may be attached at the primary or 
secondary hydroxy groups of β-CD or to the secondary hydroxy groups of the 
polypropylene side chain from one of the glucose moieties (Pitha, 1990).  In addition, 
the hydroxyl group of the hydroxypropyl substituent can exist at 1 of 3 carbons, with 
the most common HP derivative the 2-hydroxypropyl-CD (Thompson, 1997).  The CHAPTER 1 
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lower lipophilic character of the hydroxyalkylated CD derivatives results in their 
negligible surface activity and a greatly reduced tendency to cause haemolysis. Surface 
activities of these forms are between those of β-CD and the alkylated CDs, and 
increases with increasing degrees of substitution (Yoshida et al., 1988). Their 
haemolytic activity and local irritancy are less than the natural CDs and DMβCD, and in 
contrast to surface activity, the haemolytic activity decreases with increasing degrees of 
substitution (Yoshida et al., 1988).  This is probably associated with their decreased 
ability to extract membrane components and therefore they are much more compatible 
with biological membranes than both the natural CDs and DMβCD (Yoshida et al., 
1988; Brewster et al., 1989). Of the hydroxyalkylated CDs studied, 2-hydroxypropyl-β-
CD (HPβCD) has been the most extensively examined, receiving much attention in the 
last few years.  The complexing power of HPβCD is generally greater or equal to that of 
β-CD, and generally less than DMβCD (Brewster et al., 1989; Szejtli, 1991a).  More 
importantly, the greater solubility of HPβCD over β-CD allows for the complexation of 
much greater quantities of drug (Brewster et al., 1989).  Detailed toxicology studies 
have found that HPβCD is tolerated as a parenteral carrier even at extremely high doses, 
and the raw material is available at an acceptable price and in the quantities necessary 
(Szejtli, 1991a; Szente & Strattan, 1992).  Further discussion on HPβCD can be found 
in section 1.5. 
 
1.4.2.3. Branched cyclodextrin derivatives 
 
The primary hydroxyl group of CDs is substituted by mono- and disaccharides through 
the α-1,6 glucosidic linkage (Yamamoto et al., 1990).  They are amorphous with high 
aqueous solubility (>50%) and have no surface activity, differing from the alkylated and 
hydroxyalkylated CD derivatives.  They also have lower haemolytic and local tissue 
irritancy than the natural CDs and alkylated CDs (DMβCD), with the ability of the 
branched CDs to extract membrane components decreasing with increasing number of 
branched glucose residues (Duchêne & Wouessidjewe, 1990b; Yamamoto et al., 1990).  
They are also more resistant to the action of α-amylase than β-CD, probably due to 
steric hindrance of the branched glucose residues (Yamamoto et al., 1990).  They 
therefore have great potential as parenteral drug carriers (Yamamoto et al., 1990). 
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1.4.2.4. Polymerised cyclodextrin derivatives 
 
The dihydroxypropyl β−CD derivatives are prepared by reaction of β-CD in alkaline 
solution with epichlorohydrin to produce two or more covalently linked CD-units 
(Szejtli, 1988; 1991a). CD polymers may be water-soluble, insoluble but strongly 
swelling or moderately swelling amorphous powders, beads, foams etc (Szejtli, 1988).  
The water-soluble polymers usually consist of between 2-5 CD units and are excellent 
solubilizers (Szejtli, 1988).  However, they are not easily characterized because of their 
polymeric nature (Szejtli, 1991a; Szente & Strattan, 1992). Those with carboxymethyl 
groups were particularly suited for basic drugs, while those with diethylaminoethyl 
groups were particularly suited for acidic drugs (Szejtli, 1991a).  Despite showing 
neither significant surface activity nor haemolytic activity, they do contain a certain 
amount of highly soluble CD oligomeric cross-linked polymers, and therefore have not 
been extensively studied for parenteral use.  However, they can be used orally and 
externally (Szejtli, 1991a). Insoluble swelling CD polymers have a three dimensional 
network and are not soluble in any solvent (Szejtli, 1988).  Some have been developed 
to accelerate wound healing, while those that exhibit poor binding with high 
disintegrating properties have been used in tablet formulation (Szejtli, 1988; 1991b; 
Duchêne & Wouessidjewe, 1990b).   
 
1.4.2.5. Ionic cyclodextrin derivatives 
 
Mixed ether-ester  derivatives are produced by esterifying one or more of the free 
hydroxyl groups on methylated β-CD, therefore introducing highly hydrophilic ionic 
alkyl or aryl groups.  These are crystalline compounds (Szejtli, 1991a).  Another group 
is the aminoalkyl-ether derivatives and mixed alkyl-, hydroxyalkyl-, and 
carboxyalkylether derivatives, such as sulfobutyl ether-β-CDs (SBEβCDs).  These are 
amorphous and non-crystallizable, with the groups having ether linkages directly to the 
CD ring (Szejtli, 1991a).  Both groups have retained the excellent solubilizing capacity 
of β-CD. In addition, the presence of ionic groups on the torus reduces the haemolytic 
activity of the derivative, as they are unable to form strong inclusion complexes with 
cholesterol and other membrane lipids.  By establishing ionic interactions with ionic 
guest molecules, these groups can enhance the solubility and stability of the complex CHAPTER 1 
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(Szejtli, 1991a). However, this is dependent on the relative proximity of the charge to 
the CD cavity. The further the charge from the cavity the better the complexing ability. 
Compared to neutral CDs, enhanced complexation is frequently observed when the drug 
and CD have opposite charge (Másson et al., 1996). SBE7M-β-CD in particular has 
received much attention over the last few years (Stella & Rajewski, 1997).  The 
SBEβCDs are water miscible and parenterally safe, with higher degrees of substitution 
often resulting in higher drug binding (unlike other chemically-modified CDs).  
 
1.5. HYDROXYPROPYL-β-CYCLODEXTRIN 
 
1.5.1. Characteristics 
 
HPβCD is soluble in ethanol, methanol, DMSO and dimethyl formamide (>20% w/v), 
and water (>60% w/v) (Szente & Strattan, 1992). The aqueous solubility limit of 
HPβCD in water has not been determined, with concentrations up to 75% w/w attained 
by 10-20 min stirring (Pitha et al., 1986; Szente & Strattan, 1992). Also, solutions 
become more viscous with increasing concentration (Brewster, 1992). For aqueous 
solutions above 20% w/v HPβCD, the final volume of the resultant solution will 
increase 0.7 mL for every gram of HPβCD (DS 5-7) added.  For example, if 100 mL of 
50% w/v aqueous HPβCD is needed, one should not start with more than 65 mL water 
[100 mL – (0.7 mL/g x 50 g)] (Szente & Strattan, 1992).   
 
HPβCD is an amorphous mixture of many chemical individuals, all of which have good 
water solubility and good complexing power (Pitha et al., 1986).  As previously 
discussed, substitution of any of the hydrogen bond-forming hydroxyl groups result in a 
dramatic increase in water solubility.  The derivatized moiety may be attached at the 
primary or secondary hydroxy groups of β-CD, or to the secondary hydroxy groups of 
the modifying hydroxypropyl groups (Figure 1.4) (Pitha, 1990).  Since the 2-HP 
substituent contains a chiral carbon, and CDs are chiral, every specific substitution by 
racemic propylene oxide leads to a pair of diastereomers – compounds that differ in 
their chemical and physical properties (Rao et al., 1990).  Each of the geometric isomers 
is associated with 2
n (n = the number of geometric isomers) optical isomers   
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Figure 1.4: Potential structure of 2-hydroxypropyl-β-cyclodextrin with examples of 
substituents attached at the 2-, 3- and 6- positions.  The fourth substituent demonstrates 
the further polymerisation of the substituent with propylene oxide (Pitha, 1990; 
Brewster, 1992; Thompson, 1997). 
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(Szente & Strattan, 1992).  Since each CD molecule contains 28 chiral centres, and each 
hydroxypropyl group adds one asymmetrical carbon, the total amount of isomers is very 
large.  Therefore random substitution of the hydroxyl groups of β-CD generates many 
thousand possible derivatives (Loftsson & Brewster, 1996). 
 
The degree of substitution (DS) is the mean number of 2-hydroxypropyl (HP: CH2-
CH(OH)-CH3) units per CD unit.  Decreasing the average DS results in a decrease in the 
number of components in the mixture, resulting in increased crystallinity and decreased 
solubility (Rao et al., 1990).  Therefore decreasing the DS decreases the amorphous 
nature of the mixture.  There is a correlation between the degree of substitution, HPβCD 
solubility, and complexing ability (KC) (Pitha et al., 1986; Rao et al., 1992). For 
example, at a low DS, the solubility of the CD is low, while its complexing ability is 
high, and visa versa.  As DS increases, complexing ability decreases due to increased 
difficulty of guest to enter the cavity, while solubility increases due to increasing 
amorphousness (Rao et al., 1992; Buvári-Barcza et al., 1996).  Rao et al., (1992) also 
found that at very low DS, complexing ability increased.  This was attributed to 
lipophilic binding between the guest molecule and the HP-groups.  Alternatively, 
increased complexing ability may be due to the initial increase in cavity size resulting 
from derivatization, with subsequent increases in DS resulting in steric hindrance and 
therefore increased difficulty of the guest to enter the cavity. A relationship between 
complexing ability and substitution patterns was also observed, with the location of HP 
derivatization on the primary or either secondary hydroxyl groups, influencing 
complexing ability. Substitution of the secondary hydroxyl groups resulted in 
decreasing complexing ability with increasing DS, while substitution of the primary 
hydroxyl groups, or random substitution, had a more random effect on complexing 
ability (Buvári-Barcza et al., 1996).  Therefore the pattern of hydroxypropylation also 
influences steric hindrance. 
 
The physical dimensions of HPβCD should approximate its parent as far as the interior 
cavity i.e. 7.0 – 8.0 Å is concerned.  The other dimensions, such as height of the torus, 
diameter of the periphery, and the effective volume of the cavity, can only be estimated 
to fall within a relatively broad range, because of the freely rotating nature of the HP 
adducts.  The molecular weight of HPβCD of a given DS may be calculated by the CHAPTER 1 
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formula: MW=1135 + (DS x 58), where 1135 is the MW of β-CD and 58 is the 
molecular mass added by each HP group (Szente & Strattan, 1992). 
 
1.5.2. Manufacture  
 
The natural CDs are already produced on an industrial scale, although γ-CD is still 
expensive (Thompson, 1997). While manufacturers of β-CD are in the best-cost 
position to produce HPβCD, the current demand for HPβCD does not call for 
substantial HPβCD production. HPβCD price also varies greatly, as HPβCD for 
parenteral administration has to meet much stricter requirements than for oral or 
external requirements (Szejtli, 1991b; Thompson, 1997). All major manufacturing 
methods use a base-catalyzed substitution reaction to produce HPβCD (Strattan, 1992; 
Szente & Strattan, 1992). This is called the alkylene oxide method and most 
manufacturers use propylene glycol to react with β-CD.  The basic steps in the 
manufacture of HPβCD are: 
-  Dissolve sufficient β-CD in an aqueous medium using an appropriate amount of 
alkali metal base (usually NaOH). 
-  Add an appropriate amount of propylene oxide under specified conditions of 
temperature, pressure, head-space content, and reaction time. 
-  Remove the alkali metal base, unreacted β-CD, and products of propylene oxide 
side reactions (especially propylene glycol). 
-  Narrow the distribution of isomers (optional). 
-  Powder (if necessary). 
-  Reduce the powder to a uniform size. 
 
The actual process varies widely, and manufacturers are required not only to provide 
specifications for purity, residue on ignition, heavy metals and aqueous solubility, but 
also for propylene glycol content, β-CD content, residue organics, water content, degree 
of substitution and molar substitution.  Further, adduct distribution in the isomers and 
the degree to which the adducts are polymerized, specific rotation, peak asymmetry 
analysis, and microbial and endotoxin content are also required (Strattan, 1992; Szente 
& Strattan, 1992).  Differences in manufacturing processes produce materials of CHAPTER 1 
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different DS and distribution of substituents, which need to be considered (Strattan, 
1992). 
 
1.5.3. Biological effects 
 
1.5.3.1. Oral administration 
 
Gerlóczy et al., (1985) studied the absorption, distribution and excretion of orally 
administered HPβCD, and found that less than 10% was absorbed from the 
gastrointestinal tract. Hydrolysis of HPβCD by colon microflora occurs at a slower rate 
compared with the unsubstituted CDs, as the adducts interfere with enzymatic 
degradation (Müller & Brauns, 1986a; Monbaliu et al., 1990). Of the absorbed HPβCD, 
most is initially metabolized by the microflora in the large intestine.  A maximum of 2-
3% (possibly as low as 1%) of the absorbed HPβCD is intact, which is then removed by 
glomerular filtration (Frijlink et al., 1990; Gerlóczy et al., 1990; Monbaliu et al., 1990).  
Up to 86% of the administered dose is unabsorbed and passed in the faeces within 72 
hours, of which approximately 60-70% is intact HPβCD (Gerlóczy et al., 1990; 
Monbaliu et al., 1990).   
 
Oral doses as high as 15 g kg
-1 resulted in no adverse effects in monkeys (Brewster, 
1992).  Large chronic doses of oral hydroxypropyl CDs in mice were also non-toxic, but 
did cause slight liver enlargement (Pitha & Pitha, 1985).  This was attributed to the 
complexation and removal of bile acids from the intestine, so liver enlargement was 
therefore associated with the increased synthesis of bile acids. As HPβCD is capable of 
complexing a wide range of compounds, orally administered HPβCD can potentially 
complex with a wide range of endogenous compounds in the gut, influencing their 
distribution from the gastrointestinal tract (Pitha, 1990).  This may explain the various 
effects observed after administration of chronic large oral doses of HPβCD.  For 
example, both cholesterol and bile acids form complexes with HPβCD.  Therefore 
complexation may act to increase the solubility of cholesterol and bile acids, altering 
their distribution (Nakanishu et al., 1989; Gerlóczy et al., 1994).  However, Gerlóczy et 
al., (1994) did not find orally administered HPβCD to significantly effect total plasma 
cholesterol, and suggested that the untoward effects of large doses of HPβCD more CHAPTER 1 
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likely due to the CD-enhanced dissolution of various lipophilic toxins and carcinogens 
present in food.   
 
Orally administered HPβCD in human volunteers (up to 3g) could not be detected in 
either plasma or urine, indicating that no absorption from the gastrointestinal tract 
occurred, and that HPβCD is not bioavailable after oral administration (Szathmary et 
al., 1990). In addition, no specific accumulation in the tissues occurred (Gerlóczy et al., 
1985; Monbaliu et al., 1990).  Teratogenicity & embryotoxicity studies of orally 
administered HPβCD were negative in the rat and rabbit (Coussement et al., 1990; 
Brewster, 1992).   
 
1.5.3.2. Parenteral administration 
 
Over the last few years’ detailed studies of HPβCD absorption, metabolism and toxic 
properties in various formulations have been carried out (Szejtli, 1991a). No 
toxicologically meaningful data has been obtained for HPβCD in the DS range of 5-9, 
with preparations with a DS of about four or more not containing detectable amounts of 
starting CDs (Pitha et al., 1988). However, HPβCD with DS values lower than 4 should 
be avoided as precipitation may occur in the kidney upon parenteral administration (Rao 
et al., 1990).   
 
Acute dosing of very high levels of HPβCD appears to produce no observable 
manifestations or nephrotoxicity, with HPβCD eliminated from the body within a few 
hours via glomerular filtration (Anderson et al., 1990; Frijlink et al., 1990; Monbaliu et 
al., 1990).   Acute intravenous administration of 10 g kg
-1 in monkeys, and 5 g kg
-1 for 7 
days in rats resulted in no toxicity (Brewster et al., 1990; Brewster, 1992).  The tissue 
distribution was limited, with the highest concentrations found in the kidney (Monbaliu 
et al., 1990). Similar results have been observed with acute intraperitoneal 
administration, with none of the hydroxypropylated parent CDs exhibiting toxicity at 10 
g kg
-1 in mice (Pitha et al., 1988).  Szathmary et al., (1990) and Seiler et al., (1990) 
investigated the pharmacokinetics of intravenously administered HPβCD by injecting 
successively larger doses of HPβCD into human volunteers (up to 3g).  HPβCD was 
almost totally eliminated via the kidneys, with almost 80% of the total dose eliminated CHAPTER 1 
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within 2 hours (Szathmary et al., 1990).  No side effects or local irritation were 
observed, with vital parameters, haematology and clinical chemistry unaffected, and 
with no signs of renal impairment. The possibility that hormones may have been 
complexed and excreted was also investigated, with hormone concentrations found to be 
unaffected (Seiler et al., 1990). 
 
In subchronic toxicity studies in rats and dogs, daily intravenous administration of 100 
mg kg
-1 for 90 days resulted in minimal, reversible effects on the urinary tract. 
However, the same dosage regime at 400 mg kg
-1 resulted in moderate toxicity, with the 
urinary tract as the target organ, along with slightly altered blood and serum parameters 
(Coussement et al., 1990).  The main pathology was increased vacuolization of renal 
tubular cells.  This is similar to that seen following intravenous administration of large 
doses of glucose, sucrose, mannitol or dextrin (Irie et al., 1992a).  This effect is 
reversible and thought to be dependent on the absolute volume of renally filtered fluid, a 
variable often associated with animal size (Strattan, 1992).  As the DS, molar 
substitution, adduct distribution and the residual content of unreacted β-CD could affect 
the potential toxicity of HPβCD, rigid specifications would need to be established to 
reduce these potential side effects (Strattan, 1992).  
 
HPβCD is far less toxic than DMβCD, especially after acute administration.  Other 
parenteral administration routes also provide similarly encouraging results.  No 
ophthalmic, intracerebral or muscular irritation was observed at HPβCD concentrations 
as high as 40, 45 or 50% (w/v) respectively (Pitha et al., 1988; Coussement et al., 1990; 
Brewster, 1992). The lower lipophilic character of the HPβCD has resulted in its 
negligible surface activity and greatly reduced haemolytic properties in comparison to 
either DMβCD or β-CD (Yoshida et al., 1988). Aqueous solutions up to 40% (w/v) are 
not haemolytic in vivo (Brewster et al., 1990).  Mutagenicity testing using the 
salmonella/mammalian microsome plate incorporation mutagenicity assay (1000 
µg/plate), and mouse micronucleus test (5 g kg
-1) were also negative (Coussement et al., 
1990; Brewster & Bodor, 1990).   
 
As with orally administered CDs, parenterally administered CDs have the capacity to 
complex with endogenous compounds and influence their distribution throughout the CHAPTER 1 
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organism.  This also occurs after intravenous administration of drug/CD complexes, as 
only small amounts of drug remain complexed.  This results from binding competition 
between cyclodextrin and plasma protein for the drug, and also competition between the 
drug and endogenous compounds for the cyclodextrin.  In some cases increased drug 
protein binding is observed, and is attributed to the removal of cholesterol from plasma 
protein binding sites (Frijlink et al., 1991a; Sideris et al., 1994).  The complexation of 
cholesterol by HPβCD may be of therapeutic value if HPβCD assisted transport 
partially prevents cholesterol deposition (Irie et al., 1992a).  Intravenously administered 
HPβCD has been used in a case of severe hypervitaminosis A, with the intention to 
solubilize retinoids and enhance their urinary excretion (Carpenter et al., 1987).  While 
treatment did help, the observed increase in serum retinoid concentrations was greater 
than expected given the concentration of circulating HPβCD.  Therefore Irie et al., 
(1992a) proposed that HPβCD may have accelerated the transfer of retinoids to 
lipoproteins, with circulatory HPβCD acting as an intermediary, catalyzing the transport 
of cholesterol within the lipoprotein–vascular system, but not transporting 
physiologically meaningful quantities of cholesterol itself.  While HPβCD is capable of 
solubilizing and transporting lipids in organisms, they have limitations as lipid carriers.  
As both the binding affinity and specificity toward individual lipid classes are small, no 
selective removal can be expected.  This is advantageous, as HPβCD cannot compete 
with specific carrier proteins for critical lipids, such as vitamins and hormones, 
depriving the organism of these critical lipids (Irie et al., 1992a).  
 
1.6. FORMULATION OF INCLUSION COMPLEXES 
  
1.6.1. Determination of stability constants  
 
In solution, an inclusion compound is always in kinetic or thermodynamic equilibrium 
with its free components (Section 1.3).  This equilibrium is expressed by the stability 
constant (KC), and is an index of the change in physicochemical properties of a 
compound upon inclusion (Loftsson & Brewster, 1996).  All methods to determine the 
KC involve analyzing the CD concentration dependency of certain physical or chemical 
properties of the guest, such as solubility, chemical reactivity, molar absorptivity, pKa, CHAPTER 1 
__________________________________________________________________________________________________________ 
  31
or even chromatographic retention time. Examples of these methods may be found in 
Hirayama & Uekama, (1987). 
 
1.6.1.1. Phase solubility analysis  
 
Phase solubility analysis is the study of the dependence of guest solubility on CD 
concentration, and may reveal both the stoichiometry of the complex formation as well 
as the stability constant of the complex (Jones et al., 1984). The basis for reliable 
formation development is accurate determination of solubility.  The solubility of guest 
molecules is often determined by UV spectrophotometry, as CDs do not absorb in the 
UV spectrum (Jones et al., 1984). Constancy of solubility, like constancy of melting 
point and other physical properties, indicate that the solid sample is a pure substance 
and is free from foreign material (Grant & Higuchi, 1990).  However, in some cases 
accurate determination may be difficult due to solid state factors and batch to batch 
variation (different polymorphs, hydration state, crystallinity, crystal homogeneity and 
impurities) which affect reproducibility (Sweetana & Akers, 1996).   
 
Phase-solubility analysis of drug/CD complexes comprises two processes.  The 
experimental techniques for phase-solubility analysis involve multiple vials of equal 
masses of substrate (compound of interest) and solvent, with increasing amounts of the 
ligand (complexing agent), mixing a constant temperature and pressure (Grant & 
Higuchi, 1990).  This is maintained until equilibrium in reached.  As complexation 
lowers the thermodynamic activity of the dissolved drug, more drug dissolves until the 
activity of the free drug, which is in chemical equilibrium with the complex, becomes 
equal to the thermodynamic activity of the pure solid drug (Jones et al., 1984). The 
interpretation of the resultant equilibrium plots according to the phase rule results in the 
determination of the stability constant of the complex (Jones et al., 1984; Grant & 
Higuchi, 1990) (Section 2.2.1).  Phase-solubility diagrams are generated by plotting the 
total molar concentration of the substrate against the molar concentration of the ligand.  
The diagrams obtained fall into two main categories, Type A and Type B (Grant & 
Higuchi, 1990).   
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Type A diagrams are characterized by a continual increase in substrate concentration [S] 
with increasing ligand concentration [L], presumably due to the formation of soluble 
complexes between the substrate and the ligand (Grant & Higuchi, 1990). Three type A 
diagrams exist (Figure 1.5).  A strict linear rise in substrate concentration with 
increasing ligand concentration, designated AL, occurs when complexes are of the first 
order in ligand, e.g., SL, S2L, S3L… SmL.  The linear relationship between solubility 
and CD concentration has a number of advantages, one of which is the lack of 
precipitation of the formulation upon dilution (Stella & Rajewski, 1997).  Positive 
curvature, type AP, arises when the complexes contain the ligand at higher orders than 
one, e.g., SL2, SL3… SLm.  Negative curvature, type AN, may arise when the presence of 
the ligand at high concentrations changes the stability constant of the complex or 
induces self-association of the ligand.  This behaviour is rare (Grant & Higuchi, 1990). 
The plateau may also represent saturation of the solution with ligand, owing to its own 
solubility limits. However, only if the diagram reaches a plateau can the actual ratio of 
S:L be determined.   
 
Type B phase-solubility diagrams arise when complexes of limited solubility are formed 
between the substrate and the ligand (Figure 1.6). The limited solubility of the natural 
CDs often gives rise to type B phase diagrams when complexed with other compounds 
with limited aqueous solubility (Loftsson & Brewster, 1996).  Type BS diagrams 
indicate some solubility of the complex. The rise from S0 (solubility of the substrate 
without ligand) to a is interpreted as the formation of the complex which dissolves as in 
any of the type A diagrams.  At point a, however, the solubility limit of the complex is 
reached and further addition of ligand results in the formation of more complex in a 
solid form.  Since the substrate is being precipitated with the ligand, the substrate 
continues to dissolve to keep constant the thermodynamic activity and the concentration 
of dissolved substrate. At point b, no more solid substrate remains and further addition 
of ligand results in the depletion of substrate from the solution by formation and 
precipitation of the complex.  This becomes somewhat more complicated when the 
system forms more than one complex, with each complex having different solubility 
limits.  Type BI is interpreted in the same manner as BS, except that the complex formed 
is insoluble. 
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Figure 1.5: Phase solubility diagrams of Type A systems showing apparent increase in 
solubility of S caused by component L (Higuchi & Connors, 1965).   
 
 
 
 
 
 
 
 
 
Figure 1.6: Phase solubility diagrams of Type B systems showing changes in solubility 
of S caused by component L (Higuchi & Connors, 1965).    
 
1.6.2. Analysis of cyclodextrin complexes 
 
The formulation of cyclodextrins with potential guests does not guarantee true inclusion 
complex formation (Szejtli, 1988).  Therefore it is necessary to determine the guest 
content of the product, whether the guest is actually included in the cyclodextrin cavity, 
and the ratio of complexed to uncomplexed guest.  Quantitation of guest content can be 
determined using UV, GLC, HPLC or other analytical techniques.  However, the 
complex must be dissolved and dissociated, in order to account for complexation 
resulting in small shifts in UV absorption maxima and molar extinction coefficients, as 
well as modifications in the chromatographic mobility, reactivity and other 
characteristics (Szejtli, 1988). 
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The formation of CD inclusion compounds in solution can be detected by various 
methods such as circular dichroism, nuclear magnetic resonance (NMR), electron spin 
resonance (ESR), fluorescence enhancement, X-ray powder refraction, chromatography, 
infra-red spectroscopy and thermoanalytical methods (Jones et al., 1984; Szejtli, 1988).  
While most are effective techniques, some techniques are only suitable for particular 
compounds.  Thermoanalytical methods such as evolved gas analysis (EGA), 
differential thermal analysis (DTA), differential scanning calorimetry (DSC), and 
thermogravimetric analysis (TGA) are techniques used to study the thermal transitions 
of a sample.  They can be used to determine whether a true inclusion compound has 
been formed, by determining whether the guest substance undergoes some change 
before thermic degradation of the CD (250-300°C) (Jones et al., 1984; Szejtli, 1988).  
With increasing temperature, TGA and DTG reveal mass loss, EGA measures the 
specific rate of gas or vapour evolution from a sample, and DSC reveals enthalpy 
changes (Szejtli, 1988).  More specifically, DSC involves heating a sample at a specific 
rate, and as the sample undergoes endothermic and exothermic reactions, the sample 
requires more or less heat to maintain that specific rate of heating, producing 
characteristic heat flow curves as a function of temperature (Wells & Aulton, 1988; 
Szente & Strattan, 1992).   These thermoanalytical methods measure changes within the 
sample that may be due to evaporation, oxidization, out-gassing, melting, 
crystallization, polymorphic transition or decomposition (Szejtli, 1988). These 
techniques produce reproducible thermograms that are like a fingerprint for a particular 
compound. Detailed reviews on the preparation and investigation of inclusion 
compounds are provided by Hirayama & Uekama, (1987) and Szejtli, (1988).   
 
1.6.3. Solid inclusion compounds 
 
Solid drug preparations are formulated to allow oral delivery of the drug. Solid 
inclusion compounds are advantageous as they accelerate and increase drug dissolution 
and thus improve the absorption of the orally administered drug.  Their dissolution 
resembles the rapid dissolution of the CDs rather that the slow dissolution of the drugs.  
The most reliable method for the preparation of solid inclusion compounds is to isolate 
them from the saturated aqueous solution.  However, this can be time consuming and 
alternative methods may be more feasible.  However, solid inclusion compounds need CHAPTER 1 
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to be analyzed for their composition (CD, drug, water and contaminants) and 
stoichiometric ratio (Hirayama & Uekama, 1987). Analysis of dissolution kinetics of 
solid inclusion compounds is often preferable to solubility studies as it reveals not only 
solubility improvement, but also the rate of passage into solution (Duchêne et al., 1986).   
 
1.6.4. Improving complexation efficiency 
 
While large numbers of drugs can be complexed, technical and economical reasons set 
limitations on the use of CDs (Szejtli, 1991b).  For many drugs, complexation is either 
not possible, yields no advantage, or the ratio of drug to CD requires unreasonably large 
quantities to achieve sufficient doses (Szejtli, 1991b).  For K1:1 complexes, the drug 
solubility in the presence of CD cannot be any greater than the molar concentration of 
the CD used to solubilize the drug, and even this assumes that the binding constant is 
infinitely large (Stella & Rajewski, 1997).  Most K1:1 values fall within 100-20000 M
-1, 
and the CD concentration is usually less than 0.1-0.2 M.  Therefore the maximum 
increase in solubility that can be expected is 1000-2000 fold (Stella & Rajewski, 1997).  
As the mass of tablet should not exceed 500mg, and CDs have rather large molecular 
weights, the relationship between the required dose and the molecular weight of the 
drug determines the feasibility of oral administration (Szejtli, 1991b).  Oral applications 
of CDs are appropriate for dissolution rate limited drug absorption, but are limited to 
low dose drugs with large stability constants due to the mass limitations of oral dosage 
units (Rajewski & Stella, 1996).  In addition, production of dosage forms on a 
commercial scale would consume large amounts of CD.  Therefore the CD must be 
reasonably inexpensive for the dosage form to be economically feasible.  β-CD itself is 
quite inexpensive, and the costs or α-CD and γ-CD are declining.  Any modification of 
the CD structure must entail relatively inexpensive reagents and purification procedures 
(Rajewski & Stella, 1996).   
 
As the complexation efficiency of CDs is frequently quite low, increased efficiency can 
be achieved by increasing either the aqueous solubility of the drug (SO) or the stability 
constant of the complex (KC).  A number of commonly used pharmaceutical additives, 
such as organic solvents, lipophilic preservatives and surfactants, whose addition may 
increase SO, often decrease KC by competing with the drug molecule for space within CHAPTER 1 
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the CD cavity, resulting in decreased efficiency (Loftsson et al., 1999).  Therefore a 
number of methods to enhance complexation efficiency have been investigated.  Such 
methods include altering the pH (Loftsson et al., 1996a; 1998; Carrazana García et al., 
1998; Linares et al., 1998), adding components such as polymers (Loftsson et al., 1996a 
and b), organic acids (Bekers et al., 1989; Gerlóczy et al., 1996; Mura et al., 1998), 
pluronics (Topchieva et al., 1994), nanoparticles (da Silveira et al., 1998) or 
hydroxypropyl methylcellulose (Loftsson et al., 1994; Brewster et al., 1995) to aid 
complexation, or altering temperature to affect the thermodynamics of the system (Jones 
& Grant, 1984; Bekers et al., 1989; Hoshino et al., 1993; Yalkowsky, 1999; Redenti et 
al., 2000).  However, the addition of other components does increase the number of 
variables, and therefore must be accounted for.  The use of drug/cyclodextrin/hydroxy 
acid multicomponent systems is becoming increasingly popular as a means of 
increasing drug solubility (Redenti et al., 2000).  The formation of water-soluble salts 
between a basic drug and organic acid can enhance complexation, either through an 
increase in SO (through the improved solubility of the individual components, i.e. free 
unionized drug + free ionized drug + unionized drug complex + ionized drug complex) 
or an increase in KC (i.e. formation of drug/acid/CD ternary complex) or increasing both 
simultaneously (Loftsson et al., 1999).  In addition, hydroxy acids are often able to 
increase the solubility of CD (particularly β-CD), resulting from their capability to 
modify the intramolecular hydrogen bond system of the secondary hydroxyls of CD 
and/or effect their interaction with the surrounding water molecules (Redenti et al., 
2000).  Drugs that achieve the best solubility enhancement are strongly bound to the 
CD, even though they are in the ionized form.  This is because the ionized portion of the 
drug is located quite far from the included part of the drug, so the complexing ability is 
not significantly affected. Increased complexation (through KC) can also be achieved 
through non-covalent multicomponent associations between the CD, basic drug and the 
acid, such as when the hydroxy acid establishes both electrostatic interactions with the 
drug and hydrogen bonds with the hydroxyl groups of the CD.  For a review, see 
Loftsson et al., (1999) and Redenti et al., (2000).   
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1.7. CONCLUSION 
 
1.7.1. Safety issues 
 
A drug molecule needs to be water soluble to be readily delivered to the cellular 
membrane, but needs to be hydrophobic to cross the membrane.  Traditional 
formulation systems for insoluble or unstable drugs involve a combination of organic 
solvents, surfactants, and pH extremes (Thompson, 1997).  The ability of CDs to 
complex drugs enables the formulation of water-soluble drugs that are typically difficult 
to solubilize, stabilize, and deliver with the more traditional additives.  As α- and β-CD 
are parenterally unsafe due to nephrotoxicity, they are more likely to find use in oral 
products (Stella & Rajewski, 1997).  Because the major source of CD toxicity is related 
to their low aqueous solubility, the substituted CDs are generally less toxic to the kidney 
than their parent compounds (Yalkowsky, 1999).  While derivatization may decrease 
the problems associated with CD toxicity, and CD generally do not potentiate the 
toxicity of the tested compounds, they may influence the toxic effects of the solubilized 
compounds as they are more rapidly distributed throughout the organism (Pitha et al., 
1988).  
 
HPβCD is a useful solubilizing and stabilizing agent for a wide variety of poorly water-
soluble drugs.  While other CDs can provide similar complex formations, the fact that 
HPβCD is not parenterally toxic makes this material far more compatible with 
pharmaceutical dosage design, and will most likely become a widely used solubilizer 
and parenteral drug carrier (Brewster, 1992).  Strattan, (1992) has proposed dosage 
guidelines to avoid any toxic effects of HPβCD.  Toxic effects after oral administration 
are unlikely to appear when administered doses do not exceed 5-10 g kg
-1.  Parenterally, 
toxic effects are unlikely to appear in humans when administered doses do not exceed 
400 mg kg
-1 daily i.v. administration, possibly up to 1 g kg
-1 intermittent i.v. 
administration (after several days of no dosing, acute dosage levels become permissible 
again), or 1-5 g kg
-1 acute i.v. administration, with the exact dosage determined by 
vascular volume and renal parameters. However, while HPβCD is not acutely toxic after 
oral, i.v., i.p., i.m., topical or intracerebral administration,  it is necessary to evaluate the CHAPTER 1 
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toxicology of HPβCD/drug complexes as complexation affects drug distribution as well 
as its haemolytic  properties (Brewster et al., 1990).   
 
Another consideration is the ability of CDs to form complexes with endogenous 
compounds.  After oral administration CD complexes undergo dissociation, and as the 
CD is not absorbed by the tissue or otherwise consumed while delivering the drug, is 
then available to solubilize endogenous compounds in the gut.  Under laboratory 
conditions where the environment and food are standardized this generally does not 
present a problem.  However, many toxicants and carcinogens present in human food 
and environment are known to form complexes with CD and thus are of concern  (Pitha, 
1994).   
 
1.7.2. Applications 
 
As a result of complex formation, the characteristic properties of the included substance, 
such as solubility, chemical reactivity, pKa values, diffusion, electrochemical properties 
and spectral properties will be changed.  This has lead to the widespread utilization of 
CDs in pharmaceutical, food, chemical and other industrial areas (Szejtli, 1988).  In the 
pharmaceutical industry, almost all applications of CDs in pharmaceutical formulations 
involve complexation, either as solid crystalline form, or in an aqueous system, for drug 
delivery (Szejtli, 1991a).  However, CDs and their derivatives have also been used as 
auxiliary additives such as solubilizers, diluents, or tablet ingredients to improve 
physical or chemical properties (Li & Purdy, 1992).  CDs are also finding increased use 
in biotechnology. Generally, the uses of CDs in biotechnology have been to enhance 
bioavailability or stimulatory effects on metabolic processes, to protect microorganisms 
from toxic products, and as a substitute for more expensive components (Szejtli, 1992; 
Bar, 1996).   In analytical chemistry CDs also have a number of applications.   
Chromatographic separation and purification, electrochemical analysis and 
fluorescence, luminescence, NMR and UV-visible spectrometric analysis are just a few 
areas where CDs have found a use (Jones & Grant, 1984; Li & Purdy, 1992).  In the 
food, cosmetics, toiletry and tobacco industries, CDs have been widely used either for 
the stabilization of flavours and fragrances, or for the elimination of undesirable tastes, 
microbiological contaminants and other undesired components (Li & Purdy, 1992).  As CHAPTER 1 
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CD research continues, along with increased CD production and decreasing prices, the 
applications of CD and their derivatives will rapidly increase in a wide variety of 
industries.  Detailed reviews on the industrial applications of CDs can be obtained from 
Szejtli, (1982), Vaution et al., (1987), Szejtli, (1988) and Li & Purdy, (1992). 
 
There are many reviews covering the vast amounts of information concerning CDs, CD 
derivatives, complexation characteristics, toxicity, applications of CDs, approved 
products, CD analysis etc. More detailed information may be obtained from Szejtli, 
(1988), Connors, (1997), Irie & Uekama, (1997) and Thompson, (1997) and as 
otherwise stated throughout this literature review. 
 
1.8. RATIONALE AND AIM 
 
The purpose of this investigation is to formulate the antiparasitic agents albendazole, 
trifluralin and oryzalin with HPβCD, with the view of improving their aqueous 
solubility and hence, bioavailability. The efficacy of these formulations will be 
determined against the protozoan parasites Giardia duodenalis,  Cryptosporidium 
parvum and Plasmodium chabaudi (rodent malaria).  Both Giardia and 
Cryptosporidium infect the gastrointestinal tract, with Giardia attaching to the mucosa 
at the bases of the microvilla (Chapter 5), and Cryptosporidium predominately an 
intracellular parasite located at the luminal surface of the host epithelial cell (Chapter 6).  
In comparison, malaria causes systemic infections, invading the liver and RBCs 
(Chapter 7). Thus the current study will also investigate the role of CD as a drug carrier 
to protozoan parasites which inhabit different compartments within the body. 
 
Therefore this study will involve: 
 
1.  Formulating inclusion compounds between these agents and HPβCD.   
 
2.  Investigating the pharmacokinetics of these antiparasitic agents both alone and 
complexed.   
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3.  Investigating the cytotoxicity of HPβCD and these antiparasitic agents both 
alone and complexed.   
 
4.  Investigating the in vitro efficacy of HPβCD and these antiparasitic agents both 
alone and complexed against the protozoan parasites G. duodenalis, C. parvum 
and P. chabaudi.  
 
5.  Investigating the in vivo efficacy of HPβCD and these antiparasitic agents both 
alone and complexed against G. duodenalis and P. chabaudi. 
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2.1. INTRODUCTION 
 
2.1.1. Tubulin 
 
Microtubules occur in eukaryotic cells only and make up part of the cell cytoskeleton. 
They are vital for cell survival as they form the centrioles and mitotic spindles essential 
for cell division, the axoneme structures in flagella necessary for cell motility, are 
involved in special organization of the organelles in the cytoplasm, form the cilia, and 
contribute to the overall shape and integrity of the cell (Becker & Deamer, 1991).  
Microtubular structures also aid in intracellular transport, exo and endocytosis and 
secretory processes (Lacey, 1988).  Breakdown of the tubulin-microtubule equilibrium 
results in both direct and indirect biochemical and physiological changes, ultimately 
resulting in a loss of cellular homeostasis.   
 
Microtubules are polymeric hollow structures consisting of tubulin dimers. Tubulin 
comprises α- and β-subunits of approximately 50 kDa each.  Structurally, both α- and 
β-tubulin are heterogeneous proteins, products of multigene families as well as post-
transcriptional modifications (Lacey, 1990).  Microtubules exist in dynamic equilibrium 
with dimeric tubulin. The ratio of dimeric tubulin and polymeric microtubules is 
controlled by a range of co-factors such as endogenous regulatory proteins, GTP, Ca
2+ 
and Mg
2+ ions, and is temperature dependent. It is thought that tubulin dimers associate 
with the microtubule at one end and dissociate at the other, thus the microtubule 
undergoes continuous turnover (Lacey, 1990) (Figure 2.1).  This equilibrium can be 
altered in vitro and in vivo by microtubule inhibitors.  Microtubule inhibitors are a 
structurally diverse group of compounds produced by fungi, plants, marine organisms, 
possibly higher eukaryotic animals and, more recently, synthetically.  Most exert their 
action by binding to tubulin to prevent the self-association of subunits onto the growing 
microtubules.  This results in a ‘capping’ of the microtubule at the associating end while 
the microtubule continues to disassociate from the opposite end, with a net loss in 
microtubule length.  The microtubule cytoskeleton is the target site for many drugs. 
Some are used as antitumor agents (e.g. colchicine, taxol and vinblastine), as fungicides 
(e.g. benzimidazoles and griseofulvin) or as herbicides (e.g. dinitroanilines, 
phosphorothioamidates and N-phenyl-carbamates).  These anti-microtubule agents CHAPTER 2 
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generally have different affinities to tubulin from metazoan, protozoan, plant and algal 
cells (Anthony & Hussey, 1999).  Benzimidazoles and dinitroaniline derivatives are two 
examples of synthetic microtubule antagonists.  These bind to tubulin and prevent 
microtubule assembly, eventually resulting in the depolymerisation of microtubules. 
Comprehensive reviews of microtubule function can be obtained from Lacey, (1988) 
and Becker & Deamer, (1991). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Typical microtubules reach a dynamic equilibrium with tubulin, controlled 
by endogenous concentrations of co-factors such as GTP, Mg
2+, microtubule associated 
proteins (MAPs), Ca
2+ and calmodulin.  Regulation in vitro, by increasing temperatures, 
enhances polymerization, whereas reducing the temperature induces depolymerization.  
Addition of inhibitors causes ‘capping’ and halts polymerization, allowing only 
depolymerisation with the net loss of microtubule structure. Text and figure from Lacey, 
(1990). 
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2.1.2. Benzimidazoles 
 
Benzimidazoles are broad-spectrum drugs that exhibit a wide range of activities, such as 
anti-fungal, herbicidal, insecticidal, anti-bacterial and anti-protozoal effects, even 
showing activity against mammalian cells (Lacey, 1990).  While their main use has 
been anthelmintic, some have recently been used as anti-protozoal agents (Meloni et al., 
1990; Katiyar et al., 1994). Interest in the benzimidazole ring system as a basis for the 
development of potential chemotherapeutic agents was established in the 1950s when 
the compound 5,6-dimethyl-1-(α-D-ribofuranosyl)benzimidazole was found to be an 
integral part of the structure of vitamin B12.  Benzimidazole is a bicyclic ring system in 
which benzene has been fused to the 4- and 5-position of the heterocycle (Figure 2.2).   
 
 
 
 
 
Figure 2.2: Primary substituent positions of the benzimidazole anthelmintics 
(Gottschall et al., 1990; Townsend & Wise, 1990).  
 
Thiabendazole (TBZ) was discovered in 1961 and found to possess a remarkably broad 
spectrum of activity against gastrointestinal parasites. However its use was limited due 
to enzymatic hydroxylation at the 5-position, which limited its effectiveness, and due to 
its toxicity to humans.  To overcome this problem, benzimidazoles with structural 
modifications were designed to prevent metabolic inactivation. A combination of 
modifications at positions R2 and R5 of the molecule has provided the most active drugs. 
Modification at position R2 of TBZ resulted in the production of a number of 
compounds that possessed anthelmintic activity, with the 2-methylcarbamate derivative 
the most effective.  Following the introduction of this compound, additional drugs such 
as mebendazole (MBZ), flubendazole, ciclobendazole, albendazole (ABZ), 
oxibendazole, fenbendazole and oxfendazole were produced by several companies 
(Figure 2.3).  Prodrugs are also being developed with increased solubility, and thus can 
also be used against systemic infections.   They are appropriately substituted benzene 
molecules that can be enzymatically converted to an active benzimidazole carbamate 
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after absorption by the animal (Townsend & Wise, 1990). Examples of prodrugs are 
thiophanate (methyl), febantel and netobimin, all of which are converted to 
benzimidazole carbamates by the host.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Chemical structure of some of the benzimidazole anthelmintics  (Townsend 
& Wise, 1990).   
 
After oral administration the benzimidazole anthelmintics are extensively metabolised.  
The primary metabolism and toxicity of the benzimidazoles usually depends on the 
substituent present at R2 of the benzimidazole nucleus, and involves a wide variety of 
phase 1 reactions such as hydroxylation (TBZ and parbendazole), S-oxidation (ABZ and 
fenbendazole), and reduction (MBZ) (Gottschall et al., 1990).  Conjugation is also a 
frequent occurrence, and in some cases the conjugates become the predominant 
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products observed.  The metabolic profiles of individual benzimidazole anthelmintics 
follow similar patterns across species, but metabolite percentages do vary substantially.  
The elucidation of the metabolic profile of a specific compound becomes increasingly 
important for the understanding and evaluation of overall product safety (Gottschall et 
al., 1990).   
 
Currently there are only three benzimidazole compounds in human clinical practice; 
ABZ, MBZ and flubendazole (Horton, 1990).  These are both safe and highly effective 
in the treatment of the majority of intestinal helminth infections and are useful in 
individual and mass treatments (Horton, 1990).  However, due to their limited 
absorption and rapid metabolism, only high and prolonged doses are effective against 
human systemic infections such as hydatid disease and neurocysticercosis (Horton, 
1990).  Detailed reviews of the benzimidazoles can be obtained from Gottschall et al., 
(1990), McKellar & Scott, (1990), Townsend & Wise, (1990) and de Silva et al., 
(1997). 
 
2.1.2.1. Mode of action 
 
The benzimidazoles are thought to have a similar mode of action, which appears to 
involve their interaction with the eukaryotic cytoskeletal protein tubulin (Lacey, 1985).  
While most research previously focused on anthelmintic activity, recent investigations 
have found the benzimidazoles also bind to the tubulin of a number of protozoan 
parasites.  Benzimidazoles are thought to bind β-tubulin at the colchicine-binding site 
and have similar antimitotic and cellular effects to colchicine. The parasite tubulin-
benzimidazole complex, like the mammalian brain tubulin-colchicine complex, is 
pseudo-irreversible in that, although the binding is non-covalent, once bound the ligand 
cannot easily be removed without denaturing the protein (Lacey, 1990).  The potent 
inhibitory activity of benzimidazoles against parasites as opposed to host tissue is 
attributed to a higher affinity for parasite tubulin, as well as differing benzimidazole 
pharmacokinetics within the host and the parasite (Lacey, 1990; McKellar & Scott, 
1990).   
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Other reports disagree that the tubulin mechanism is the primary mode of action, instead 
proposing that the benzimidazoles act as lipid-soluble proton ionophores, resulting in 
bioenergetic disruptions (McCraken & Stillwell, 1991).  Alternatively the 
benzimidazoles are thought to disrupt enzymes of the respiratory pathways, therefore 
disrupting energy synthesis, resulting in insufficient ATP (Behm & Bryant, 1985).   
Other postulated modes of action are the inhibition of glucose, amino acid and fatty acid 
uptake, and inhibition of various metabolic enzymes such as malate dehydrogenase and 
fumarate reductase (Lacey, 1990; McKellar & Scott, 1990).  However, such effects are 
not seen in all parasites, which may reflect differential metabolic processes between 
parasites.  It is also proposed that the effect of benzimidazoles on tubulin 
polymerization and the biochemical effects on respiratory enzymes may be linked 
(McKellar & Scott, 1990). Despite the diverse effects of benzimidazoles at the 
biochemical and cellular levels, the primary action of these drugs appears to involve 
their interaction with the eukaryote cytoskeletal protein, tubulin.  Detailed reviews on 
the benzimidazole mode of action can be obtained from Lacey & Snowdon, (1988), 
McKellar & Scott, (1990) and Reynoldson et al., (1992).   
 
2.1.2.2. Resistance 
 
While benzimidazoles have been effective in the control of nematode parasites in 
livestock, benzimidazole drug resistance is becoming increasingly evident (Horton, 
1990; Waller, 1990; de Silva et al., 1997). Specific mutations in the β-tubulin gene have 
been implicated in mediation of both resistance and super-sensitivity to the 
benzimidazoles (Roos, 1990; Katiyar et al., 1994). However the relevance of these 
mutations is as yet unclear as the BZ binding site has not been identified. Difficulties in 
determining the benzimidazole-binding site arise because the mutations that confer 
benzimidazole resistance are scattered along the ß-tubulin molecule, along with those 
that lead to supersensitivity to benzimidazoles.  A possible reason for this may be that 
the benzimidazole-binding site spans several domains of the β-tubulin molecule, folded 
together into a specific conformation. There is also some evidence to suggest that these 
recessive mutations may already exist within parasite populations, and have been 
selected for by drug use.  For example, selection for thermosensitivity has produced β-
tubulin mutants with variable benzimidazole-binding properties.  One hypothesis is that CHAPTER 2 
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the variants that exist are functional at the different temperatures encountered by the 
different stages of the life cycle.  Further information on benzimidazole resistance can 
be found in the reviews of Lacey, (1988) and Roos, (1990).   
 
2.1.2.3. Albendazole  
 
ABZ is a benzimidazole carbamate with a broad anti-parasitic spectrum (Theodorides et 
al., 1976).  ABZ was first approved for treatment of helminth infections in sheep in 
1977, and subsequently approved for human use in 1983 (de Silva et al., 1997). In 
general, most ascariasis, trichuriasis, enterobiasis and hookworm infections can be 
successfully treated with single dose ABZ, and strongyloidiasis with multiple doses of 
ABZ.  ABZ has also used in the treatment of capillariasis, gnathostomiasis, and 
trichostrongyliasis, the cestode infections hydatidosis, taeniasis and neurocysticercosis, 
and the tissue nematodes cutaneous larval migrans, toxicariasis, trichinosis and filariasis 
(in combination with other anthelmintics).  ABZ has also been used successfully against 
mixed infections. Reviews on the efficacy of ABZ against a range of parasites can be 
obtained in Horton, (1989), Cook, (1990), de Silva et al., (1997) and Parfitt, (1999).    
Absorption of ABZ from the gastrointestinal tract is poor, so orally administered ABZ 
is of most value against intestinal nematodes.  Once absorbed however, the drug is 
rapidly metabolised in the liver before reaching the systemic circulation. The primary 
metabolite, albendazole sulfoxide, also has anthelmintic activity, and ABZ efficacy is 
attributed to this metabolite (Bogan & Marriner, 1984; Marriner et al., 1986; Hussar, 
1997).   
 
2.1.2.3.1. Characteristics  
ABZ is a colourless crystaline or white to faint yellow powder with a MW of 265.33 
(C12H15N3O2S) and mp between 208-210°C (Budavari, 1989; Parfitt, 1999). It is 
practically insoluble in water and alcohol, slightly soluble in ether and dichloromethane, 
and freely soluble in anhydrous formic acid (Parfitt, 1999).  Commercially sold under 
trade names such as Eskazole, Valbazen, Zentel, Zenteland, Albenza and Proftril   
(Budavari, 1989; Campbell, 1990). Present in both the Chinese and US pharmacopoeias 
(Parfitt, 1999). CAS-54965-21-8. 
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2.1.2.3.2. Metabolism 
Placement of a sulfur atom in the benzimidazole side chain has a major effect on 
metabolism (Gottschall et al., 1990).  The most important biotransformations are 
sulphur oxidation, oxidation and carbamate hydrolysis (Gyurik et al., 1981).  Oxidation 
to the sulfone is the primary metabolic reaction, with further metabolism of the sulfone 
by oxidation and carbamate hydrolysis (Figure 2.4). ABZ is metabolised to ABSO in 
the presence of microsomal flavin-containing monooxygenase and/or cytochrome P-
450.  The degree of involvement of P-450 versus MFMO varies, both between species 
and between tissues, depending on enzyme concentrations.  Unlike ABZ sulfoxidation, 
the oxidation to ABSO2 has been exclusively attributed to cytochrome P-450.  The 
sulfoxide and sulfone metabolites dominate the plasma profile and are also found as the 
major metabolites in the urine, although the exact proportion of each varies 
considerably among species.  However, in all species studied, ABZ itself was detected 
in only trace amounts. Other minor metabolic pathways include aromatic hydroxylation, 
and nitrogen and sulfur methylation.   It was also determined that ABZ can induce its 
own metabolism, by promoting cytochrome P-450 synthesis and activity.  Since ABSO 
has been implicated as both the active pharmacological and embryotoxic agent, enzyme 
induction has the potential to influence both the efficacy and overall product safety. 
More detailed reviews of ABZ metabolism can be obtained from Gyurik et al., (1981), 
Galtier et al., (1986) and Gottschall et al., (1990). 
 
2.1.2.3.3. Toxicity 
The oral LD50 of ABZ in rats is 2.4 g kg
-1 (Theodorides et al., 1976). Adverse effects 
reported include epigastric pain, diarrhoea, nausea and vomiting, headache, dizziness 
and rare allergic phenomena.  With higher doses and prolonged use, abnormalities in 
liver function, leucopenia and alopecia have also been reported (Davis et al., 1986; 
Morris & Smith, 1987; Horton, 1989; Teggi et al., 1993).  After very high oral doses 
ABZ has also been shown to be teratogenic in rats and rabbits, and this effect is thought 
to be associated with its antimicrotubular activity (McKellar & Scott, 1990)  (See 
further discussion in Chapter 7).  Both ABZ and ABSO exhibit embryotoxicity, but as 
the plasma concentrations of ABZ are negligible, embryotoxicity has been associated 
with the ABSO. Therefore ABZ should not be used in the first trimester of pregnancy 
(Delatour et al., 1981; de Silva et al., 1997). Adverse affects are rare at the dosages used CHAPTER 2 
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for the treatment of nematode infections.  The proposed dose rate in humans is 400 mg 
day
-1, which is considerably less than both the teratogenic and toxic dose (Bogan & 
Marriner, 1984). However, higher doses over extended periods of time are given for 
neurocysticercosis and hydatidosis (400mg twice daily with meals), with manufacturers 
recommending monitoring of liver function and WBC counts during treatment cycles 
(Smith et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: The main metabolic pathways for ABZ (modified from Gyurik et al., 1981). 
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2.1.3. Dinitroanilines 
 
The dinitroanilines were found to exhibit both fungicidal and herbicidal activity, with 
2,6-dinitroaniline possessing marked general herbicidal activity. 2,6-dinitroaniline 
exhibited both contact and pre-emergence herbicidal activity against multiple plant 
species, with selective herbicidal activity obtained by substitutions onto the amino 
group (Figure 2.5). The dinitroanilines were introduced in the 1960s as selective 
herbicides.  Trifluralin (TF) was the most prominent and first registered for use on a 
food crop in 1964 (Probst et al., 1975).  Subsequently a number of dinitroanilines have 
been produced for the selective pre-emergence control of a wide variety of grasses and 
broadleaf weeds.  For a general review of the dinitroaniline herbicides, see Probst et al., 
(1975). 
 
 
 
 
 
 
Figure 2.5: Substitution pattern of the 2,6-dinitroanilines (Probst et al., 1975). 
 
The nitroanilines are crystalline substances that are orange-yellow in colour.  The 
electron withdrawing properties of the nitro groups greatly decrease the water solubility 
and basicity of these compounds (Weber & Monaco, 1972). All of the dinitroaniline 
herbicides are soluble in most organic solvents, especially acetone, but have low 
aqueous solubility (Weber & Monaco, 1972).  Prosulfalin and oryzalin (OZ) are the 
most soluble at 5.6 ppm and 2.4 ppm respectively. All substituted dinitroanilines are 
weakly basic with pKa values less than 0, except OZ (Weber & Monaco, 1972).  
 
The dinitroanilines are all susceptible to photodecomposition, and are generally 
degraded in a similar pattern in soil, plants and animals. The dinitroanilines are 
degraded via oxidative and reductive pathways, as well as a variety of other reactions 
such as dealkylation, hydrolysis and cyclization  (Probst et al., 1975). Intermediates, 
including benzimidazole-type compounds, are detectable only in small amounts, 
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suggesting the rapid conversion to a mixture of polar products after the initial 
degradation steps (Probst et al., 1975; Helling, 1976). In addition, as nitro groups are 
strong hydrogen bonders, the nitroanilines are readily absorbed to proteinaceous 
substances such as hair and skin (Weber & Monaco, 1972). 
 
2.1.3.1. Mode of action 
 
The primary mode of action of the dinitroanilines against plants is via tubulin 
antagonism (Bartels & Hilton, 1973; Hess & Bayer, 1974; Struckmeyer et al., 1976; 
Parka & Soper, 1977; Upadhyaya & Nooden, 1978).  OZ has been used as a model 
dinitroaniline due to its higher aqueous solubility, and has been found to bind to tubulin, 
but not intact microtubules (Strachan & Hess, 1983).  This causes rapid dissociation of 
dimers from the microtubule both in vitro and in vivo (Bajer & Molè-Bajer, 1986; 
Morejohn et al., 1987).  These drugs have also been found to affect Ca
2+ transport, but 
at significantly higher concentrations (Hertal et al., 1980; Bajer & Molè-Bajer, 1986).  
The dinitroanilines have different affinity for tubulin from different organisms, and 
appear to have little effect on mammalian microtubules.  Recently the microtubules of 
certain parasites have been found susceptible to the dinitroanilines, and this finding has 
lead to the suggestion that the dinitroanilines may be used for the chemical control of 
these parasites. Leishmania, Toxoplasma gondii, Cryptosporidium parvum and malaria 
are protozoan parasites that have been found to be susceptible to the dinitroanilines 
(Chan et al., 1993a and b; Stokkermans et al., 1996; Arrowood et al., 1996; Bell, 1998; 
Benbow et al., 1998; Armson et al., 1999b). 
 
2.1.3.2. Resistance 
 
Although the dinitroanilines have been used extensively and in a sustained manner, only 
a few examples of herbicide resistance in weeds have been recorded.  The development 
of dinitroaniline resistance is rare, but once established in the natural population, 
spreads rapidly.  Resistance appears to be inherited as a single nuclear recessive gene, 
but there is evidence of semi-dominance as heterozygous plants also have a degree of 
resistance. The molecular basis for the resistant phenotype is a mutation in α-tubulin 
(Anthony et al., 1998). As the development of resistance to other anti-microtubule CHAPTER 2 
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agents from mutations in either α- or β-tubulin has resulted in either resistance or super 
sensitivity of the organism to the dinitroanilines, it is proposed that these mutations 
might form part of the dinitroaniline-binding site, with the mechanism for resistance due 
to increased microtubule stability rather than alteration in a specific drug-binding site.  
For a review on the dinitroaniline mode of action and herbicide resistance, see Anthony 
& Hussey, (1999).   
 
2.1.3.3. Trifluralin 
 
TF is a soil-incorporated herbicide that controls a variety of grasses and broadleaf 
weeds (not established weeds) and was first marketed for use on cotton in 1963 
(Helling, 1976). Tolerant crops include soybeans, cotton, sugarcane, various bean and 
pea crops, safflower, rape seed, sugar beet, cantaloupes, sunflower, potato, nuts, 
established alfalfa, wheat, as well as some fruits, vegetables and ornamentals (Tepe & 
Scroggs, 1967; Helling, 1976).  TF was initially considered as the model for 
dinitroaniline herbicide studies, but due to its very low water solubility and its capacity 
to bind to glass, this needed to be re-evaluated.  It was therefore recommended that OZ 
be considered as the model dinitroaniline for in vitro studies as OZ concentrations 
remain constant in aqueous solutions (Strachan & Hess, 1982). 
 
2.1.3.3.1. Characteristics 
TF (Figure 2.6) is a yellow-orange crystal with a MW of 335.29 (C13H16F3N3O4) and a 
mp of 46-47°C (Budavari, 1989). It is freely soluble in acetone, chloroform, acetonitrile, 
toluene and ethyl acetate, and is practically insoluble in water (<0.05 ppm) (Tepe & 
Scroggs, 1967; Weber & Monaco, 1972; Tomlin, 1994). The compound is 
commercially sold as a herbicide under trade names such as Treflan, Triflurex, Olitref, 
Tri-4, Trigard, Triplen, Tristar and Zeltoxone (Budavari, 1989; Tomlin, 1994).  CAS-
1582-09-8. The ultraviolet absorption of dilute methanolic solutions exhibits maxima at 
275 and 376µm (Tepe & Scroggs, 1967).  
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Figure 2.6: Structure of trifluralin (Budavari, 1989). 
 
2.1.3.3.2. Degradation 
In soil, plants and animals, TF is extensively and rapidly degraded by N-dealkylation, 
nitro reduction, aliphatic hydroxylation and cyclization (Figure 2.7), resulting in the 
continuous accumulation of a heterogeneous mixture of polar products (Emmerson & 
Anderson, 1966; Probst et al., 1967; Golab et al., 1969; Erkog & Menzer, 1985).  In 
comparison, photodecomposition mainly involves N-dealkylation, nitro reduction and 
cyclization (Leitis & Crosby, 1974).   Following oral administration, TF is poorly 
absorbed and extensively metabolised within the gut, with complete elimination in the 
urine and faeces (up to 80%). Low tissue residues are also observed following oral 
administration (Golab et al., 1969; Erkog & Menzer, 1985).  With increasing dose size, 
the proportion of TF and metabolites excreted in the faeces increases, indicating 
saturation of TF absorption and urinary excretion systems (Erkog & Menzer, 1985).  
While the majority of TF metabolites are unidentified polar compounds, the principal 
identifiable metabolites in faeces result from nitro reduction, and in urine from nitro 
reduction and N-dealkylation (Emmerson & Anderson, 1966; Golab et al., 1969). In 
vitro the predominant metabolic pathway is aliphatic hydroxylation and N-dealkylation 
(Nelson et al., 1977).  However, the number of metabolites and significance of the 
various pathways varies with dose size (Erkog & Menzer, 1985).  Conjugation reactions 
have also been reported, as well as the production of benzimidazoles through N-
dealkylation and cyclization reactions (Nelson et al., 1977; Erkog & Menzer, 1985).   
NO2
NO2
N F3C
CH2CH2CH3
CH2CH2CH3CHAPTER 2 
__________________________________________________________________________________________________________ 
  55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Three pathways for TF metabolism are nitro reduction, N-dealkylation and 
hydroxylation.  Intermediates of these processes are common, such as (8), resulting 
from both nitro reduction and N-dealkylation. These metabolites often undergo further 
metabolism, such as (9), resulting from oxidative dealhylation of the reduced drug, 
ultimately producing a benzimidazole (Emmerson & Anderson, 1966; Erkog & Menzer, 
1985; Golab et al., 1969; Nelson et al., 1977). 
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Parenteral TF administration results in the accumulation of TF and its metabolites in fat.  
This is particularly so for fat at the site of administration, where TF may be localized 
(Emmerson & Anderson, 1966; Golab et al., 1969; Heck et al., 1977).  Heck et al., 
(1977) also found that i.p. administered TF was not detectable in most plasma samples 
and suggested that TF was strongly tissue bound. The oral route of administration 
results in relatively little systemic absorption of the unchanged herbicide, while 
parenteral studies reveal that once absorbed, the compound and its metabolites may 
persist in fat for lengthy periods of time. 
 
2.1.3.3.3.  Toxicity 
Due to the extensive use of TF as a herbicide, the toxicology of TF has been extensively 
studied and reviewed (Robens, 1980; Ebert et al., 1992; Byrd et al., 1995). TF has a low 
acute toxicity in rats, mice and dogs, with LD50 values of approximately 2, 5 and >10 g 
kg
-1 respectively (Ebert et al., 1992).  However age is an important factor, with an oral 
LD50 in 1-2 day old rats of 500 mg kg
-1, while in 49-56 day old rats the LD50 is 36.5 g 
kg
-1 (Goldenthal, 1971).  Adverse effects observed in rats and mice included motorial 
activity, squatting, bristled fur, abdominal position, passivity, trembling, mydriasis, 
exophthalmos and increased lacrimation (Ebert et al., 1992).  In subchronic studies, 
depression of body weight and food consumption, and alopecia was observed (Byrd et 
al., 1995).  In addition, a yellowish to orange-brown discolouration of the urine and 
abdominal fatty tissue was observed (Ebert et al., 1992; Byrd et al., 1995).  The main 
target organs for TF toxicity are red blood cells and to a lesser extent, the liver, which 
was reversible after a two-week recovery period (Ebert et al., 1992).  In developmental 
studies, TF also resulted in the depression of body weights in both mothers and foetuses 
(Ebert et al., 1992; Byrd et al., 1995).  However, no interference with fertility, 
reproductive performance, gestation, lactation, growth or maturation were noted, and no 
teratogenic effect was observed (Ebert et al., 1992).  Long-life feeding with TF at levels 
that caused marked decreases in body weights and anaemia did not produce a general 
increase in tumours and indicated no carcinogenic effects (when free of nitrosamines) 
(Ebert et al., 1992). While some studies have shown TF to be carcinogenic, this has 
been attributed to the contaminant dipropylnitrosamine, which is a liver, oesophagus 
and tongue carcinogen (Robens, 1980).  
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2.1.3.4. Oryzalin 
 
The herbicidal properties of OZ were first reported in 1969.  The compound is used to 
control most annual grasses and broad leaf weeds such as carpetweed, purslane, 
lambsquarters and pigweed.  Tolerant crops include soybean, cotton, fruit trees, nut 
trees, peanuts, oilseed rape, sunflowers, alfalfa, peas, sweet potato, mint and 
ornamentals (Decker & Johnson, 1976; Tomlin, 1994).   
 
2.1.3.4.1. Characteristics 
OZ (Figure 2.8) is a yellow-orange crystal with a MW of 346.36 (C12H18N4O6S), mp of 
137-138°C and pKa of 9.4 (Budavari, 1989; Tomlin, 1994). It is soluble in acetone, 
ethanol, methanol and acetonitrile, slightly soluble in benzene, and insoluble in hexane.  
Its aqueous solubility at 25°is 2.5 ppm (Budavari, 1989), and it is commercially sold as 
a herbicide under trade names such as Dirimal, Ryzelan and Surflan (Decker & 
Johnson, 1976; Budavari, 1989).  CAS-19044-88-3. The ultraviolet absorption of dilute 
methanolic solutions exhibits maxima at 283 and 383µm (Decker & Johnson, 1976).  
 
 
 
 
 
 
 
Figure 2.8: Structure of OZ (Budavari, 1989). 
 
OZ exhibits acidic properties, being highly soluble in alkaline solutions and titratable 
with a strong base in a non-aqueous media (Decker & Johnson, 1976).  The higher 
water solubility and weakly acidic properties of OZ are thought to result from the 
substitution of the slightly ionisable aminosulfonyl group at R4 (Weber & Monaco, 
1972).  OZ is also one of the least volatile dinitroanilines, due to the sulfonyl at R4 
(Helling, 1976). 
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2.1.3.4.2. Degradation and toxicity 
Despite the extensive use of OZ as a herbicide, there are few published reports on the 
absorption, metabolism or elimination of OZ in animals.  As OZ and TF share similar 
chemical structures (except at R4), it is susceptible to the same degradation reactions in 
sunlight, soil, plants and animals (Section 2.1.3.3.2) (Golab et al., 1975; Helling, 1976).  
Additional reactions involving the R4 group include its conversion from a sulfonamide 
(-SO2NH2) to sulfanilic acid (-SO3H) (Golab et al., 1975). Oral administration of OZ 
results in the elimination of OZ and its metabolites from the body within 72 hours in the 
faeces and urine (Tomlin, 1994).  Plasma concentrations of OZ are low and has been 
attributed to either poor drug absorption or first pass metabolism (Dvorakova et al., 
1997).    Following oral and i.p. administration, OZ is metabolised in the liver to its 
major metabolite, N-depropyl oryzalin, which is cleared from the body more rapidly 
than the parent compound (Dvorakova et al., 1997).     
 
OZ has a low acute toxicity, with an LD50 in adult rats and gerbils of greater than 10 
g kg
-1 (Decker & Johnson, 1976) and in cats and dogs, 1 and >1 g kg
-1 respectively 
(Tomlin, 1994). In addition, dermal and optical exposure of rats, and subchronic doses 
in dogs caused no adverse effects.  OZ has been identified as an inhibitor of mitogen 
and growth factor-mediated intracellular free Ca
2+ signalling in mammalian cells 
(Dvorakova et al., 1997; Powis et al., 1997). Subsequently, OZ was revealed to exhibit 
anti-tumour activity in vitro and in vivo.  N-depropyl oryzalin also revealed similar anti-
tumour activity to the parent compound in vitro.  However, the anti-tumour activity of 
OZ and its major metabolite was not observed against established tumours in vivo 
(Powis et al., 1997).   
 
2.1.4. Improving drug efficacy through formulation design 
 
With the development of resistance to the current chemical classes of broad-spectrum 
anthelmintics, and the absence of a new effective class of antiparasitic agents on the 
horizon, existing drugs must be used more efficiently (Section 1.1).   While 
benzimidazole resistance is developing, numerous techniques are available to restore 
efficacy. As the benzimidazoles are rapidly metabolised and removed from the body, 
increased efficacy can be achieved with increased systemic duration as well as increased CHAPTER 2 
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systemic concentration (Waller, 1990; Hennessy, 1997).  In addition, the efficacy of 
ABZ against systemic parasite infections such as hydatid disease and neurocysticercosis 
would be vastly improved.  The low water solubility and poor absorption of ABZ from 
the gastrointestinal tract results in low bioavailability and reduced efficacy against 
systemic parasites.  In the absence of new and improved anti-hydatid drugs, the focus 
has been on increasing ABZ solubility and absorption from the gastrointestinal tract, 
improving ABZ transport and targeting, and altering ABZ pharmacokinetics by 
modulation of the metabolic decomposition of benzimidazoles. Examples of the 
techniques applied to achieve these goals can be found in Kwan et al., (1988), Lange et 
al., (1988), Jung et al., (1990), Lanusse & Prichard, (1991 and 1992), Yang & Fung, 
(1991), Barger et al., (1992), del Estal et al., (1993), Justel et al., (1994), New et al., 
(1994), Rodrigues et al., (1995), Wen et al., (1994, 1996a and b), Torrado et al., (1996a, 
b and 1997), Hussar, (1997), Sarciron et al., (1997), Domínguez et al., (1998), Redondo 
et al., (1998) and Savio et al., (1998).  In a similar manner, these techniques can be 
applied to other insoluble and poorly absorbed compounds such as the dinitroanilines. 
 
2.1.5. Aim 
 
The purpose of this investigation is to formulate the antiparasitic agents albendazole, 
trifluralin and oryzalin with ΗPβCD by forming inclusion compounds, with a view to 
provide an alternative oral formulation, and to potentially formulate these agents in 
parenteral forms.  This will involve: 
 
1.  Formulating inclusion compounds between these agents and ΗPβCD. 
 
2.  Increasing drug solubility using techniques such as temperature and pH 
manipulation. 
 
3.  Investigation of the formation of inclusion compounds using DSC-TGA 
analysis. CHAPTER 2 
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2.2. METHODS 
 
2.2.1. Phase-solubility analysis 
 
In solution an inclusion compound is always in kinetic or thermodynamic equilibrium 
with its free components, with this equilibrium expressed by the stability constant (KC).  
Phase solubility (Section 1.6.1) analysis allows the study of the dependence of guest 
solubility on CD concentration, and may be used to determine the stability constant of 
the complex. The KC was determined as described by Higuchi & Connors, (1965) and 
Grant & Higuchi, (1990) from the slope and the intercept SO (in M
-1) of equilibrium 
plots according to the following equation: 
slope) - (1 [S]
Slope
  =   K
0
1 : 1  
 
The molecular weight of ΗPβCD was calculated as described in section 1.5.1  (See 
Appendix 10.1). 
 
2.2.2. Albendazole/ΗPβCD complex formulation  
 
2.2.2.1. HPLC conditions 
 
The HPLC system consisted of a GBC HPLC pump (model LC 1120) and a Rheodyne 
valve injector (model 7125) fitted with a 20 µL loop.  The chromatography was carried 
out using a 300 x 3.9 mm Phenomemex (Torrence USA) Bondclone 10 µm C18 reverse 
phase column.  Detection of ABZ was carried out using a GBC UV/Vis detector (model 
1200) at a wavelength of 295 nm (UV spectrum figure 2.9). The chromatography was 
recorded using a Hewlett Packard integrator (model 3396 A) and the peak area was 
integrated.  The mobile phase consisted of 40% tetrahydrofuran, 1% formic acid and 
59% water (v/v/v) filtered through Millipore filters (0.45 µm, type FHUP).  The 
retention time for ABZ was 3.8 min with a flow rate of 1.5 mL min
-1 (Figure 2.10). 
ABZ was quantified using a calibration curve.  
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2.2.2.2. Detection and quantitation limits 
 
The limit of detection (LOD) for ABZ was calculated at three times the baseline noise 
and was 15 ng mL
-1.  The limit of quantitation (LOQ) was calculated at five times the 
baseline noise and was 20 ng mL
-1.  These are standard procedures for determining the 
LOD and LOQ. 
 
 
Figure 2.9: UV spectrum of ABZ (10 µg mL
-1) in DMSO/methanol (0.5:99.5 v/v). 
 
 
 
 
Figure 2.10: Chromatogram of ABZ (10µg mL
-1 Att. 7), mobile phase consisted of 
40% tetrahydrofuran, 1% formic acid and 59% water (v/v/v). 
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2.2.2.3. ABZ/ΗPβCD complex formation analysis 
 
Phase solubility analysis of ABZ and ΗPβCD was carried out by equilibrating excess 
ABZ in 10 mL solutions of between 1-10% ΗPβCD (w/v) in triplicate in borosilicate 
tubes. The samples were then incubated in a Lab-Line orbit incubator-shaker (model 
3529-1) at 25˚C for two days before the samples were filtered (Gelman GHP 25 mm 
acro disc), diluted appropriately with mobile phase, and 20 µL then submitted for HPLC 
analysis.  ABZ was quantified by a calibration curve.  
 
The effect of temperature and filtration on ABZ concentration was investigated by 
dissolving ABZ (100µg mL
-1) in 6% ΗPβCD (w/v), followed by filtration or incubation 
at 37˚C, 42˚C and 45˚C and 121˚C (autoclave). Treated samples were subsequently 
compared to the original sample. 
 
The ABZ/ΗPβCD complex concentration needed to be amplified for biological 
experiments.  Therefore excess ABZ was added to a 20 mL solution of 74% ΗPβCD 
(w/v) in water and incubated at 35˚C for seven days before gentle filtration (0.2µm).  A 
sample was diluted with mobile phase and analysed as above. The ABZ/ΗPβCD 
solution was stored at 4˚C and the concentration was checked before all experiments to 
ensure its stability.  
 
2.2.2.4. Effect of pH on ABZ solubility 
 
To determine the effect of pH on ABZ solubility, excess ABZ was added to 10 mL 
solutions of 50 mM phosphate buffer at pH's 1.2-10 (n=2) in borosilicate tubes. The 
samples were then rotated on a rotary mixer (Selby) at room temperature for two days 
before the samples were filtered (0.45µm) and pH determined. Samples were diluted 
appropriately with mobile phase and analysed as above. 
 
2.2.2.5. Effect of pH on ABZ/ΗPβCD complex formation  
 
Buffer selection was based on the amount of interference with spectrophotometry, 
effectiveness in the pH ranges being investigated and in vivo toxicity (Perrin & CHAPTER 2 
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Dempsey, 1974; Yalkowsky, 1999).  Excess ABZ was added to 10 mL samples of 0, 10 
and 20% ΗPβCD (w/v) solutions made up in 50 mM phosphate buffer or 50 mM citric 
acid buffer at pH 2, 2.5 and 3. Samples were rotated on a rotary mixer (Selby) at 35˚C 
and ABZ added until samples contained excess ABZ. Once achieved the samples were 
incubated at room temperature for two days before samples were filtered, pH 
determined, and analysed as above. 
 
After optimisation of buffer strength, the above was repeated at between 0-50% ΗPβCD 
(w/v) at pH 2 (500 mM phosphate buffer). After determination of pH samples were 
analysed as above.  
 
For in vivo experimentation, the ABZ/ΗPβCD complex was made up in 100 mL 60% 
ΗPβCD (w/v) in 200mM phosphate buffer (pH 2.1) and incubated at 35˚C for one week 
before filtration.  After measurement of pH, ABZ concentration was determined as 
above. The ABZ/ΗPβCD solutions were stored at 4˚C and the concentration checked 
before all biological experiments to ensure their stability. 
 
2.2.3. Trifluralin/ΗPβCD complex formulation  
 
2.2.3.1. HPLC conditions 
 
The HPLC system was as described for ABZ (Section 2.2.2.1).  The chromatography 
was carried out using a 150 x 3.9 mm Waters Nova Pak C18 reverse phase column and 
detection of the TF was carried out at a wavelength of 273 nm (UV spectrum Figure 
2.11). The mobile phase consisted of 65% acetonitrile and 35% water (v/v) filtered 
through 0.45 µm filters.  The retention time for TF was 4.3 min with a flow rate of 2 mL 
min
-1 (Figure 2.12).  TF was quantified by a calibration curve. 
 
2.2.3.2. Detection and quantitation limits 
 
The LOD of TF was calculated at three times the baseline noise and was 15 ng mL
-1.  
The LOQ was calculated at five times the baseline noise and was 25 ng mL
-1. 
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Figure 2.11: UV spectrum of TF (10 µg mL
-1) in methanol. 
 
 
 
 
 
 
 
Figure 2.12: Chromatogram of TF (4µg mL
-1 Att. 4), phase consisted of 65% 
acetonitrile and 35% water (v/v). 
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2.2.3.3. Measurement of TF  
 
The effects of glass, plastic, light, filtration and methanol concentration on TF 
availability were investigated. A 1 µg mL
-1 TF sample in 10% methanol and added to 
both borosilicate tubes and plastic centrifuge tubes wrapped in alfoil, borosilicate tubes 
left in light, and compared to TF samples (1 µg mL
-1) dissolved in 40% and 70% 
methanol wrapped in alfoil.  All samples were rotated on a rotary mixer for up to 5 h. 
Methods devised for the measurement of TF were also used for the measurement of OZ. 
 
2.2.3.4. TF/ΗPβCD complex formation 
 
Phase solubility analysis of TF and ΗPβCD was carried out by incubating excess TF 
was added to 10 mL solutions of between 2-10% ΗPβCD (w/v) in triplicate in 
borosilicate tubes wrapped in alfoil. The samples were then incubated in a Lab-Line 
orbit incubator-shaker at 25˚C for two days after which the samples were centrifuged at 
2000 g for 10 min.  A sample was then added to equal volumes of 50% methanol and 20 
µL submitted for HPLC analysis using a glass syringe.  TF was quantified by a 
calibration curve. 
 
The TF/ΗPβCD complex concentration needed to be amplified for drug experiments.  
Therefore excess TF was added to a 10 mL solution of 75% ΗPβCD (w/v) in water and 
incubated at 35˚C for two days before centrifugation at 2000 g for 10 min.  A sample 
was diluted appropriately with 50% methanol and analysed as above. The TF/ΗPβCD 
solution was stored at 37˚C and the concentration was checked before all experiments to 
ensure its stability. 
 
2.2.3.5. Effect of pH on TF solubility 
 
To determine the effect of pH on TF solubility, excess drug was added to 10 mL 
solutions of 50 mM phosphate buffer (pH 4-10) (n=1) in borosilicate tubes wrapped in 
alfoil. The samples were then rotated on a rotary mixer at room temperature for two 
days before the samples were centrifuged at 2000 g for 10 min. Samples were analysed 
as above. CHAPTER 2 
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2.2.4. Oryzalin /ΗPβCD complex formulation  
 
2.2.4.1. HPLC conditions 
 
The HPLC system was as described in section 2.2.2.1.  Detection of the OZ was carried 
out at a wavelength of 282 nm (UV spectrum figure 2.13) and the mobile phase 
consisted of 50% acetonitrile and 50% water (v/v) filtered through 0.45 µm filters.  The 
retention time for OZ was 3.2 min (Figure 2.14) with a flow rate of 2 mL min
-1. For pH 
experiments the mobile phase was 50% acetonitrile and 50% 100 mM phosphate buffer 
pH 3 (v/v), with a retention time of 3 min (Figure 2.15).  OZ was quantified by a 
calibration curve. 
 
2.2.4.2. Detection and quantitation limits 
 
The LOD of OZ was calculated at three times the baseline noise and was 10 ng mL
-1.  
The LOQ was calculated at five times the baseline noise and was 15 ng mL
-1. 
 
2.2.4.3. OZ/ΗPβCD complex formation 
 
Phase solubility analysis of OZ and ΗPβCD, and the OZ/ΗPβCD formulation for in 
vitro experiments was determined as described for TF (Section 2.2.3.4).  
 
The effect of autoclaving on OZ/ΗPβCD complex formation/degradation was 
investigated by analysis of an OZ/ΗPβCD solution in 10% ΗPβCD (w/v) before and 
after autoclaving. Excess OZ in 75% ΗPβCD (w/v) was also autoclaved to determine 
the maximum OZ concentration achievable. Samples were analysed as above. 
 
2.2.4.4. Effect of pH on OZ solubility 
 
The effect of pH on the solubility of OZ was determined at pH 2-12  (n=2), as described 
for TF (Section 2.2.3.5). Drug concentration was determined as above. 
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Figure 2.13: UV spectrum of OZ (10 µg mL
-1) in methanol. 
 
Figure 2.14: Chromatogram of OZ (50µg mL
-1 Att. 9), mobile phase consisted of 50% 
acetonitrile and 50% water (v/v). 
 
 
Figure 2.15: Chromatogram of OZ (10µg mL
-1 Att. 7), mobile phase consisted of 50% 
acetonitrile and 50% 100 mM phosphate buffer pH 3 (v/v). 
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2.2.4.5. Effect of pH on OZ/ΗPβCD complex formation 
 
Solubility studies were carried out over varying pH and ΗPβCD concentrations. Excess 
OZ was added to 10 mL samples of 0, 10 and 20% ΗPβCD (w/v) solutions made up in 
50 mM phosphate buffer or 100 mM phosphate buffer at pH's 10.5, 11, 11.5, 12 and 
12.5. Initial samples were rotated on a rotary mixer (in alfoil) at 35˚C and OZ added 
until samples contained excess OZ. Once achieved the samples were incubated at room 
temperature for two days before samples were centrifuged at 2000g for 10 min and pH 
determined. Samples were diluted appropriately with 50% methanol and analysed as 
above.  As both ΗPβCD and OZ were found to decrease pH once added to solutions, 
buffer strength needed to be increased.  However, buffer solubility decreased with 
increasing  ΗPβCD concentration at high pH values.  Therefore a maximal buffer 
strength was selected for the requirements of each experiment. 
 
To further investigate the interaction between OZ and ΗPβCD, excess OZ was added to 
3 mL samples of 0-30% ΗPβCD (w/v) solutions made up in 500 mM phosphate buffer 
at pH 11.4.  Samples were incubated at 35˚C for 1 week followed by 2 days incubation 
at room temperature. Samples were centrifuged before dilution with 50% methanol and 
analysed as above. 
 
For in vivo experimentation, the OZ/ΗPβCD complex was made up in 20 mL 60% 
ΗPβCD (w/v) in 200mM phosphate buffer (pH 11.2) and incubated at 35˚C for two 
days (in alfoil) before centrifugation at 2000 g for 10 min.  The final pH was determined 
before samples were diluted with 50% methanol and analysed as above. The 
OZ/ΗPβCD solutions were autoclaved, cooled to 37˚C, and the concentration checked 
before all biological experiments to ensure stability. 
 
2.2.5. Verification of complex formation 
 
Complex formation was assessed by Differential Scanning Calorimetry (DSC) and 
Thermogravimetry Analysis (TGA) (Section 1.6.2).  Analysis was carried out using a 
SDT 2960 Simultaneous DSA-TGA (TA Instruments) with the software Instrument 
Analysis: Thermal Solutions (Version 1.4E) and Universal Analysis for Windows CHAPTER 2 
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95/98/NT (Version 2.5) (TA Instruments, Release Version 2.5). The temperatures 
ranged from 17˚C to 600˚C with a heat flow of 10˚C/min for ABZ and OZ, and 5˚C/min 
for ΗPβCD and drug/ΗPβCD complexes. 
 
2.2.6. Glassware 
 
All glassware used in drug analysis was cleaned with water and methanol to remove 
excess drug and ΗPβCD.  The glassware was then soaked in chromic acid for a 
minimum of two hours before rinsing in Millipore water. 
 
2.2.7. Statistical analysis 
 
Data analysis was carried out using linear regression, non-linear regression (exponential 
growth or sigmoidal dose response curves) or one way ANOVAs with Bonferinni’s post 
test as appropriate, as indicated in the results.  Analysis was performed using GraphPad 
Prism version 3.0a for Macintosh, GraphPad Software, San Diego California USA.   CHAPTER 2 
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2.3. RESULTS 
 
2.3.1. Albendazole/ΗPβCD complex formulation 
 
2.3.1.1. Effect of ΗPβCD on ABZ solubility 
 
ABZ was found to be practically insoluble in water, with approximately 0.29 µg mL
-1 
ABZ dissolved. The solubility of ABZ increased linearly with ΗPβCD concentration, 
corresponding to an AL phase diagram (linear regression, r=0.9997) (Figure 2.16). The 
apparent stability constant (KC) was determined with the assumption that the complex 
formed was of a 1:1 molar ratio of ABZ and cyclodextrin as described by Higuchi & 
Connors, (1965) and Grant & Higuchi, (1990), and had a KC of 9940 M
-1 at 25°C.  A 
10%  ΗPβCD (w/v) solution was capable of dissolving approximately 200 µg mL
-1 
ABZ, a 670 fold increase. 
 
 
Figure 2.16: Solubility of ABZ in the presence of ΗPβCD after 48 h at 25˚C (mean ± 
SE, n=3). 
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Temperature was found to affect ABZ concentrations at temperatures greater that 42˚C, 
while filtration had no effect (Table 2.1).  A degradation product was observed in the 
samples that were treated above 45˚C, with a retention time of 2.66 min. 
  
Table 2.1: The effect of temperature and filtration on ABZ solutions. 
Conditions: 37˚C 42˚C 45˚C Autoclaved  filtered 
ABZ (% of original)  100  99.8  94.8  75.9  100 
Degradation product  -  -  9  9  - 
 
The ABZ/ΗPβCD complex needed to be synthesised in sufficient concentrations for in 
vitro and in vivo drug experiments.  Incubation of excess ABZ in 74% ΗPβCD (w/v) at 
35°C for one week resulted in a substantial increase of ABZ solubility, with a final 
concentration of 2.98 mg mL
-1 (11.2 mM).  The molar ratio of ABZ to ΗPβCD was 
1:46. This solution was found to be extremely stable, with no precipitation of ABZ from 
a sample stored at 4˚C for 3 years. However, to investigate the efficacy of the 
ABZ/ΗPβCD complex against malaria in vivo, it was necessary to produce the 
ABZ/ΗPβCD complex at an ABZ concentration in excess of 15 mg mL
-1.  As these 
concentrations were not achieved, the effect of pH on ABZ complex formation was 
investigated. 
 
2.3.1.2. The effect of pH on ABZ/ΗPβCD complex formation 
 
Figure 2.17 shows the pH-solubility profile for ABZ in the absence of ΗPβCD. At pH 
values less than 3, ABZ solubility was found to increase exponentially (exponential 
regression, r=0.998). 
 
The effect of pH on the ABZ/ΗPβCD complex was investigated in an attempt to further 
increase the concentration of the ABZ/ΗPβCD complex.  Solubility studies were carried 
out comparing phosphate buffer and citric acid buffer at varying pH and ΗPβCD 
concentrations. A synergistic increase in ABZ solubility was observed with decreasing 
pH and increasing ΗPβCD concentrations for both the phosphate and citric acid 
buffering systems (Figures 2.18  and 2.19). However, a difference between the 
solubilizing power of the two systems was observed (one way ANOVA with 
Bonferonni’s post test) (Table 2.2). CHAPTER 2 
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Figure 2.17: Effect of pH (50 mM phosphate buffer) on ABZ solubility after 2 days at 
room temperature (mean ± SE, n=2). 
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Figure 2.18: Solubility of ABZ with varying pH and ΗPβCD concentrations (50 mM 
citric acid, n=1). 
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Figure 2.19: Solubility of ABZ with varying pH and ΗPβCD concentrations (50 mM 
phosphate buffer, n=1). 
 
Table 2.2: One way ANOVA of ABZ solubility, pH and ΗPβCD concentration. 
Compared data  
(Bonferonni’s multiple comparison test) 
Significantly 
different 
Expected 
Between 0, 10, 20% ΗPβCD data within each system  Yes, p<0.001  Yes 
Between 0, 10, 20% ΗPβCD data between each system  Yes, p<0.001  Yes 
Between equivalent data sets across each system 
0:0
10:10
20:20
 
No, p>0.05 
No, p>0.05 
Yes, p<0.01 
 
Yes 
Yes 
No 
 
As there was a significant difference observed between the two systems at a 
concentration of 20% ΗPβCD, the data for the buffering systems could not be 
amalgamated. Based on results of the ANOVA and figures 2.18 and 2.19, the phosphate 
buffering system was seen to be the more successful system and hence subsequently 
used in preference to the citric acid buffering system.  To further investigate the 
interactions between pH adjustment and ΗPβCD concentration, the data for the 
phosphate buffering system was plotted as ABZ solubility at each ΗPβCD 
concentration over varying pH (Figure 2.20).  Again ABZ solubility was observed to 
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increase exponentially with decreasing pH at each ΗPβCD concentration. From the 
above figures the expected ABZ solubility at 3 pH values over increasing ΗPβCD 
concentrations were determined, all of which corresponded to AL phase diagrams 
(Figure  2.21). From this it was estimated that a pH between 2-2.2 at ΗPβCD 
concentrations of approximately 50-70% would be necessary to achieve an ABZ 
concentration of 15 mg mL
-1.  To investigate this, the effect of pH on ABZ/ΗPβCD 
complexation was further investigated at pH 2 (500mM phosphate buffer) over a range 
of  ΗPβCD concentrations at 35°C (Figure 2.22). The solubility of ABZ increased 
linearly with ΗPβCD concentration, corresponding to an AL phase diagram (Linear 
regression, r=0.991) and a KC of 1075 M
-1. 
 
For  in vivo experimentation, a final solution of 16.2 mg mL
-1 ABZ/ΗPβCD (60% 
ΗPβCD (w/v), 200mM phosphate buffer) at pH 2.1 was formulated.  The molar ratio of 
ABZ to ΗPβCD was 1:7.  This solution was found to be extremely stable, with no 
precipitation of ABZ when stored at 4˚C.  
 
Figure 2.20: Effect of pH (50 mM phosphate buffer) on solubility of ABZ in the 
presence of ΗPβCD after incubation for 1 w at 35˚C followed by 2 d at room 
temperature (n=1). 
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Figure 2.21: Effect of ΗPβCD on the solubility of ABZ at different pHs (50 mM 
phosphate buffer) after incubation for 1 w at 35˚C followed by 2 d at room temperature 
(n=1). 
Figure 2.22: Solubility of ABZ in the presence of ΗPβCD at pH 2 (500 mM phosphate 
buffer) after incubation for 1 w at 35˚C followed by 2 d at room temperature (mean ± 
SE, n=3). 
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2.3.2. Trifluralin/ΗPβCD complex formulation  
 
2.3.2.1. Measurement of TF 
 
The effect of glass, plastic, light, filtration and methanol concentration on TF 
availability was investigated (1 µg mL
-1 solution) (Figure 2.23). Methanol 
concentrations above 40% dissolved 100% TF when in a glass vial.  In comparison, 
10% methanol solutions lost 18% of TF when incubated in glass vials, with an 
additional 30% lost when incubated in glass exposed to daylight for 5 hours. In 
addition, 10% methanol solutions lost 94% TF when filtered through 0.45µm Millipore 
filters, and 91% TF when in a plastic vial.   
 
2.3.2.2. Effect of ΗPβCD on TF solubility 
 
TF was found to be practically insoluble in water, with approximately 0.18 µg mL
-1 
TF 
dissolved. The solubility of TF increased linearly with ΗPβCD concentration, 
corresponding to an AL phase diagram (linear regression, r=0.9973) (Figure 2.24).  The 
apparent stability constant was determined with the assumption that the complex formed 
was of a 1:1 molar ratio of TF and cyclodextrin as described by Higuchi & Connors, 
(1965) and Grant & Higuchi, (1990), and had a KC of 626 M
-1 at 25°C. A 10% ΗPβCD 
(w/v) solution was capable of dissolving approximately 7.9 µg mL
-1  TF, a 45 fold 
increase. Adjusting pH was found to have no effect on TF solubility. 
 
The TF/ΗPβCD complex needed to be synthesised in sufficient concentrations for in 
vitro drug experiments.  Incubation of excess TF in 75% ΗPβCD (w/v) at 37°C for two 
days resulted in a substantial increase of TF solubility, with a final concentration of 60 
µg mL
-1 (176 µM).  The molar ratio of TF to ΗPβCD was 1:2945.  CHAPTER 2 
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Figure 2.24: Solubility of TF in the presence of ΗPβCD after 48 h at 25˚C (mean ± SE, 
n=3). 
 
 
 
2.3.3. Oryzalin/ΗPβCD complex formulation 
 
2.3.3.1. Effect of ΗPβCD on OZ solubility 
 
OZ was found to have low water solubility, with approximately 2.52 µg mL
-1 
OZ 
dissolved. The solubility of OZ increased linearly with ΗPβCD concentration, 
corresponding to an AL phase diagram (linear regression, r=0.9996) (Figure 2.25).  The 
apparent stability constant was determined with the assumption that the complex formed 
was of a 1:1 molar ratio of OZ and cyclodextrin as described by Higuchi & Connors, 
(1965) and Grant & Higuchi, (1990), and had a KC of 430 M
-1 at 25°C. A 10% ΗPβCD 
(w/v) solution was capable of dissolving approximately 77.7 µg mL
-1 OZ, a 30.6 fold 
increase. 
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Figure 2.25: Solubility of OZ in the presence of ΗPβCD after 48 h at 25˚C (mean ± SE, 
n=3). 
 
 
The OZ/ΗPβCD complex needed to be synthesised in sufficient concentrations for in 
vitro drug experiments.  Incubation of excess OZ in 75% ΗPβCD (w/v) at 35°C for two 
days resulted in a substantial increase of OZ solubility, with a final concentration of 2.8 
mg mL
-1 (8 mM).  The molar ratio of OZ to ΗPβCD was 1:65. A second solution was 
autoclaved and while there was no degradation of OZ, precipitation of the drug occurred 
as the solution cooled. However, this allowed samples to be sterilised by autoclaving. 
Therefore fresh drug solutions were autoclaved, cooled to 37˚C and OZ concentration 
verified before all biological experiments.   
 
While the OZ/ΗPβCD complex was synthesised in sufficient concentration for in vitro 
experimentation, these concentrations were insufficient for pharmacokinetic 
experiments.   Therefore the effect of pH adjustment on OZ complex formation was 
investigated. 
0 2 4 6 8 10
0
20
40
60
80
100
Hydroxypropyl-β-cyclodextrin (%)CHAPTER 2 
__________________________________________________________________________________________________________ 
  80
2.3.3.2. The effect of pH on OZ/ΗPβCD complex formation 
 
Figure 2.26 shows the pH-solubility profile for OZ in the absence of ΗPβCD. At pH 
values greater than 9.5, OZ solubility was found to increase exponentially (exponential 
growth, r=0.995).  
 
The effect of both pH and ΗPβCD on OZ solubility was investigated over 5 pH values 
and 3 ΗPβCD concentrations using phosphate buffer at two concentrations.  Increasing 
pH and increasing ΗPβCD concentrations significantly increased OZ solubility for both 
the 50 mM and 100 mM phosphate buffering systems.  No significant difference was 
observed between the two buffering systems so the data was amalgamated (Figure 2.27) 
(one way ANOVA with Bonferonni’s post test).  As OZ is a weak acid, the addition of 
OZ acted to decrease the pH of the samples. To further investigate the interactions 
between pH adjustment and ΗPβCD concentration, the above data was plotted as OZ 
solubility at each ΗPβCD concentration over varying pH (Figure 2.28). It appeared that 
with the addition of ΗPβCD into the system, the increase in OZ concentration with pH 
became sigmoidal. However, further analysis became highly speculative. To investigate 
this further, the effect of pH on OZ/ΗPβCD complexation was investigated at pH 11.2 
(500mM phosphate buffer) over a range of ΗPβCD concentrations at 35°C (Figure 
2.29).  However, determination of the stability constant was complicated by the fact that 
the final pH at equilibrium was often different from initial values.  Therefore only 
samples with a pH of 11.2 were used in the calculations.  The solubility of OZ increased 
linearly with ΗPβCD concentration, corresponding to an AL phase diagram (linear 
regression, r=0.996) and had a KC of 1164 M
-1. 
 
To investigate the pharmacokinetics of the OZ/ΗPβCD complex, it was necessary to 
synthesise the OZ/ΗPβCD complex at as high a concentration as possible, without using 
extreme pH ranges. Subsequently, incubation of excess OZ in 60% ΗPβCD (w/v) in 
200mM phosphate buffer (pH 11.2) at 35°C was found to contain 21.3 mg mL
-1 OZ, 
with a final pH of 11. The molar ratio of OZ to ΗPβCD was 1:7. 
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Figure 2.26: Effect of pH (50 mM phosphate buffer) on OZ solubility after 2 days at 
room temperature (mean ± SE, n=2). 
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Figure 2.27: Solubility of OZ with varying pH and ΗPβCD concentrations (either 50 
mM or 100 mM phosphate buffer, n=1). 
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Figure 2.28: Effect of pH (50-100 mM phosphate buffer) on solubility of OZ in the 
presence of ΗPβCD after equilibration for 1 w at 35˚C, 2 d at room temperature (n=1). 
 
Figure 2.29: Solubility of OZ in the presence of ΗPβCD at pH 11.2 (500 mM 
phosphate buffer) after equilibration for 1 w at 35˚C, 2d at 21˚C (mean ± SE, n=1-3). 
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2.3.4. DSC-TGA analysis 
 
2.3.4.1. ABZ complex formation 
 
Figure 2.30 shows the DSC-TGA thermograms for ABZ, 60% ΗPβCD (w/v) pH 2.1 
(200mM phosphate buffer), and ABZ/ΗPβCD pH 2.1 (60% ΗPβCD (w/v), 200mM 
phosphate buffer).  The DSC-TGA thermogram of ABZ had an endothermic peak at 
209°C with an associated weight loss, which comprised two processes, as seen by the 
lack of symmetry within the peak and uniformity in weight loss.  A second weight loss 
was observed between 280 and 350°C and consisted of an endotherm followed by an 
exotherm.   
 
The ΗPβCD and ABZ/ΗPβCD samples were highly viscous and therefore were heated 
at 5˚C/min to reduce the risk of the samples bubbling.  Both the ΗPβCD and 
ABZ/ΗPβCD exhibited weight loss with endothermic peaks due to the evaporation of 
water, and continued until approximately 130°C.  A second weight loss occurring in 
both samples at approximately 230°C is exothermic, indicating oxidisation. Subsequent 
weight loss after 290°C was due to carbon charring.  The ABZ/ΗPβCD sample 
contained excess ΗPβCD (ratio ABZ/ΗPβCD: ΗPβCD = 1:6), therefore the 
characteristic peaks of ΗPβCD were observed.  The characteristic endothermic and 
exothermic peaks of ABZ were not present, indicating that the ABZ and ΗPβCD 
formed a true inclusion complex.   
 
2.3.4.2.OZ complex formation 
 
Figure 2.31 shows the DSC-TGA thermograms for OZ, 60% ΗPβCD (w/v) pH 11.2 
(200mM phosphate buffer), and OZ/ΗPβCD pH 11 (60%ΗPβCD (w/v), 200mM 
phosphate buffer).  OZ has a distinct DSC with a single clear endothermic peak 140˚C 
with no associated weight loss, correlating with the melting point of OZ.  A single clear 
exothermic peak at 271˚C with associated weight loss was due to decomposition by 
oxidisation. 
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Figure 2.30: DSC-TGA thermograms (5˚C/min) of (a) ABZ, (b) 60% ΗPβCD (w/v) pH 
2.1 (200mM phosphate buffer) and (c) ABZ/ΗPβCD pH 2.1 (200mM phosphate buffer). 
 
 
The ΗPβCD and OZ/ΗPβCD samples were highly viscous and therefore were heated at 
5˚C/min to reduce the risk of the samples bubbling.  Both the ΗPβCD and OZ/ΗPβCD 
samples exhibited weight loss with endothermic peaks due to the evaporation of water, 
and continued until approximately 130°C, as observed with the ΗPβCD (pH 2.1) and 
ABZ/ΗPβCD (pH 2.1) samples.  Weight loss occurring in both samples after 260°C is 
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contained excess ΗPβCD (ratio OZ/ΗPβCD: ΗPβCD = 1:6), therefore the characteristic 
peaks of ΗPβCD were observed.  The characteristic endothermic and exothermic peaks 
of OZ were not present, indicating that the OZ and ΗPβCD formed a true inclusion 
complex. 
 
 
Figure 2.31: DSC-TGA thermograms (5˚C/min) of (a) OZ, (b) 60% ΗPβCD (w/v) pH 
11 (200mM phosphate buffer) and (c) OZ/ΗPβCD pH 11 (200mM phosphate buffer). 
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2.4. DISCUSSION  
 
2.4.1. Albendazole   
 
2.4.1.1. Phase solubility analysis 
 
The intrinsic aqueous solubility of ABZ was very low, at 0.29 µg mL
-1
.  This is 
comparable to that found by previous researchers (Bogan & Marriner, 1984; Evrard et 
al., 1998; Piel et al., 1999), although different authors have observed a vast range in 
solubility (Kata & Scheuer, 1991; Torrado et al., 1996a).  These differences are most 
likely to be predominately due to the techniques used for solubility determination.  In 
addition, ABZ has been found to form polymorphs, which may affect its solubility (Zhu 
et al., 1995). 
 
 It has already been shown in the literature that ABZ aqueous solubility can be increased 
by forming inclusion compounds with β-cyclodextrin, dimethyl-β-cyclodextrin 
hydroxypropyl-β-cyclodextrin and sulphobutylether7-β-cyclodextrin (Kata & Scheuer, 
1991; Chun & Park, 1993; Bassani et al., 1996; Evrard et al., 1998; Castillo et al., 1999; 
Piel et al., 1999). Phase solubility analysis in the present study revealed that ABZ and 
ΗPβCD formed first order complexes, and the KC was determined with the assumption 
that the complex formed was of a 1:1 molar ratio ABZ:HPβCD.  Similar results were 
obtained by Chun & Park, (1993), Castillo et al., (1999) and Piel et al., (1999). In 
addition, increases in drug solubility at very high concentrations of HPβCD may not 
only involve complexation but also a general change in polarity of the solvent.  The 
stability constant for the ABZ/ΗPβCD complex indicates an inclusion complex of very 
high stability, which was also observed by Evrard et al., (1998). However, different 
authors have found widely differing stability constants for the ABZ/HPβCD complex. 
This may be due to the different methods used to determine KC, and may indicate that 
the stoichiometry deviates from the assumed 1:1 ratio (Szejtli, 1988).  The stability 
constant of the inclusion complex depends on the degree to which the two molecules 
interact, which is affected by the relative sizes of the guest in relation to host cavity size. 
Therefore, in water, ΗPβCD accommodates the molecular portion of ABZ involved in 
complexation very well.   CHAPTER 2 
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2.4.1.2. Temperature 
 
Manipulation of temperature to increase the overall solubility of drug/CD complexes 
has been investigated by a number of authors (Gelb et al., 1984; Bekers et al., 1989; 
Hoshino et al., 1993; Dordunoo & Burt, 1996).  To formulate the ABZ/ΗPβCD 
complex at a maximal ABZ concentration for in vitro experimentation, a combination of 
increased temperatures and high ΗPβCD concentrations were utilized. Temperature 
affects complex formation, with increasing temperatures resulting in an increase in 
component solubility and a decrease in the stability constant, with complete 
disassociation occurring above 80°C (Szejtli, 1988). As a complex is more ordered than 
a mixture of its components, increasing temperature favours the individual species and 
thus decreases complexation.  However, the solubility of the reactants increases with 
increasing temperature.  Therefore the increase in solubility of the components may 
partially or wholly offset the effect of the decreased stability constant that accompanies 
an increase in temperature (Yalkowsky, 1999). This was the case for the ABZ/ΗPβCD 
complex, as an overall increase in solubility was achieved with increased temperature.  
However, as ABZ was degraded at temperatures greater than 45°C, the use of 
temperature to increase solubility was limited to 35°C.  Previous investigators used high 
temperatures to form solid ABZ/CD complexes (Kata & Scheuer, 1991; Bassani et al., 
1996; Torrado et al., 1996b).  However, it was not discussed whether they found similar 
degradation products.  One unusual characteristic however, was the fact that neither the 
unionised nor the ionised ABZ/ΗPβCD complexes precipitated upon cooling when 
formulated at high temperatures.  Further, these complexes could be stored at 4°C for 
extended periods of time.  The lack of precipitation indicates that the formulations had 
not reached equilibrium (saturated solutions).  However, this did not appear to be the 
case.  Extended equilibration times did not result in increased ABZ in solution in phase 
solubility experiments. Alternatively, this may be due to the very high stability constant, 
with the drug remaining complexed instead of precipitating out, or precipitation 
occuring very slowly. 
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2.4.1.3. pH 
 
In vivo experiments required significantly higher ABZ concentrations than that achieved 
using unionised ABZ.  Therefore a combination of decreasing pH and increased 
temperature to increase ABZ solubility was investigated.   Multicomponent systems 
using CDs and hydroxy acids to increase overall ABZ solubility have been investigated 
in the literature (Chun & Park, 1993; Castillo et al., 1999; Piel et al., 1999), and found 
to follow a pseudo-first order kinetic model (Torrado et al., 1996a).  ABZ/ΗPβCD 
complexation, at a pH of 2, resulted in higher ABZ solubility due to its ionisation, but 
had a lower stability constant than for the complex in water. The extent of CD 
complexation depends of the polarity of the guest molecule. The stability of the 
complex is proportional to the hydrophobic character of the substituents, with ionic 
species usually, but not always, unfavoured in complex formation.  This is because 
ionised molecules produce weaker interactions with the hydrophobic cavities of CDs  
(Szejtli, 1988; Loftsson & Brewster, 1996).  Therefore, if a pH change produces an 
ionic form of the drug, it increases the solubility of the complex but decreases the 
formation constant (Yalkowsky, 1999). This was observed with ABZ, with the KC of 
ABZ and its ionic form to be 9940 and 1075M
-1 respectively. However, improved 
overall solubility with decreasing pH was observed despite the decreased solubility 
constant, as the solubility difference between the two ABZ forms outweighed the effect 
of the difference in complexation.   The improved solubilizing capacity of the phosphate 
buffer over the citric acid buffer at low pHs may result from interference from the citric 
acid between the ionised ABZ and the ΗPβCD molecule.  The likelihood is that 
hydroxy acids may establish electrostatic interactions with the drug, and hydrogen 
bonds with the hydroxyl groups of the CD (multicomponent systems) (Redenti et al., 
2000).   Differential solubilizing ability between phosphate buffer and citric acid buffer 
has also been observed by Linares et al., (1998). 
 
2.4.1.4. DSC-TGA 
 
The formation of true inclusion compounds was determined by DSC-TGA.  The DSC-
TGA thermograms of ABZ showed an asymmetrical endothermic peak at 209°C with 
an associated weight loss, corresponding to the melting point of ABZ.  Castillo et al., CHAPTER 2 
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(1999)  also found asymmetry in an endothermic peak at approximately 200°C, and 
attributed it to the presence of polymorphous and enantiomeric compounds (Zhu et al., 
1995).  The second weight loss observed between 280 and 350°C consisting of an 
endotherm followed by an exotherm was probably related to bond breakage followed by 
oxidation.  ABZ was previously observed to degrade at greater than 45°C, with 
substantial degradation occurring when samples were autoclaved.  However there is no 
indication of structural change or degradation from the DSC-TGA thermograms below 
200°C.  The degradation of ABZ at high temperatures in the aqueous solution is 
therefore likely to be due to hydrolysis.   
 
DSC-TGA thermograms of 60% ΗPβCD (w/v), in 200mM phosphate buffer (pH 2.1), 
exhibited weight loss with an endothermic peak due to the evaporation of water, and 
continued until approximately 130°C.  Evaporation of water content from inclusion 
complexes is generally complete below 100°C, while the evaporation of absorbed or 
bound water occurs at just above 100°C (Szejtli, 1988).  The difference in temperature 
is caused by different strengths of the bonds between water molecules and cyclodextrin 
molecules (Pedersen et al., 1998).  The second weight loss occurring at approximately 
230°C is exothermic, indicating oxidisation.  Cyclodextrins have no defined melting 
point, but decompose above 200°C (Szejtli, 1988).   
 
The DSC-TGA thermograms of ABZ/ΗPβCD complex in 200mM phosphate buffer (pH 
2.1) (Section 2.2.2.5) indicated that the drug was completely converted into the 
complex.  The endothermic and exothermic peaks of ABZ were not present, indicating 
that there was no free ABZ.  ABZ was therefore protected by ΗPβCD, decomposing 
with the ΗPβCD instead of as a separate compound. 
 
2.4.2. Trifluralin 
 
2.4.2.1. Phase solubility analysis 
 
The intrinsic aqueous solubility of TF was very low, at 0.18 µg mL
-1
.  This is 
comparable to values found by previous researchers (Tepe & Scroggs, 1967; Weber & 
Monaco, 1972; Tomlin, 1994).  Phase solubility analysis revealed that TF and ΗPβCD CHAPTER 2 
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formed first order complexes, and the KC was determined with the assumption that the 
complex formed was of a 1:1 molar ratio TF: ΗPβCD.  The stability constant for the 
TF/ΗPβCD complex was 626 M
-1 at 25°C, which is considered to be sufficiently high to 
result in its improved bioavailability (Blanco et al., 1991).   
 
2.4.2.2. Temperature 
 
For in vitro and in vivo experimentation, significantly higher TF concentrations were 
required. By increasing temperature, a substantial increase in TF solubility was 
achieved at high ΗPβCD concentrations.  However, this was still insufficient for in vitro 
experimentations. In addition, pH did not affect TF solubility, as it is non-ionic, with a 
pKa < 0 (Weber & Monaco, 1972; Tomlin, 1994).  Therefore, while the stability 
constant indicated potential for improved bioavailability of TF, in actuality, TF 
complexation with ΗPβCD, with or without pH adjustment, was not a viable alternative 
to increasing TF concentration for in vitro or in vivo efficacy studies against parasitic 
agents.  
 
TF was especially prone to either precipitation or sorption onto surfaces when stored in 
plastic vials, and dissolved TF was removed from solutions when filtered.  Strachan & 
Hess, (1982) found that TF bound to both glass and, to a greater extent, plastic, and this 
effect increased over time. They also found other dinitroanilines (isopropalin, 
pendimethalin, nitralin and OZ) bound to glass, with only nitralin and OZ maintaining 
constant concentrations due to their higher solubility.  It was thought that the 
dinitroaniline herbicides bound to glass by chelating a cation on the glass surface, or by 
forming π complexes with transition metals on the surface of the glass. In addition, 
nitroanilines readily absorbed to proteinaceous substances by virtue of the nitro groups, 
which are strong hydrogen bonders (Weber & Monaco, 1972).  Therefore it is important 
to avoid using plastic vials, to reduce exposure to light, to remove excess drug by 
centrifugation rather that filtration, and to avoid situations where sample analysis was 
carried out in low methanol concentrations.   
 
It was observed that TF was susceptible to decomposition by ultraviolet radiation. 
Similar results were also reported by Tepe & Scroggs, (1967) and Leitis & Crosby, CHAPTER 2 
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(1974), who found that TF was very unstable in sunlight, especially in the presence of 
an organic solvent.  Methods devised for the measurement of TF were also used for the 
measurement of the non-filterable OZ, which, like all substituted aromatic nitro 
compounds, is susceptible to photodecomposition (Decker & Johnson, 1976). 
 
2.4.3. Oryzalin 
 
2.4.3.1. Phase solubility analysis 
 
The intrinsic aqueous solubility of OZ was 2.52 µg mL
-1
, and is comparable to that 
observed by previous researchers (Weber & Monaco, 1972; Decker & Johnson, 1976), 
although different authors have observed a vast range in solubility (Budavari, 1989; 
Benbow et al., 1998).  These differences are likely to be predominantly due to the 
techniques used for solubility determination.  Like TF, OZ could not be filtered through 
Millipore filters.  Therefore the methods devised for the measurement of TF were used 
to analyse OZ.   
 
Phase solubility analysis revealed that OZ and ΗPβCD formed first order complexes, 
and that the KC was determined with the assumption that the complex formed was of a 
1:1 molar ratio OZ: ΗPβCD.  The stability constant for the OZ/ΗPβCD complex was 
430M
-1 at 25°C, which is considered to be sufficiently high to result in its improved 
bioavailability (Blanco et al., 1991).   
 
2.4.3.2. Temperature 
 
To formulate of the OZ/ΗPβCD complex at a maximal OZ concentration for in vitro 
experimentation, a combination of increased temperatures and high ΗPβCD 
concentrations were utilized. An overall increase in OZ solubility was achieved with 
increased temperature. Therefore the increases in component solubility were greater 
than the decrease in the stability constant, resulting in increases in overall solubility 
with increasing temperature.  However, unlike ABZ, samples could not be substantially 
cooled without precipitation of the drug.  As the sample cools, the components decrease 
in solubility, and either complex with ΗPβCD or precipitate out.  As the stability CHAPTER 2 
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constant increases with decreasing temperature, complex formation is favoured. 
However, this is not sufficient to offset the decreased solubility of the components.  One 
advantage this did permit was the sterilization of drug samples.  While autoclaving 
samples was not a viable method for increasing drug concentration (due to 
precipitation), it did allow for sterilization of pre-formulated samples. Repetitive 
autoclaving however, resulted in an increase in viscosity, presumably due to a loss of 
water from the formulation. 
 
2.4.3.3. pH 
 
In vivo experiments required significantly higher OZ concentrations than that achieved 
using unionised OZ.  Therefore a combination of increased pH and increased 
temperature to increase OZ solubility was investigated.  OZ exhibits acidic properties, 
being highly soluble in alkaline solutions (Weber & Monaco, 1972; Decker & Johnson, 
1976).   OZ/ΗPβCD complexation in pH-adjusted media resulted in higher drug 
solubility at a pH of 11.2. The stability constants for OZ and its ionic form were 430 
and 1075 M
-1 respectively.  Therefore the ionised OZ/ΗPβCD complex also had a 
higher stability constant than the complex in water. While this is uncommon, examples 
have been reported in the literature (Higuchi & Kristiansen, 1970; Connors et al., 1982; 
Connors, 1995; Esclusa-Díaz et al., 1996, and reviewed by Loftsson et al., 1999).  In the 
case of OZ, a pH change producing an ionic form of the drug not only increased the 
solubility of the drug and its complex, but also increased the stability constant i.e., the 
ionised drug was able to complex more strongly. This is unusual and indicated that the 
ionised portion of the drug was involved in the interaction between OZ and ΗPβCD, 
and actually favoured complexation.  This may result from the ionised portion of the 
drug interacting with either the ΗPβCD cavity (resulting from a stronger dispersion 
force field between the guest and ΗPβCD cavity) or derivatised groups on the outside of 
the ΗPβCD (resulting from increased interactions such as hydrogen bonding or dipole-
dipole) (Lin & Connors, 1983; Connors, 1997). Alternatively, ionisation may have 
influenced electron density on the ring and therefore binding indirectly. The unusually 
shaped pH profiles observed in figure 2.31 may result from 1) alternative stoichiometric 
relationships, 2) salt formation or 3) differential complexing ability of the ionised and 
unionised forms of OZ with ΗPβCD. CHAPTER 2 
__________________________________________________________________________________________________________ 
  93
 
2.4.3.4. DSC-TGA 
 
Confirmation that the OZ and ΗPβCD formed true inclusion compounds was 
determined by GSC-TGA.  Both the ΗPβCD and OZ/ΗPβCD samples exhibited weight 
loss with endothermic peaks due to the evaporation of water, and continued until 
approximately 130°C, as observed with the ΗPβCD (pH 2.1) and ABZ/ΗPβCD (pH 
2.1) samples.  Therefore the evaporation of water content occurred below 100°C, while 
the evaporation of absorbed or bound water occurred above 100°C.  In previous 
experiments, it was observed that phosphate buffer solubility at pH 11.2 decreased with 
increasing ΗPβCD concentrations.  Therefore this may be due to ΗPβCD effectively 
‘mopping up’ water.  If the addition of ΗPβCD resulted in an increase in the amount of 
bound water, there would be a decrease in available water for the buffer to be dissolved 
in.    
 
The DSC-TGA thermograms of OZ/ΗPβCD complex in 200mM phosphate buffer (pH 
11) (Section 2.2.4.5) indicated that the drug was completely converted into the complex.  
The endothermic and exothermic peaks of OZ were not present, indicating that there 
was no free OZ.  OZ was therefore protected by ΗPβCD, decomposing with the ΗPβCD 
instead of as a separate compound. 
 
2.4.4. Conclusion 
 
All three antiparasitic agents exhibited improved solubility with ΗPβCD complexation.  
However, only ABZ and OZ exhibited increases in solubility with potential for 
assessment of antiparasitic efficacy.  Additional increases in ABZ and OZ solubility 
were achieved by manipulation of temperature and pH in combination with increased 
ΗPβCD concentrations.  OZ/ΗPβCD complexation was especially improved by pH 
adjustment, with ionisation of OZ favouring complex formation.   
 
While the stability constant of the TF/ΗPβCD complex indicated potential for improved 
bioavailability of TF, drug concentrations were insufficient for in vitro or in vivo 
efficacy studies against parasitic agents. In comparison, the ABZ/ΗPβCD and CHAPTER 2 
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OZ/ΗPβCD complexes were formulated in sufficient concentration for in vitro 
experiments. The pH-adjusted ABZ/ΗPβCD and OZ/ΗPβCD complexes were 
formulated for in vivo experimentation, as substantially higher drug concentrations were 
required.  However, these formulations could not be investigated in vitro as in vitro 
systems are cultivated at a specific pH.  Therefore the addition of pH-adjusted 
formulations to parasite cultures would change the pH of the formulation, resulting in 
drug precipitation. 
 
The above formulations were made with the view of investigating the efficacy of the 
antiparasitic agents when complexed with ΗPβCD in comparison to conventional drug 
formulations.  Therefore the efficacy of the aqueous complexes was investigated in 
order to guarantee precise drug dose for assessment of efficacy, toxicity and 
bioavailability. While the ABZ/ΗPβCD and OZ/ΗPβCD complexes are in sufficient 
concentration for in vivo experimentation, they would be insufficient for human 
treatment.  Subsequent drug formulation development would entail the manufacture of 
solid inclusion complexes with more specific investigations into stoichiometry as well 
as dissolution studies and clinical trials, such as those described by Evrard et al., (1998), 
Castillo et al., (1999) and Piel et al., (1999).   
 
The interest in designing newer and more effective drug delivery systems is the main 
reason for research into CD-drug combinations (Szejtli, 1991a). For ABZ in particular, 
its improved formulation will consequently result in improved treatment of systemic 
parasites such as Echinococcus granulosis. CHAPTER 3 
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3.1. INTRODUCTION 
 
Many drugs are effective at nanomolar concentrations in vitro, but this is often not 
reflected in vivo.  This may result from enzymatic or chemical breakdown of the drug, 
or insufficient solubility in physiological conditions preventing specific and effective 
delivery to their site of action.  While the activity of the drug is often related to the 
lipophilicity of the compound, adequate bioavailability of the drug requires a degree of 
aqueous solubility.  Therefore CDs and their derivatives can improve drug delivery, 
with HPβCD a potential drug carrier for parenteral, oral and local administration.   
However, it is of particular importance that the individual pharmacokinetics of the 
complex, carrier and drug are known in the overall assessment of drug effect.  
 
3.1.1. Oral formulations 
 
For oral drug administration, solid drug/CD complexes have a number of advantages 
over solid drug.  They improve the formulation of the drug (e.g. remove smell or taste), 
improve the physical and chemical stability of the drug (resulting in a longer shelf life), 
reduce the time it takes for the drug to move from the solid phase into the liquid phase 
(dissolution), and reduce drug induced local irritation (Szejtli, 1988 and  1991a).  When 
a drug is very soluble, its absorption is the limiting factor.  In such cases, CD 
complexation will not increase the absorption, and eventually may decrease it.   
However, when a drug is poorly soluble, dissolution is the limiting factor (Jones & 
Grant, 1984; Szejtli, 1991a).  Complexation increases dissolution and solubility, and 
hence increases the available concentration of drug in the intestine, with the extent of 
enhanced dissolution and solubility controlled by various factors such as the solubilities 
of the components, the stability constants of the complexes, and the molar ratio of 
drug:CD (Habon et al., 1984; Jones & Grant, 1984; Szejtli, 1991a).    
 
As solid drug/CD complexes are usually much more hydrophilic than the free drug, the 
solid wets easier, resulting in increased dissolution (Habon et al., 1984).  In the same 
way that a drug/CD complex in liquid medium is governed by an equilibrium reaction 
between host and guest molecules, when a solid drug/CD complex is placed in contact 
with water, it dissolves and decomposes following the equilibrium reaction:  CHAPTER 3 
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solid inclusion ↔ dissolved inclusion ↔ free CD + free drug (Duchêne & 
Wouessidjewe, 1990a).  If the concentration of the free drug (released by dissociation) 
surpasses its saturation concentration, the excess precipitates as solid drug (Figure 3.1) 
(Habon et al., 1984). Consequently, drug absorption results in a displacement of this 
equilibrium, with the appearance of new free molecules of drug from either the drug/CD 
complex or precipitated drug (if any) (Duchêne & Wouessidjewe, 1990a).    
 
Orally administered drug can only enter the circulation once dissolved in the 
gastrointestinal fluid, with the concentration of dissolved drug one of the parameters 
determining the rate of absorption processes.  Habon et al., (1984) have developed 
computer-simulated theoretical blood level curves that allow predictions of the 
pharmacokinetics of CD complexes in oral dosage form. The differences in the blood 
level curves obtained after administration of free or complexed drug can be attributed to 
the different dissolved free drug concentrations in the gastrointestinal fluid (Habon et 
al., 1984; Cho et al., 1995).  The computer-simulated theoretical blood level curves 
developed by Habon et al., (1984) allow predictions of pharmacokinetics based on the 
stability constant and the presence of excess CD (Figure 3.2). As a consequence of the 
higher dissolution rates of the complexes, not only is the blood concentration higher, 
with its peak occurring sooner, but also the area under the curve (AUC) is larger 
(Duchêne et al., 1987).   These increases in blood level curves can resemble i.v. 
application (Habon et al., 1984).  At lower stability constants, the saturation 
concentration of the drug can easily be reached, with the degree of dissociation high 
enough to ensure a high free drug concentration in the gastrointestinal fluid.  These 
result in a rapid increase in the blood level curve and high value of the peak.  If the 
stability constant is high, then dissociation is weak, and even if the solubility of the 
inclusion compound is high, the bioavailability of the drug remains low, as there are few 
free molecules available for absorption.  Therefore the blood level peak will be shifted 
toward higher values on the time abscissa and a decrease in the peak height.  An 
enhanced biological response is however expected in all cases as compared to the free 
drug. Thus the absorption rate of drugs can be accelerated or retarded by appropriately 
manipulating the complex dissociation equilibria (Habon et al., 1984). 
 
 
 CHAPTER 3 
__________________________________________________________________________________________________________ 
  98
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Schematic representation of the dissolution-dissociation-recrystallization 
process of a CD complex of a poorly water soluble guest.  The complex rapidly 
dissolves, and a metastable oversaturated solution is obtained.  The anomalously high 
level of dissolved guest drops back but remains higher than the level that can be 
obtained with non-complexed drug. Complexed drug () and non-complexed drug 
(---).  Text and figure from Szejtli, (1991a). 
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Figure 3.2: Theoretical blood level curves obtained after oral administration of a free 
drug (F) or its CD complexes with different stability constants. Text and figure from 
Szejtli, (1988). 
 
In addition, the complex dissociation equilibria can be shifted toward complex 
formation in the aqueous phase by adding excess CD to the system (Habon et al., 1984).  
When administering excess CD together with the drug/CD complex, the dissociation 
equilibria can be shifted toward a higher ratio of complexed drug in the gastrointestinal 
fluid. These changes have a great influence on the shape and peak-height of the blood 
level curves.  At lower stability constants, the excess amount of CD enhances the 
concentration of free dissolved drug, thus a higher blood level can be attained in a 
shorter time. At higher stability constants however, the dissociation is suppressed 
remarkably on addition of excess CD, and a decrease in the height of the blood level 
peak as well as an increase in the time necessary to reach the peak can be observed.  In 
extreme cases a real retardation can be achieved compared to the free drug.  Therefore 
the absorption of an orally administered drug can be enhanced or retarded through the 
addition of excess CD (Habon et al., 1984).  These effects also occur in drug/CD 
formulations that have not had excess CD added, with this trend stronger for higher 
stability constants.  When the stability constant is high, the free drug concentration 
decreases during absorption processes due to the increasing CD excess in the 
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gastrointestinal fluid.  Since CD itself cannot get into circulation either in the free or 
complexed form (or only to an insignificant extent), the rate of absorption, which is 
proportional to the free drug concentration, also decreases (Habon et al., 1984).   
 
Additives may also be administered at the same time to improve the in vivo 
effectiveness of the inclusion complex.  For example, the bioavailability of complexes 
administered at a particular pH may improve from the addition of pH modifiers that 
better adapt the stomach pH to its dissolution (Duchêne et al., 1987).  It is also possible 
to increase dissociation by adding competing agents, such as phenylalanine or bile salts 
(Duchêne et al., 1987; Nakanishu et al., 1989).  Pharmaceutically it is desirable to use 
drug/CD complexes with stability constants between 100-1000 M
-1 to take advantage of 
the effect of endogenous bile salts.  Drugs with small stability constants form unstable 
complexes, while those with high stability constants are too stable for exchange with 
bile acids to occur.  For stability constants within this range, competition between the 
drug and bile acids for complex formation occurs, resulting in exclusion of the drug 
molecules from the cavity, with the free molecules then available for absorption.   
 
3.1.2. Parenteral formulations  
 
Complexation behaviour following parenteral administration is not well understood, 
with dissociation of the complex occurring with dilution of the complex by the 
distribution fluids and competition for the drug and CD by plasma components (Mesens 
et al., 1992).  Therefore only small fractions of the drug remain complexed with the CD 
once the complex enters the circulation.  Competition in vivo results from the binding 
competition between CD and plasma protein for the drug, and also competition between 
the drug and endogenous compounds for the CD (Frijlink et al., 1991a; Sideris et al., 
1994).  Drug/plasma proteins interactions have very high stability constants, with 
competition between plasma proteins and CD for the drug favouring plasma proteins 
(Mesens et al., 1992). In addition, parenterally administered CDs have the capacity to 
complex with endogenous compounds, resulting in displacement of the drug from the 
CD by plasma/lipid fractions. Cholesterol in particular has a very high affinity for 
HPβCD, and is also in much higher concentrations in plasma than the drugs 
administered as complexes (Mesens et al., 1992; Frijlink et al., 1991b).  In some cases CHAPTER 3 
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increased drug protein binding is observed, and is attributed to the removal of 
cholesterol from plasma protein binding sites (Frijlink et al., 1991a).  A significant 
effect of CD complexation on drug disposition can therefore be expected only for those 
drug/CD complexes that possess a relatively high complex stability constant, as 
compared with the association constant with plasma proteins, and do not undergo 
displacement from the CD complex by endogenous lipids (Frijlink et al., 1991b).   
 
Following parenteral administration, CD complexation can also affect tubular 
reabsorption of drugs resulting in increased renal clearance of the drug in the complexed 
form.  While dissociation is expected with dilution in the bloodstream, concentration of 
both the drug and HPβCD in the kidneys may result in their recomplexation and 
therefore accelerated elimination (Dietzel et al., 1990).  As renal clearance of HPβCD is 
rapid, these effects should be manifested soon after drug complex administration 
(Habon et al., 1984; Anderson et al., 1990; Dietzel et al., 1990).   
 
3.1.3. Aim 
 
The purpose of this investigation was to compare the pharmacokinetics of the 
antiparasitic agents albendazole and oryzalin both alone and complexed.   This 
involved: 
 
6.  Investigating the pharmacokinetics of ABZ and the ABZ/HPβCD complex 
following oral administration of 6 mg kg
-1.   
 
7.  Investigating the pharmacokinetics of ABZ and a pH adjusted ABZ/HPβCD 
complex following oral administration of 30 mg kg
-1.   
 
8.  Investigating the pharmacokinetics of OZ and a pH adjusted OZ/HPβCD 
complex following i.p. administration of 25 mg kg
-1.   
 CHAPTER 3 
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3.2. METHODS 
 
3.2.1. Origin and housing of experimental animals 
 
Three to four-week-old male albino Rattus norvegicus (Sprague Dawley strain) were 
used in all pharmacokinetic experiments.  They were housed in an animal house 
maintained on a 12:12 h photoperiod at 21-24°C and were fed Rat and Mouse Cubes 
manufactured by Glen Forrest Stockfeeders, Western Australia. Rats were housed three 
animals per standard rat cage and both food and water were provided ad libitum.  All 
animals were obtained from the Western Australian State Animal Resource Centre, 
Perth, Western Australia. The Murdoch University Animal Ethics Committee, in 
accordance with national animal welfare standards, approved the following 
experiments. 
 
3.2.2. Pharmacokinetic experiments 
 
3.2.2.1. In vivo albendazole pharmacokinetic study design 
 
3.2.2.1.1. Pharmacokinetics of the ABZ/HPβCD complex 
Sprague Dawley rats were given a single oral dose of 6 mg kg
-1 ABZ as ABZ/HPβCD 
(Section  2.3.1.1) (HPβCD concentration 1.5 g kg
-1) and blood samples were taken 
between 1-12 h after drug administration. Animals were anaesthetised with halothane in 
a special delivery chamber of clear perspex (40x20x20 cm) with an inlet hose from an 
in-line vaporiser (Ohio Medical Products, USA) using oxygen as the carrier for 0.5-1% 
halothane. An outlet hose from the chamber was connected to a rat mask, and the 
delivery chamber and rat mask were set up within a fume cupboard. Rats were placed 
within the chamber until anaesthetised after which they were removed and their heads 
placed into the mask to maintain halothane anaesthesia during blood collection. Blood 
was collected via cardiac puncture using 21 G needles attached to 5 mL syringes 
containing 0.1 mL of 200 U mL
-1 porcine heparin in PBS to prevent blood clotting.  
After blood collection the animals were euthanased by halothane overdose and cervical 
dislocation.  Blood samples were centrifuged at 2500 rpm for 10 min and the plasma CHAPTER 3 
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collected and stored at -20˚ C for analysis of ABZ and its metabolites ABSO and 
ABSO2 by HPLC. 
 
In a second experiment, the pharmacokinetics of the ABZ/HPβCD complex at pH 2.1 
was investigated (Section 2.3.1.2).  Sprague Dawley rats were given a single oral dose 
of 30 mg kg
-1 ABZ as ABZ/HPβCD (HPβCD concentration 1.11 g kg
-1) and blood 
samples were taken between 15min and 12.5 h after drug administration. Animals were 
anaesthetised with halothane and blood was collected via cardiac puncture, after which 
the animals were euthanased by halothane overdose and cervical dislocation (as above).  
Blood samples were centrifuged at 2500 rpm for 10 min and the plasma collected and 
stored at -20˚ C for analysis of ABZ and its metabolites ABSO and ABSO2 by HPLC. 
 
3.2.2.1.2. Pharmacokinetics of a commercial ABZ formulation 
In two separate experiments, Sprague Dawley rats were given a single oral dose of 6 mg 
kg
-1 ABZ (Valbazen® (Appendix)) with blood samples taken between 1-12 h after drug 
administration, or 30 mg kg
-1 ABZ (Suspension, formulated as a ‘white drench’ – Table 
3.1) with blood samples taken between 15 min - 12.5 h after drug administration.  In 
both experiments, animals were anaesthetised with halothane and blood was collected 
via cardiac puncture, after which the animals were euthanased by halothane overdose 
and cervical dislocation (Section 3.2.2.1.1).  Blood samples were centrifuged at 2500 
rpm for 10 min and the plasma collected and stored at -20˚ C for analysis of ABZ and 
its metabolites ABSO and ABSO2 by HPLC. 
 
Table 3.1: Preparation of standard commercial 'white drench' vehicle used in a number 
of commercial drenches.  
Aerosil   10 g 
Citric acid  15 g 
Sodium citrate  9.25 g 
PEG 6000 (polyethylene glycol)  30.625 g 
MYRJ 52  22.5 g 
Potassium sorbate  1.5 g 
Keltrol F  2.125 mL 
HCl (32%)  1.125 mL 
Formalin (37% formaldehyde)  1.225 mL 
Distilled H2O (dH2O)  up to 1L 
With 400 mL dH2O, add dry ingredients in the order listed, add liquids, then make up to 
1L with distilled water.  Blend for 1 min. CHAPTER 3 
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3.2.2.2. In vivo oryzalin pharmacokinetic study design 
 
3.2.2.2.1. OZ/HPβCD pharmacokinetic experiment 
Sprague Dawley rats were given a single i.p. dose of 25 mg kg
-1 OZ as OZ/HPβCD 
(Section 2.3.3.2) (HPβCD concentration 0.72 g kg
-1) and blood samples were taken 
between 8 min and 24 h after drug administration. Animals were anaesthetised with 
halothane and blood was collected via cardiac puncture, after which the animals were 
euthanased by halothane overdose and cervical dislocation (Section 3.2.2.1.1).   Blood 
samples (not heparinized) were centrifuged at 2500 rpm for 10 min and the plasma 
collected and stored at -20˚ C for analysis of OZ by HPLC. 
 
3.2.2.2.2. OZ pharmacokinetic experiment 
Sprague Dawley rats were given a single i.p. dose of 25 mg kg
-1 OZ formulated as 12.5 
mg mL
-1 OZ in 36% ethanol, 16% DMSO, 8% tween 80, and 40% 0.9% NaCl.  Blood 
samples were taken as above and analysed as described in section 3.2.2.2.1. 
 
3.2.3. HPLC analysis  
 
3.2.3.1. HPLC analysis of albendazole 
 
3.2.3.1.1. UV spectrum 
The UV spectra were determined using a HP 8452A Diode Array Spectrophotometer 
with General Scanning MS-DOS Software HP 89532A (A.00.00).  The UV spectra of 
ABZ, ABSO, and ABSO2 were used to determine the appropriate wavelength for HPLC 
analysis (Figure 3.3).  The internal standard butyl aminobenzoate (BAB) was selected 
based on its UV absorption at the selected wavelength and its retention time during 
HPLC analysis (Figure 3.3).   
 
3.2.3.1.2. HPLC conditions 
The HPLC system consisted of a Waters solvent controller and pump (model 600) and a 
Shimadzu auto injector (model SIL-10 AD VP).  The chromatography was carried out 
using a 250 x 4.6 mm Altech Econosil 10µm C18 reverse phase column. Detection of 
ABZ and its metabolites was carried out using a Waters Tunable Absorbance Detector CHAPTER 3 
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Figure 3.3: UV spectrums of ABZ in 0.5% DMSO in methanol (a); ABSO in 0.5% 
DMSO in methanol (b); ABSO2 in 0.5% DMSO in methanol (c) and BAB in methanol 
(d) (10µg mL
-1).  100% methanol was used as the blank. 
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(model 486) at a wavelength of 290 nm. The chromatography was recorded using a 
Hewlett Packard integrator (model 3396 series II) and the program Hewlett Packard 
Peak 96 Data Storage and Information Manager. The peak area was integrated and ABZ 
quantified by a calibration curve.   
 
The chromatographic procedure consisted of a gradient of two mobile phases to 
measure ABZ, ABSO and ABSO2 simultaneously. Mobile phase A consisted of 30% 
acetonitrile, 40% 50mM phosphate buffer pH 6.6 and 30% water (v/v/v). Mobile phase 
B consisted of 60% acetonitrile and 40% 50mM phosphate buffer pH 6.6 (v/v).  Both 
mobile phases were filtered through 0.45 µm filters. Flow rate was 1.5 ml min
-1.  The 
gradient was as described below: 
 
Time Interval (min)  Concentration of Solvent 
0.0 – 0.5  100% mobile phase A 
0.5 – 2.0  Linear gradient to 100% mobile phase B 
2.0 – 10  100% mobile phase B 
10 – 12  Linear gradient to 100% mobile phase A 
12 – 14  100% mobile phase A 
 
Standard integration events and parameters were: 
Attenuation   1-8 
Chart speed  0.5 cm min
-1 
Area Reject  10 000 
Threshold 3 
Peak Width  0.3 
Time   2.5 min  Start integration 
 14  min   Stop  integration 
 
3.2.3.1.3. HPLC standards 
The accuracy of the HPLC assay was determined by preparing standard curves of ABZ, 
ABSO, ABSO2 and the internal standard BAB. Standard ABZ, ABSO and ABSO2 
solutions were prepared in 5% DMSO in mobile phase A at concentrations between 2-
25 µg mL
-1.   BAB was prepared at the same concentrations in mobile phase A.  50µL 
was then submitted for HPLC analysis. 
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3.2.3.1.4. Sample preparation 
The extraction procedure was a modification of the method of Valois et al., (1994).  The 
drugs were extracted with 5 mL dichloromethane-isopropanol (9:1, v/v) from 0.5 mL 
plasma aliquots to which 50 µL of internal standard (BAB, 10 µg mL
-1) and 1 mL 100 
mM phosphate buffer (pH 6.6) were added.  After shaking the sample on a rocking 
platform (VariMix Thermolyne) at 1 cps for 30 min, the layers were separated by 
centrifugation (Selbys ECCO) at 2000 g for 2 min.  The organic phase was then 
transferred to conical tubes and evaporated to dryness under a nitrogen air flow in a 
heated water bath.  The residues were reconstituted with 100 µL trimethylpentane and 
200 µL mobile phase A.  After shaking for 30 s and centrifugation at 2000 g for 2 min, 
50 µL of the lower phase were submitted for HPLC analysis (Figure 3.4).  All glassware 
was scrubbed before cleaning with chromic acid as described in section 2.2.6.  
 
3.2.3.1.5. Extraction validation 
To determine the concentration of ABZ, ABSO and ABSO2 in plasma samples, standard 
curves of ABZ, ABSO and ABSO2 against the internal standard BAB after extraction 
from blank plasma were generated. Stock solutions between 10-200 µg mL
-1 ABZ, 
ABSO and ABSO2 were prepared in 5% DMSO in methanol, and 200 µg mL
-1 BAB 
prepared in methanol. 50 µL of ABZ, ABSO, ABSO2 and BAB were added to triplicate 
plasma samples (0.5 mL), with final concentrations between 0.5-10 µg mL
-1 plasma for 
ABZ, ABSO and ABSO2, and 10 µg mL
-1 plasma for BAB. Samples were then 
extracted, 50 µL submitted for HPLC analysis, and the ratio to BAB determined. 
 
To determine the efficiency of the extraction method for ABZ, ABSO, ABSO2 and 
BAB, blank plasma samples were enriched with these compounds at a concentration of 
10 µg mL
-1 plasma (above) in triplicate.  After extraction (using exactly 3 mL of the 
organic phase) and chromatographic analysis, actual drug recovery was determined by 
comparison to a standard curve. 
 
The repeatability of the assay was evaluated by determining the relative standard 
deviation of blank plasma enriched with ABZ, ABSO and ABSO2 at concentrations of 
0.5 and 10 µg mL
-1 plasma (n=10).  The RSD is expressed as a percentage and is 
calculated by dividing the standard deviation by the mean and then multiplying by 100. 
RSD (%) =
SD
x
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Figure 3.4: Extraction procedure for the measurement of ABZ, ABSO, ABSO2 and 
BAB from plasma samples.   
 
0.5 mL plasma sample
50 µL internal standard
1 mL 100 mM phosphate buffer, pH 6.6
5 mL dichloromethane/isopropanol (9:1)
Shake on a rocking platform at 1 cps for 30 min followed by 
seperation of the layers by centrifugation (2000 g for 2 min)
Remove upper 
layer and transfer 
2-3 mL of the 
lower organic 
layer to a conical 
glass tube
Evaporate to dryness 
under a stream of 
nitrogen at 35ÞC
200 µL Solvent A 
[30% acetonitrile, 40% 50mM phosphate 
buffer pH 6.6 and 30% water (v/v/v)]
100 µL trimethylpentane
Shake for 30 sec followed by 
separation of the layers by 
centrifugation (2000 g for 2 min)
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The mean values (above) were also used to determine the sample bias relative to the 
standard curves.  Bias is expressed as a percentage and is calculated by taking the 
standard curve mean from the sample mean and dividing this with the standard curve 
mean and then multiplying by 100. 
 
3.2.3.2. HPLC analysis of oryzalin 
 
3.2.3.2.1. HPLC conditions 
A Shimadzu HPLC system consisted of a communications bus module (CBM-10A), 
low pressure gradient valve (FCV-10AL), solvent delivery unit (LC-10AD), auto 
injector (SIL-10A) and UV-VIS detector (SPD-10AD) connected to a chromatography 
workstation (CLASS-LC10).  The chromatography was carried out using a 150 x 3.9 
mm Waters Symmetry C8 reverse phase column and detection of the OZ was at a 
wavelength of 282 nm (UV spectrum of OZ, Figure 2.13 Section 2.2.4.1). The peak area 
was integrated. The mobile phase consisted of 35% acetonitrile, 30% methanol and 35% 
water (v/v) filtered through 0.45 µm filters.     
 
3.2.3.2.2. HPLC standards 
The accuracy of the HPLC assay was determined by preparing a standard curve of OZ. 
Standard OZ solutions were prepared in 50% methanol at concentrations between 0.5-
10 µg mL
-1.  50µL was then submitted for HPLC analysis. 
 
3.2.3.2.3. Sample preparation 
The plasma samples were initially extracted on C18 solid phase extraction tubes (200 
mg Extract-Clean tubes - Altech) as per instructions.  Each Extract-Clean tube was 
conditioned with two tube volumes of methanol followed by two tube volumes of water.  
Sample extraction was then carried out with 0.5 mL plasma sample and 1 mL phosphate 
buffer (100 mM, pH 6.9) applied to the Extract-Clean tube.  The tube was then washed 
with 2 mL 2% acetonitrile and vacuum dried for 2 min.  The drugs were eluted with 2 
Bias (%) =
x(actual)− x(standard curve)
x(standard curve)
×100CHAPTER 3 
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mL 100% acetonitrile.  Samples were evaporated to dryness under a nitrogen air flow in 
a heated water bath and the residues reconstituted with 200 µL hexane and 200 µL 
mobile phase.  After shaking for 30 s and centrifugation at 2000 g for 2 min, 50 µL of 
the lower phase were submitted for HPLC analysis (Figure 3.5). All glassware was 
scrubbed before cleaning as described in section 2.2.6. 
 
3.2.3.2.4. Extraction validation 
To determine the concentration OZ in plasma samples, a standard curve of OZ after 
extraction from blank plasma was generated. Stock solutions between 5-100 µg mL
-1 
OZ were prepared in methanol, with 50 µL of OZ added to triplicate plasma samples 
(0.5 mL), with final concentrations between 0.5-10 µg mL
-1 plasma. Samples were then 
extracted and 50 µL submitted for HPLC analysis. 
 
To determine the extraction efficiency of the extraction method for OZ, blank plasma 
samples were enriched with OZ at a concentration of 10 µg mL
-1 plasma (above) in 
triplicate.  After extraction and chromatographic analysis, actual drug recovery was 
determined by comparison to a standard curve.  The relative standard deviation (RSD) 
and bias were determined as described in section 3.2.3.1.5. 
 
3.2.4. Statistical analysis 
 
Data analysis of pharmacokinetic experiments was carried out to determine the 
summary statistics (AUC (no smooth curving, 0-t), Cmax and Tmax) of each 
pharmacokinetic experiment, and to compare between pharmacokinetic experiments 
using repeated measures ANOVA and Bonferonni’s post test. In addition, linear 
regression was performed on all standard curves. All analysis was performed using 
GraphPad Prism version 3.0a for Macintosh, GraphPad Software, San Diego California 
USA. 
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Figure 3.5: Extraction procedure for the measurement of OZ from plasma samples. 
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3.3. RESULTS 
 
3.3.1. Albendazole  
 
3.3.1.1. Albendazole chromatography and standard curves 
 
Under the HPLC conditions described, the retention times for ABZ, ABSO, ABSO2 and 
BAB were 7.6, 3.6, 5.2 and 8.7 min respectively, at a flow rate of 1.5 mL min
-1 (Figure 
3.6).  The accuracy of the HPLC assay was determined by preparing standard curves of 
ABZ, ABSO and ABSO2 and BAB. A comparison between standard curves generated 
using peak area and peak height found peak height to be more accurate for all four 
compounds.  Peak height was therefore used for the rest of experiments. Peak height of 
ABZ, ABSO, ABSO2 and the internal standard BAB was found to increase linearly at 
drug concentrations between 2-25 µg mL
-1 (Figure 3.7) (Linear regression, r=0.9992, 
0.9984, 0.9991 and 0.9995 for ABZ, ABSO, ABSO2 and BAB respectively). 
 
3.3.1.2. Albendazole extraction validation 
 
Following plasma extraction, ABZ, ABSO and ABSO2 were quantified by height 
against that of the internal standard BAB (Figure 3.6). No interfering peaks were 
present in blank plasma for ABZ, ABSO, ABSO2 or BAB.  The LOD of the drugs for 
the assay following plasma extraction was calculated at three times the baseline noise.  
The LOQ was calculated at five times the baseline noise (Table 3.2). 
 
Table 3.2: The HPLC detection and quantitation limits for ABZ, ABSO, ABSO2 and 
BAB following extraction from plasma. 
Compound  Detection Limit (ng mL
-1)  Quantitation Limit (ng mL
-1) 
ABZ 120  200 
ABSO 80  130 
ABSO2 45  75 
BAB 55  90 
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Figure 3.6: Chromatograms of blank rat plasma (Attn. 6) (a); spiked with ABZ (7.7 
min), ABSO (3.6 min), ABSO2 (5.2 min) and BAB (8.7 min) (10 µg mL
-1) (Attn. 7) (b); 
and plasma from rat treated orally with ABZ and spiked with BAB (10 µg mL
-1) (Attn. 
6) (c). 
(a) 
(b) 
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Figure 3.7: HPLC standard curves of ABZ (Ã), ABSO (▲), ABSO2 (▼) and BAB 
() using peak height (mean ± SE, n=3). 
 
To determine the concentration of ABZ, ABSO and ABSO2 in plasma samples, standard 
curves of ABZ, ABSO and ABSO2 were generated against the internal standard BAB 
after extraction from blank plasma (Figure 3.8). The ratio of the ABZ, ABSO and 
ABSO2 peak height to the internal standard (BAB) was calculated and found to be linear 
between the drug concentrations 0.5-10 µg mL
-1.  For ABZ determination, data for the 
RSD (below) was included into the standard curve (Linear regression, r=0.9957, 0.9978 
and 0.9975 for ABZ, ABSO and ABSO2 respectively).  The repeatability of the assay 
was evaluated by determining the RSD of blank plasma enriched with ABZ, ABSO and 
ABSO2 at concentrations of 0.5 and 10 µg mL
-1 (n=10). The mean values were also 
used to determine the sample bias relative to the standard curves (Table 3.3). The RSD 
of 10 replicate samples from the mean HPLC response for ABZ, ABSO and ABSO2 
was 4.8, 4.05 and 4.9% respectively.  At 0.5 µg mL
-1, ABZ substantially deviated from 
the HPLC standard curve, with an over-estimation by 22.2%.  However, ABZ is rarely 
observed in the plasma of animals orally treated with ABZ. The extraction efficiency of 
ABZ, ABSO, ABSO2 and BAB using peak height was 98.5%, 147%, 142%, and 85% 
respectively, with the overestimation of ABSO and ABSO2 possibly due to 
contaminating metabolites (accounted for in the standard curve). 
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Figure 3.8: HPLC standard curves of ABZ (), ABSO (z) and ABSO2 (▲) using 
height ratio to BAB (10 µg mL
-1) following extraction from spiked blank plasma (mean 
± SE, n=3-13 – includes RSD values). 
 
Table 3.3: The RSD and Bias of the ABZ assay. 
Drug  RSD (%)  Bias (%) 
ABZ (0.5 µg mL
-1) 6.3  22.2 
ABZ (10 µg mL
-1) 3.3  -0.8 
ABSO (0.5 µg mL
-1) 5.2  4.4 
ABSO (10 µg mL
-1) 2.9 -1.0 
ABSO2 (0.5 µg mL
-1) 5.9  -4.2 
ABSO2 (10 µg mL
-1) 3.9  -1.8 
 
3.3.1.3. Albendazole pharmacokinetics  
 
3.3.1.3.1. ABZ pharmacokinetics at 6 mg kg
-1 
Pharmacokinetic experiments were carried out by dosing rats orally with 6 mg kg
-1 ABZ 
(Valbazen®) or ABZ/HPβCD and determining the plasma concentration of the two 
main metabolites of ABZ, ABSO and ABSO2, by HPLC. As ABZ was never detected in 
plasma, the two main metabolites ABSO and ABSO2 were evaluated (Figure 3.9). The 
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overall concentration time curves were similar between the two formulations, with 
ABSO peaking earlier and higher than ABSO2 (Table 3.4).  Both the AUC and Cmax of 
ABSO were greater for the ABZ/HPβCD complex, resulting in significantly higher 
plasma concentrations than that of the commercial formulation (repeated measures 
ANOVA with Bonferonni’s post test, p<0.05).  However, while the AUC and Cmax of 
ABSO2 were greater for the ABZ/HPβCD complex, the plasma concentrations of 
ABSO2 of the two formulations were not significantly different (repeated measures 
ANOVA with Bonferonni’s post test, p>0.05).   
 
Figure 3.9: Plasma concentrations of ABSO () and ABSO2 (---) following oral 
administration of a commercial formulation of ABZ (Valbazen® ) and ABZ/HPβCD 
(z) in rats (6 mg kg
-1) (mean ± SE, n=3). 
  
Table 3.4: Plasma concentrations of ABSO and ABSO2 after oral administrations of 
ABZ (Valbazen®) and ABZ/HPβCD (6 mg kg
-1)  (mean ± SE, n=3). 
 ABZ  (Valbazen®)  ABZ/HPβCD complex 
Compound  ABSO ABSO2 ABSO ABSO2 
TMAX (h)  1 9 1 4 
CMAX (µg mL
-1)  0.66 0.08 2.59 0.35 
AUC (µg mL
-1 h)  3.06 0.62  14.91  2.77 
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3.3.1.3.2. ABZ pharmacokinetics at 30 mg kg
-1 
In a second pharmacokinetic experiment, the pharmacokinetics of the ABZ/HPβCD 
complex were compared to that of an ABZ suspension when administered orally at 30 
mg kg
-1. As ABZ was detected in plasma samples, the plasma concentration of ABZ, 
ABSO and ABSO2 were determined by HPLC (Figure 3.10  and 3.11). Again, the 
overall concentration time curves were similar between the two formulations, with 
ABSO peaking higher than both ABZ and ABSO2 (Table 3.5).  Both the AUC and Cmax 
of ABSO were greater for the ABZ/HPβCD complex, resulting in significantly higher 
plasma concentrations of ABSO than that of the commercial formulation (repeated 
measures ANOVA with Bonferonni’s post test, p<0.05).  However, while the AUC and 
Cmax of ABZ and ABSO2 were greater for the ABZ/HPβCD complex, the plasma 
concentrations of ABZ and ABSO2 of the two formulations were not significantly 
different (repeated measures ANOVA with Bonferonni’s post test, p>0.05). 
 
Table 3.5: Plasma concentrations of ABSO and ABSO2 after oral administrations of 
ABZ (suspension) and ABZ/HPβCD (30 mg kg
-1)  (mean ± SE, n=3). 
 ABZ  (Suspension)  ABZ/HPβCD complex 
Compound  ABZ ABSO  ABSO2 ABZ ABSO  ABSO2 
TMAX (h)  1 6 6 1 6 9 
CMAX (µg mL
-1)  0.66 14.08 2.04  1.45 23.39  3.9 
AUC (µg mL
-1 h)  3.19 114.9 15.5  7.4  224.9 29.6 
 
At both 6 and 30 mg kg
-1, the ABZ/HPβCD formulations achieved significantly higher 
plasma ABSO concentrations than the commercial formulations. In comparing the two 
ABZ/ΗPβCD formulations, there is a 10 fold increase in the Cmax and 15 fold increase 
in the AUC for a five fold increase in dose.   
 
3.3.2.Oryzalin 
 
3.3.2.1. Oryzalin chromatography and standard curves 
 
Under the HPLC conditions described, the retention time for OZ was 4.7 min, at a flow 
rate of 2 mL min
-1 (Figure 3.12).  No interfering peaks were observed. CHAPTER 3 
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Figure 3.10: Plasma concentrations of ABZ (), ABSO (z) and ABSO2 (▲) following 
oral administration of ABZ/ΗPβCD (pH 2.1) in rats (30 mg kg
-1) (mean ± SE, n=3). 
 
Figure 3.11: Plasma concentrations of ABZ (), ABSO (z) and ABSO2 (▲) following 
oral administration of ABZ (Suspension) in rats (30 mg kg
-1) (mean ± SE, n=3). 
 
0 2 4 6 8 10 12 14
0
3
6
9
12
15
18
21
24
27
ABZ/CD - ABSO2
ABZ/CD - ABSO
ABZ/CD - ABZ
Time After Dosage (h)
0 2 4 6 8 10 12 14
0
3
6
9
12
15
18
21
24
27
ABZ - ABSO2
ABZ - ABSO
ABZ - ABZ
Time After Dosage (h)CHAPTER 3 
__________________________________________________________________________________________________________ 
  119
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Chromatogram of blank rat plasma (a) spiked with OZ  (4.7 min) (2 µg 
mL
-1) (b), and plasma from rat treated i.p. with OZ (c). 
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The accuracy of the HPLC assay was determined by preparing a standard curve of OZ 
(Figure 3.13). Peak area of OZ increased linearly at concentrations between 0.5-10 µg 
mL
-1 (Linear regression, r=0.9987). 
 
 
Figure 3.13: HPLC standard curve of OZ using peak area (r=0.9987) (mean ± SE, n=3). 
 
3.3.2.2. Oryzalin extraction validation 
 
Following plasma extraction, the LOD and the LOQ of OZ were 20 ng mL
-1 and 30 ng 
mL
-1 respectively.  To determine the concentration of OZ in plasma samples, a standard 
curve of OZ after extraction from blank plasma was generated. The peak area of OZ 
was calculated and found to be linear within drug concentrations 0.5-10 µg mL
-1 (Figure 
3.14). For OZ determination, data for the RSD (below) was included into the standard 
curve (Linear regression, r=0.978).  The repeatability of the assay was evaluated by 
determining the RSD of blank plasma enriched with OZ at concentrations of 0.5 and 10 
µg mL
-1 (n=10). These values were also used to determine the sample bias relative to 
the standard curves (Table 3.6). The RSD of 10 replicate samples from the mean HPLC 
response for OZ was 11.75%.  At 0.5 µg mL
-1, OZ deviated from the HPLC standard 
curve with an over-estimation by 11.65%.  The extraction efficiency of OZ was 66.4%. 
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Figure 3.14: HPLC standard curve of OZ following extraction from spiked blank 
plasma (r=0.987) (mean ± SE, n=3-15 – includes RSD values). 
 
Table 3.6: The RSD and Bias of the OZ assay. 
Drug  RSD (%)  Bias (%) 
OZ (0.5 µg mL
-1) 8 11.6 
OZ (10 µg mL
-1) 15.5 0.5 
 
3.3.2.3. Oryzalin pharmacokinetics 
 
Pharmacokinetic experiments were carried out by dosing rats i.p. with 25 mg kg
-1 OZ or 
OZ/ΗPβCD and determining plasma concentration of OZ by HPLC (Figure 3.15). The 
overall concentration time curves were similar between the two formulations, with 
plasma OZ peaking within the first hour, after which it was observed in very low 
concentrations for 8 and 16 h for OZ/ΗPβCD complex and OZ respectively (Table 3.7).  
While plasma OZ following OZ/ΗPβCD administration peaked earlier and higher than 
after OZ administration, no significant difference was observed between the two overall 
concentration time curves (repeated measures ANOVA with Bonferonni’s post test, 
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p>0.05). In addition, a yellowish discolouration of the urine was observed for the first 
two hours after OZ/ΗPβCD administration.   
 
 
Figure 3.15: Plasma concentration of OZ following i.p. administration of OZ () and 
OZ/ΗPβCD (z) in rats (25 mg kg
-1) (mean ± SE, n=3). 
 
Table 3.7: Plasma concentrations of OZ after oral administrations of OZ and 
OZ/ΗPβCD (25 mg kg
-1)  (mean ± SE, n=3). 
 OZ  OZ/ΗPβCD 
TMAX (min)  30 8 
CMAX (µg mL
-1)  5.85 8.06 
AUC (µg mL
-1 h)  5.30 6.18 
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3.4. DISCUSSION 
 
3.4.1. Albendazole 
 
3.4.1.1. Pharmacokinetics of ABZ (Valbazen®) at 6 mg kg
-1 
 
The pharmacokinetics of orally administered ABZ in a number of animals (over a range 
of doses) has been investigated by numerous researchers (Marriner & Bogan, 1980; 
Bogan & Marriner, 1984; Marriner et al., 1986; Delatour et al., 1990; 1991; Wen et al., 
1996a; Torrado et al., 1997; Evrard et al., 1998; Castillo et al., 1999; Dow, 2000).  In all 
studies the metabolic conversion of ABZ occurred rapidly in the liver.    ABSO and 
ABSO2 were the main metabolites found, with the occurrence of ABZ negligible or 
undetected.  The pharmacokinetic profiles of both ABSO and ABSO2 were similar in all 
studies, with ABSO peaking earlier and higher than ABSO2.  However, the 
bioavailability of ABZ is very different across different species.  In addition, variable 
plasma metabolite concentrations were observed within species at comparable doses, 
which may be due to the formulations of ABZ used.  Poor absorption of ABZ is likely 
due to its low water solubility, with the different formulations of ABZ resulting in 
different concentrations of dissolved ABZ in the gastrointestinal fluid.  Within studies, 
variable plasma concentrations were also often observed, and attributed to the variable 
absorption of ABZ rather than to inter-individual differences in the rate of metabolism. 
The results of the present study are considerably lower than that observed by previous 
comparable studies, which may reflect the Valbazen® suspension, as it tended to 
separate quickly.  
  
3.4.1.2. Pharmacokinetics of ABZ/ΗPβCD complex at 6 mg kg
-1 
 
The pharmacokinetics of the ABZ/ΗPβCD complex was similar to previous studies, in 
that ABSO and ABSO2 were the main metabolites found.  However, comparison 
between the pharmacokinetic profiles of ABSO for the ABZ/ΗPβCD complex and the 
commercial formulation of ABZ (Valbazen®) indicated improved bioavailability of 
ABZ when complexed with ΗPβCD, with the AUC and Cmax of ABSO 4.9 and 3.9 
times greater than for ABZ (Valbazen®) respectively.  This would be due to the CHAPTER 3 
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increased concentration of dissolved ABZ in the gastrointestinal fluid available for 
absorption, and the relatively faster dissociation of the ABZ/ΗPβCD complex to release 
free dissolved ABZ, as opposed to suspended ABZ formulations. In addition, ΗPβCD 
complexation did not affect ABZ metabolism. The improved bioavailability of the 
ABZ/ΗPβCD formulations over conventional formulations is comparable to that 
observed by Lange et al., (1988) when ABZ concentrations improved 4 fold in patients 
administered 400mg ABZ with a fatty meal over ABZ alone. 
 
3.4.1.3. Pharmacokinetics of ABZ (Suspension) at 30 mg kg
-1 
 
As in previous studies, the pharmacokinetics of ABZ using the commercial ‘white 
drench’ formulation (Section 3.2.2.1.2) resulted in the rapid metabolic conversion of 
ABZ to ABSO and ABSO2, with only low concentrations of ABZ observed.  Based on 
the relative areas under the curve, the suspension was more effective than the 
commercial formulation of Valbazen®. Valbazen® is a commercial formulation 
designed for use in cattle and sheep, and is made from raw ABZ. Therefore differences 
between the two formulations may result from differences in particle size or other 
physiochemical characteristics.  In addition, unlike Valbazen®, the white drench did not 
separate, with ABZ staying in suspension for longer periods of time.   
 
3.4.1.4. Pharmacokinetics of ABZ/ΗPβCD complex (pH 2.1) at 30 mg kg
-1 
 
The pharmacokinetics of the ABZ/ΗPβCD complex (pH 2.1) was also similar to 
previous studies, resulting in the rapid metabolic conversion of ABZ to ABSO and 
ABSO2, with only low concentrations of ABZ observed.  Comparison between the 
pharmacokinetic profiles of ABSO for ABZ/ΗPβCD and ABZ (suspension) given at 30 
mg kg
-1 indicated improved bioavailability of ABZ when complexed with ΗPβCD, with 
the AUC and Cmax of ABSO 1.7 and 2 times greater than for ABZ (suspension) 
respectively.   
 
The pharmacokinetics of ABZ/CD in multicomponent systems compared to commercial 
formulations has been investigated in sheep and mice at 5 and 20 mg kg
-1 respectively, 
by Evrard et al., (1998) and Castillo et al., (1999).  These formulations were CHAPTER 3 
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administered as solutions of low pH (approximately 3) in order to achieve sufficient 
ABZ concentrations.  In both cases, ABZ/CD complexation resulted in reduced Tmax, 
and greater AUC and Cmax of ABSO (approximately double) over commercial 
formulations.  In the present study the ABZ/ΗPβCD complex given at 30 mg kg
-1 was 
also of low pH (pH 2.1), and resulted in approximately double the AUC and Cmax of 
conventional formulations at the same dose. Again, this would be due to the increased 
solubility of ABZ in the gastrointestinal tract. 
 
At both 6 and 30 mg kg
-1, the ABZ/ΗPβCD formulations achieved significantly higher 
plasma ABSO concentrations than the commercial formulations.  In comparing the two 
ABZ/ΗPβCD formulations, there is a 10 fold increase in the Cmax and 15 fold increase 
in the AUC for a five fold increase in dose.  This indicates improved bioavailability of 
ABZ from the pH modified formulation.   
 
ABZ is metabolised to ABSO in the presence of MFMO and/or cytochrome P-450, with 
the involvement of these enzymes varying between species and tissues (Section 
2.1.2.3.2).  ABSO exhibits chirality with two enantiomeric forms present in the plasma.  
The plasma concentration of the enantiomers varies between animal species depending 
on the involvement of these enzymes, with the (-) ABSO enantiomer dominant in mice 
and rats, and (+) ABSO dominant in sheep, dogs and humans (Delatour et al., 1990; 
Delatour et al., 1991; García-Rodriguez et al., 2001).  After administration the plasma 
concentration ratio of (-) and (+) ABSO also changes, which is thought to be due to 
substrate enantio-selectivity of the cytochrome P-450-dependent sulphonating reaction 
(Auret et al., 1968; Delatour et al., 1991).  García-Rodriguez et al., (2001) investigated 
the proportion of the enantiomers in mice following oral administration of an ABZ 
suspension and an ABZ/ΗPβCD complex.  They found that complexation significantly 
increased the proportion of the more abundant enantiomer (-), and as the ABZ/ΗPβCD 
formulation also exhibited improved anthelmintic activity, proposed that it was the form 
responsible for anthelmintic activity.  However, these researchers did not elaborate on 
the actual plasma concentrations of the enantiomers.  This is particularly important as 
the ABZ/ΗPβCD complex also resulted in increased plasma ABSO concentrations 
(García-Rodriguez et al., 2001). Therefore further research is required into the 
relationship between overall the ABSO concentration, the ratio of the enantiomers, and CHAPTER 3 
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the actual concentrations of the enantiomers following oral administration of an 
ABZ/ΗPβCD complex.  This is particularly so for species where (+) ABSO is the more 
abundant enantiomer.  Overall however, these results indicate that ABZ/ΗPβCD 
complexation may improve anthelmintic activity not only due to increased ABSO 
concentrations, but also due to increased proportions of the anthelmintic enantiomer.  
 
3.4.2. Oryzalin 
 
3.4.2.1. Pharmacokinetics of OZ 
 
The pharmacokinetics of parenterally administered OZ in mice has been investigated by 
Dvorakova et al., (1997) and Powis et al., (1997).    As was observed in the present 
study, orally administered OZ resulted in very low OZ plasma concentrations, and was 
attributed to either poor absorption or first pass metabolism.  Therefore the 
pharmacokinetics of parenterally administered OZ was evaluated, with the 
pharmacokinetic profile of OZ similar across studies. Both Dvorakova et al., (1997) and 
Powis et al., (1997) also identified a major metabolite of OZ as N-depropyl oryzalin.  A 
metabolite was observed in the current experiment (Figure 3.12, metabolite A), although 
it was not identified and its pharmacokinetics was not followed.   
 
3.4.2.2. Pharmacokinetics of OZ/ΗPβCD complex 
 
In general, the pharmacokinetics of OZ following i.p. administration of OZ was 
unaffected by ΗPβCD complexation.  Similar results have been observed for other 
drug/ΗPβCD complexes following intravenous administration (Arimori & Uekama, 
1987; Frijlink et al., 1991b; Löscher et al., 1995). While no significant difference was 
observed between the pharmacokinetic profiles of OZ and the OZ/ΗPβCD complex, OZ 
plasma concentrations following OZ/ΗPβCD administration peaked earlier and higher 
than after OZ administration, and the drug was eliminated from the plasma sooner.  Due 
to dilution of the complex by distribution fluids and competition for the OZ and ΗPβCD 
by plasma components (Section 3.1.2), only a small fraction of parenterally 
administered OZ/ΗPβCD is likely to remain complexed.  This would be exacerbated as 
the nitro groups of OZ are strong hydrogen bonders, with OZ strongly tissue bound.  CHAPTER 3 
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The faster Tmax and higher Cmax of the OZ/ΗPβCD formulation observed is most likely 
due to the initial higher mobility of the complex as it moved into the circulatory system 
before dissociation occurred.  In comparison, the faster plasma OZ elimination and 
urine discolouration following OZ/ΗPβCD administration is likely to be due to 
increased renal clearance of the drug in the complexed form.  While dissociation of the 
OZ/ΗPβCD complex is expected in the bloodstream, concentration of both OZ and 
ΗPβCD in the kidneys may result in their recomplexation and accelerated elimination. 
Similar results have been observed following the intravenous administration of 
dexamethasone/HPβCD complex in dogs (Dietzel et al., 1990).  As the renal clearance 
of HPβCD is rapid, these effects should be manifested soon after drug complex 
administration (Habon et al., 1984; Anderson et al., 1990; Dietzel et al., 1990).   
 
Arimori & Uekama, (1987) followed the pharmacokinetics of prednisolone both alone 
and complexed with (β and γ) CD following intravenous and intramuscular 
administration.  While prednisolone/CD complexation did not improve prednisolone 
serum levels following intravenous administration, it was improved following 
intramuscular administration as a suspension (but not when a solution).  This can be 
explained by intramuscular administration resulting in similar 
dissolution/dissociation/re-complexation characteristics as when administered orally.   
Therefore intramuscular administration of OZ may be an alternative to its oral 
administration. 
 
3.4.3. Complexation behaviour of inclusion compounds in the gastrointestinal tract 
 
As in the present study, both Evrard et al., (1998) and Castillo et al., (1999) 
administered an ABZ/ΗPβCD complex for pharmacokinetic experiments as a solution.  
As these experiments did not use the ABZ/ΗPβCD complex as a solid inclusion 
compound, dissolution of the formulation was not necessary.  This would result in free 
ABZ immediately available for absorption.  In addition, as the ABZ/ΗPβCD complex 
given at 6 mg kg
-1 was of a neutral pH, the formulation would not undergo the 
dissociation process as a solid inclusion compound would after administration. There 
would have been no precipitation of ABZ, with the ABZ not present in all the phases as 
described in figure 3.1  CHAPTER 3 
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ABZ/ΗPβCD complex-dissolved + ABZ-dissolved + ΗPβCD-dissolved + ABZ-solid  
 
Therefore, as ABZ was absorbed from the gastrointestinal tract, the amount of free ABZ 
would start to immediately decrease, and the amount of excess ΗPβCD would hence 
start to increase.  Due to the very high stability constant of the ABZ/ΗPβCD complex at 
a neutral pH (Chapter 2), excess ΗPβCD would have had a negative impact on the 
pharmacokinetics by reducing the amount of free ABZ available for absorption.  As can 
be seen in figure 3.9 and table 3.4 however, there was still a substantial increase in both 
AUC and Cmax over conventional formulations.   
 
In comparison, the ABZ/CD formulations of Evrard et al., (1998) and Castillo et al., 
(1999), and the ABZ/ΗPβCD complex given at 30 mg kg
-1, were of a low pH (between 
2.1-3).  Upon reaching the small intestine, where the pH is between 7-8, the pH of the 
formulations would be raised, resulting in the precipitation of ABZ.  Therefore the 
amount of excess CD would not increase until free ABZ started to decrease. This would 
occur only after all precipitated ABZ was redissolved, as the equilibrium that exists 
between free CD, free ABZ and the ABZ/CD complex would continue to redissolve the 
precipitated ABZ as the free ABZ is removed by absorption into the circulation. This is 
because complexation lowers the thermodynamic activity of the dissolved drug, with 
more drug dissolving until the activity of the free drug, which is in chemical equilibrium 
with the complex, becomes equal to the thermodynamic activity of the pure solid drug 
(Jones et al., 1984).  The detrimental effect of excess CD would not be observed until 
the majority of the ABZ was already absorbed, resulting in greater AUC and Cmax.   
 
3.4.4. Conclusion 
 
Orally administered ΗPβCD did not exceed 1.5 g kg
-1, and thus within the limits for 
orally administered HPβCD as described by Strattan, (1992) (Section 1.7.1).  The 
ABZ/ΗPβCD complex at 30 mg kg
-1 was formulated in 60% ΗPβCD at pH of 2.1.  
Intragastric administration by intubation of this formulation had no adverse effects. The 
ABZ pharmacokinetic experiments revealed that complexation of ABZ with ΗPβCD 
improved drug bioavailability systemically, indicating a potential for improved efficacy CHAPTER 3 
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of ABZ against systemic parasites such as malaria and Echinococcus over conventional 
ABZ formulations. 
 
ΗPβCD administered i.p. did not exceed 0.72 g kg
-1, and was also within the limits for 
single dose of HPβCD by parenteral administration as described by Strattan, (1992).  In 
comparison, the OZ/ΗPβCD complex at 25 mg kg
-1 was formulated in 60% ΗPβCD at 
pH of 11.  Administration of this formulation i.p. at 0.1 mL kg
-1 appeared to cause no 
adverse effects. However larger or multiple doses of this formulation resulted in 
chemical peritonitis and metabolic alkalosis. In addition, the results of the OZ 
pharmacokinetic study did not indicate that the OZ/ΗPβCD complex would result in 
improved bioavailability of OZ for the treatment of systemic parasites. CHAPTER 4 
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4.1. INTRODUCTION  
 
4.1.1. Cellular interactions of CDs 
 
Various components of cells, such as membrane incorporated cholesterol, phospholipids 
and proteins, are solubilized by CD (Ohtani et al., 1989; Irie et al., 1992c; Bar, 1994; 
Nakanishu et al., 1994). However CDs do not bind to cells or enter the cholesterol 
monolayer, but extract membrane components by forming a new lipid-containing 
compartment in the aqueous phase into which the components of the cell surface can be 
extracted (Ohtani et al., 1989). The removal of cholesterol and phospholipids may result 
in increase membrane fluidity, resulting in membrane invagination through a loss of 
bending resistance, and consequently lead to lysis of the cell (Ohtani et al., 1989; Irie & 
Uekama, 1997). The haemolytic activity of CDs correlates with their ability to form 
inclusion compounds with membrane lipids, rather than their intrinsic solubility or 
surface activity. The haemolytic activity of the natural CDs is in the order of β-CD > α-
CD > γ-CD (Irie et al., 1982). These differences are due to the differential solubilization 
of membrane components by each CD, which is dependent on the size and 
hydrophobicity of the cavity in which the lipids are included (Irie et al., 1992c; Bar, 
1994).  For example, the acyl chain of phospholipid fits tightly into the hydrophobic 
cavity of α-CD and more loosely in to the larger CDs, while cholesterol is preferentially 
included into the β-CD cavity (Bar, 1994).  
 
 Ohtani et al., (1989) investigated the differential effects of the parent CDs on 
erythrocytes, and found the solubilization and extraction of lipids was in the order of β-
CD >> α-CD > γ-CD for cholesterol, and α-CD > β-CD >> γ-CD for phospholipids.  As 
the interaction between CDs and proteins is limited, the extraction of proteins from 
membranes was thought to result more from the disintegration of the membrane 
accompanied by the release of proteins, rather than from protein solubilization through 
complexation (Ohtani et al., 1989). As variable cytotoxicity has been observed in 
different cell types (Garay et al., 1994), the ratio of these lipids within cells may affect 
their susceptibility to different CDs.  
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The surface activity of the chemically modified CDs is an additional factor that may 
further enhance their interactions with cells (Bar, 1994). The haemolytic activity of 
some derivatized CDs in comparison to β-CD is reported to be in the order of partially 
methylated β-CDs ≈ methyl β-CD > DMβCD ≈ RMβCD ≈ β-CD > HPβCD (Garay et 
al., 1994). Irie et al., (1992c)  found that methylated CDs significantly extracted 
membrane lipids such as cholesterol and phospholipids from the nasal mucosa, and 
were capable of interacting with, and sequestering, Ca
2+, which is also likely to result in 
membrane erosion. In comparison, HPβCD resulted in minimal membrane erosion (Irie 
et al., 1992c; Shao et al., 1992; Marttin et al., 1995). In addition, certain types of CDs 
(at appropriate concentrations) may weakly and non-destructively interact with certain 
cells based on hydrogen bonding between the hydroxylic groups of CDs and ionophoric 
groups on the cell wall and membrane.  It is also possible for hydrophobic interactions 
to take place between chemically modified CDs and hydrophobic components of the 
cell wall and membrane (Bar, 1994).  These interactions have been suggested to explain 
enhancement in microbial growth of Streptomyces (Sawada et al., 1990) and enhanced 
microbial conversions in Saccharomyces cerevisiae (Singer et al., 1991) and 
Rhodococcus erythropolis (Jadoun & Bar, 1993b).  Either interaction could generate a 
higher affinity of CD complexes to cells, potentially resulting in the targeting of 
compounds to particular cells. 
 
Damage due to CDs observed in vitro is often not observed in vivo.  While dilution is 
the most obvious factor, plasma and tissues also have considerable buffering capacity 
towards the adversary action of CD solubilizers (contain a variety of complexable 
lipophiles) (Pitha, 1992; Garay et al., 1994).  In addition, CDs are non-specific 
solubilizers that deplete membrane lipids in a uniform way, a type of damage that cells 
can repair efficiently (Pitha, 1992).  In the intestine, β-CD was found to liberated 
cholesterol from the intestine only after the removal of mucin from the luminal surface 
of the gastrointestinal tract by treatment with N-acetyl-L-cysteine (Nakanishu et al., 
1990 and 1994).  Therefore, mucin potentially disturbs the direct interaction of CD (and 
drugs) with the mucosal membrane after oral administration. 
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4.1.2. Effect of CD on drug membrane diffusion 
 
As already discussed, CD molecules bring the hydrophobic guest molecules into 
solution, keep them in the dissolved state, transport them to the lipophilic membrane, 
and deliver them to the cell (Szejtli, 1991b).  Therefore transepithelial transport is 
attributed to a sequential dissociation-diffusion-partition process that provides free drug 
molecules to the cell, rather than the complex transferring the drug to the cell surface 
via a collision-mediated process (Ohtani et al., 1989; Cho et al., 1995).  The rate of 
passive diffusion of complexed drugs is affected by both drug characteristics (size, 
solubility, lipophicity) and complex characteristics (stability constant, solubility) 
(Duchêne et al., 1987). For example, the more stable the complex, the lower the 
diffusion, and the longer the time period over which drug diffusion can be maintained 
(Jones & Grant, 1984).  
 
At low CD concentrations, the extraction of membrane components can result in 
increased cell permeability without adversely affecting cell viability.  Therefore CDs 
may also act as drug absorption enhancers, with the transport enhancing properties of 
the CDs correlating with the lipophilicity of their core (Hovgaard & Brøndsted, 1995).  
DMβCD in particular has been found to be one of the most powerful CD drug 
absorption enhancers (Merkus et al., 1991; Irie et al., 1992c; Shao et al., 1992; 1994; 
Garay et al., 1994; Hovgaard & Brøndsted, 1995; Marttin et al., 1995).  For example, 
DMβCD has been found to be a potent enhancer of insulin absorption after oral or nasal 
administration, with enhanced absorption attributed to increased membrane 
permeability (Merkus et al., 1991; Irie et al., 1992c; Shao et al., 1992; 1994).  However, 
the effects of CDs on cell membranes can also be inhibited by drug complexation (Irie 
& Uekama, 1997). Other factors that may contribute to increased drug bioavailability 
due to CDs is the inhibition of proteolytic activity on complexed drugs, and the 
disassociation of drug oligomers upon complexation (Irie et al., 1992c; Shao et al., 
1992). For a review of drug absorption enhancement by CDs, see Marttin et al., (1996).   
 
Administration of drug/CD complexes has also been found to reduce drug-induced 
hemolysis or irritation. This is achieved at low CD concentrations, where CDs both 
reduce the surface activity and decrease the uptake of drugs by cells (Uekama et al., CHAPTER 4 
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1981).  This has been attributed to a decrease in the effective drug concentration 
through inclusion complex formation rather than the direct stabilizing interaction of CD 
with the cell membrane (Uekama et al., 1981; 1983).  Hence the tolerable level of toxic 
substances that can be complexed by CD increases (Szejtli, 1992).  This protective 
effect correlates with the stability constants of the drug/CD complexes (Uekama et al., 
1983).   
 
4.1.3. Aim 
 
The purpose of this study was to investigate the in vitro cytotoxicity of the antiparasitic 
agents ABZ and OZ both alone and complexed, and to investigate the cytotoxicity of 
HPβCD. In addition, the in vivo consumption of ΗPβCD by rats was investigated to: 1) 
determine if rats would drink ΗPβCD solutions, and 2) ensure no adverse effects would 
come to animals when given drug/ΗPβCD solutions in later experiments (Chapter 5). 
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4.2. METHODS 
 
4.2.1. Cytotoxicity of drug/ΗPβCD complexes and ΗPβCD 
 
Cytotoxicity to host cells was determined using the CytoTox 96® assay kit (Promega, 
USA).  This is a colourmetric assay that measures lactate dehydrogenase released as a 
consequence of compromised cellular and membrane integrity.  The assay was 
performed according to the manufacturer’s instructions in quadruplicate, with 
absorbance values determined in duplicate.   
 
4.2.1.1. Preparation of HCT-8 cells 
 
The cultivation of the human ileocaecal adenocarcinoma cells (HCT-8 cells) was as 
described in section 6.2.1.2, and cultivated HCT-8 cells were prepared for growth in 24 
microwell plates as described in section 6.2.2.1.  The cells were suspended in 12.5 mL 
of warm medium and 500 µL aliquots per well were then dispensed into 24 microwell 
plates.  These were incubated at 37°C in 5% CO2 for 24 h before media was removed 
and drugs administered. Cells were confluent when exposed to drugs. 
 
4.2.1.2. Administration of drugs  
 
The cytotoxicity of ABZ and OZ dissolved in DMSO was compared to these drugs 
when formulated in ΗPβCD, and evaluated against HCT-8 cells.  In addition, the 
cytotoxicity of ΗPβCD was investigated.  100 mM solutions of ABZ and OZ were 
made up in 100% DMSO and then diluted in 100% DMSO to x1000 the concentration 
required in the experiments.  These were then diluted 1/1000 in 1% FBS RPMI media 
(Section  6.2.1.2.1) to create the concentrations required during the course of the 
experiment. The final DMSO concentration in the cultures containing DMSO was 0.1%. 
The required ΗPβCD concentration was made up in 1% FBS RPMI media. 
ABZ/ΗPβCD and OZ/ΗPβCD were diluted from stock solutions with 1% FBS RPMI 
media and investigated over the same concentration range as the drugs dissolved in 
DMSO. 500 µL of each drug solution was added to the HCT-8 cells randomly in 
quadruplicate and incubated for 24 h. The control cultures contained either drug vehicle CHAPTER 4 
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or dH2O as appropriate.  The assay also required 4 additional controls, which were 
included in quadruplicate.  These were: 
 
1.  Media Control (background absorption) 
2.  Cell Spontaneous Release Control (accounts for LDH spontaneously released) 
3.  Cell Lysis Control (maximum LDH release) 
4.  Media Volume Control (control for Cell Lysis) 
 
4.2.1.3. CytoTox 96 assay procedure  
 
Drug experiments were carried out for 24 h.  45 min before the completion of the 
experiment, 50 µL lyse solution (9%(v/v) Triton® X-100) was added to the Cell Lysis 
Control and the Media Volume Control.  On completion of the experiment, all the 
samples were centrifuged at 240 g for 4 min before dilution.  The Cell Lysis Control 
samples were diluted 1:50, all other samples were diluted 1:20.  50 µL was then added 
to a 96 well plate, followed by 50 µL reconstituted substrate mix (kit), and the plate 
covered in alfoil and incubated of 30 min at room temperature.  After 30 min, 50 µL 
stop solution (1M acetic acid) was added, any bubbles were removed, and the 
absorbance read at 490 nm within 1 h. 
 
4.2.1.4. Calculations 
 
1.  Determine averages and account for dilutions 
2.  Subtract the absorbance of the Media Control from the experimental samples 
and Cell Spontaneous Release Control 
3.  Subtract the absorbance of the Media Volume Control from Cell Lysis Control 
4.  Determine cytotoxicity with the formula: 
 
% Cytotoxicity=
Experimental - Spontaneous Release
Corrected Total Cell Lysis
×100CHAPTER 4 
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4.2.1.5. Statistical analysis 
 
LDH release from control and drug treated cultures were compared using t-tests.   
Analysis was performed using GraphPad Prism. 
 
4.2.2. ΗPβCD consumption in vivo 
 
4.2.2.1. Origin and housing of experimental animals 
 
Three to seven-week-old albino male Rattus norvegicus (Sprague Dawley Strain) were 
used in all Giardia in vivo experiments.  They were housed in an animal house 
maintained on a 12:12 h photoperiod at 21-24°C and were fed Rat and Mouse Cubes 
manufactured by Glen Forrest Stockfeeders, Western Australia. Rats were housed two 
to three animals per standard rat cage and food was provided ad libitum.  All animals 
were obtained from the Western Australian State Animal Resource Centre, Perth, 
Western Australia. The Murdoch University Animal Ethics Committee, in accordance 
with national animal welfare standards, approved the following experiments. 
 
4.2.2.2. ΗPβCD consumption 
 
To determine if the rats would drink ΗPβCD solutions, animals (of specific age) were 
housed two to three animals per standard rat cage and given a range of ΗPβCD 
concentrations over three to four days. Preference/tolerance for ΗPβCD was determined 
by twice daily monitoring of fluid consumption and rat weight.  Experiments were 
terminated if there was no fluid consumption or if animal weight declined.  
 
 
 CHAPTER 4 
__________________________________________________________________________________________________________ 
  138
4.3. RESULTS 
 
4.3.1. Cytotoxicity of drug/ΗPβCD complexes and ΗPβCD alone 
 
4.3.1.1. Cytotoxicity of drug formulations 
 
The cytotoxicity of ABZ and OZ against HCT-8 cells was investigated over a range of 
concentrations up to 100 µM.  Both ABZ and OZ, formulated with ΗPβCD or dissolved 
in DMSO, were found to have insignificant cytotoxicity (< 0.8% LDH release compared 
to controls) against HCT-8 cells up to 100 µM (t-test, p>0.05).  However, while ABZ 
was not cytotoxic to cells (insignificant LDH release), it did cause cells to lift from the 
wells when administered either alone or as a ΗPβCD complex. 
 
4.3.1.2. Cytotoxicity of ΗPβCD 
 
The cytotoxicity of ΗPβCD alone against HCT-8 cells was evaluated (Figure 4.1).  It 
was found that ΗPβCD concentrations of 2.5% and higher resulted in significant 
cytotoxicity, with LDH release greater than 2.5% (t-test at ≥2.5% ΗPβCD, p<0.05). 
Figure 4.1: Cytotoxicity of ΗPβCD against HCT-8 cells after 24 h incubation (mean ± 
SE, n=4). 
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4.3.2. ΗPβCD consumption 
 
In vivo ΗPβCD consumption by rats was measured to determine if they would drink 
ΗPβCD solutions, and to ensure no adverse effects would come to animals when given 
drug/ΗPβCD solutions in later experiments (Chapter 5). The maximum concentration of 
ΗPβCD that was tolerated by the rats was determined as the concentration at which the 
animals continued to drink ‘normal’ volumes while maintaining a ‘normal’ increase in 
body weight when compared to control animals (given water only). ΗPβCD 
concentrations above 5% were found to be less tolerable than water, with concentrations 
of 10% ΗPβCD and greater being unacceptable to the animals.  This was correlated 
with drops in body weight, which resulted in termination of experiments (Figure 4.2).  
Tolerance of the ΗPβCD solutions appeared to vary with age (Figure 4.3), with three-
week-old rats having a higher tolerance for ΗPβCD solutions.  In fact, ΗPβCD 
solutions of 5% and less were consumed in slightly greater amounts than water by 
control animals. 
 
Figure 4.2: Average fluid consumption by five to seven-week-old rats given either 
water or ΗPβCD solution (mean, n=3). 
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Figure 4.3: Average fluid consumption by three-week-old rats given either water or 
ΗPβCD solution (mean, n=3). 
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4.4. DISCUSSION 
 
4.4.1. Drug cytotoxicity 
 
4.4.1.1. Albendazole 
 
 Whittaker & Faustman, (1991) investigated the in vitro developmental toxicity of ABZ 
and ABSO on rat embryo cells by assessing their effect on cell growth, cell 
differentiation and cytotoxicity using a number of methods.  Both ABZ and ABSO were 
found to be potent inhibitors of cell growth and differentiation.  ABZ was found to be 
approximately 50-fold more potent than ABSO, with IC50s of approximately 0.3-0.4 µM 
for ABZ and 15-18 µM for ABSO. Cytotoxicity assays for both compounds yielded 
higher IC50s, with the inhibition of cell growth and differentiation in the absence of 
cytotoxicity attributed to the toxicants being selective for proliferating or differentiating 
cells.  In addition, both compounds elicited an accumulation of cells in the mitotic phase 
of the cell cycle, with these cells raised from the surface of the culture dish.  The 
increased toxicity of ABZ over ABSO was attributed to the inability of rat embryo cells 
to metabolise ABZ to ABSO, and the lower potency of ABSO attributed to its higher 
polarity and hence lower lipophilicity, resulting in its lower cellular penetration and 
interaction with the target site(s) relative to ABZ.  The lack of ABZ cytotoxicity against 
HCT-8 cells observed in the present study (greater than 100 µM) could therefore be 
attributed to the lack of cellular differentiation or growth occurring during the 
cytotoxicity assay, and the cells ability to metabolise ABZ to ABSO.  In addition, ABZ 
was found to cause cells to lift from the wells when administered either alone or as a 
ΗPβCD complex, without any increase in cytotoxicity.  Whittaker & Faustman, (1991) 
also observed similar results, with >90% of suspended cells (that were previously 
attached) still viable, as they were able to exclude trypan blue dye in viability 
determinations.  However, care must be taken when comparing between different 
cytotoxicity systems as differing sensitivities to the benzimidazoles exist between 
species.  The benzimidazoles are microtubule inhibitors and act by binding dimeric 
tubulin (Section 2.1.2), and subsequently interfere with a range of cellular functions 
(Section 2.1.1).  The ultimate fate of arrested cells after ABZ administration is unclear, 
and is probably dependent on the drug concentration, cell type and length of exposure CHAPTER 4 
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(Whittaker & Faustman, 1992).  Therefore the effect of ABZ and its metabolites on both 
rapidly proliferating and differentiating cells must be considered when evaluating 
treatment regimes for parasitic infections. 
 
In the ABZ pharmacokinetic experiments (Chapter 3), ABZ was rapidly metabolised to 
ABSO, with low concentrations of plasma ABZ observed in animals dosed orally with 
30 mg kg
-1 ABZ and ABZ/ΗPβCD (up to 5.4 µM).  The highest concentration of ABSO 
achieved in the ABZ pharmacokinetics experiments was 83 µM, with the majority of 
ABZ metabolites eliminated from the body within 12 hours. Therefore at these 
concentrations (<100 µM), ABZ and its metabolites would have resulted in minimal 
overall cytotoxicity. However, their effect on rapidly proliferating and differentiating 
cells within the body would be relative to the cells ability to metabolise ABZ and the 
length of toxicant exposure.   
 
4.4.1.2. Oryzalin 
 
Previously published results found OZ to inhibit a variety of tumour cells in culture, 
with IC50s in the range of 2-25 µM (Dvorakova et al., 1997; Powis et al., 1997). Here 
however, OZ exhibited no cytotoxicity against HCT-8 cells (up to 100 µM) using the 
CytoTox 96® kit.  Reasons for the different results may involve the types of cancer 
cells selected, or the criteria for evaluating cytotoxic effect.  The method used here 
measured cytotoxicity based on LDH release from cultured cells, while previous 
methods measured cytotoxicity based on cell proliferation assays.  This suggests that 
OZ may also be selective for proliferating or differentiating cells, similar to ABZ. These 
results are not surprising, as both drugs affect the microtubule system (Section 2.1.1).   
This may also explain the reduced efficacy of OZ observed against tumours inoculated 
into mice when time between tumour inoculation and OZ administration increased 
(Powis et al., 1997).   
 
The maximum plasma concentrations (Cmax) achieved in pharmacokinetic experiments 
(Chapter 3) were 17 and 23.3 µM for the OZ and OZ/ΗPβCD formulations respectively 
when given to rats i.p at 25 mg kg
-1.  The pharmacokinetics of OZ in other studies also 
resulted in Cmax < 100 µM. Powis et al., (1997) achieved a maximum of 37 µM after s.c. CHAPTER 4 
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administration of up to 1200 mg kg day
-1 for 3 days, while Dvorakova et al., (1997) 
achieved 72.2 µM after a single i.p. dose of 200 mg kg
-1. Therefore these concentrations 
were insufficient to result in any cytotoxic effect against living cells based on the 
CytoTox 96® kit.  However, the effect of OZ on rapidly proliferating and 
differentiating cells within the body must be evaluated, and taken into consideration in 
future when determining treatment regimes for parasitic infections. 
 
4.4.1.3. Effect of complexation on drug cytotoxicity 
 
Complexation of ABZ or OZ with ΗPβCD did not induce either positive of negative 
effects on drug cytotoxicity.  Therefore complexation of these drugs with ΗPβCD did 
not result in either increased cytotoxicity due to increased membrane permeability, or 
reduced cytotoxicity, particularly for ABZ, due to reduced drug surface activity and 
decreased the uptake of drugs by cells due to complexation (Section 4.1.2) .    T h e  
maximum  ΗPβCD concentration for both formulations (at 100 µM) was 0.67 and 
0.94% ΗPβCD for ABZ/ΗPβCD and OZ/ΗPβCD respectively, so no adverse effects 
from the ΗPβCD alone were expected (see below). 
 
4.4.2. ΗPβCD cytotoxicity  
 
The lack of selectivity and the rapidity with which the guests in CD complexes may be 
exchanged make it necessary to evaluate the impact CD has on tissue components. 
ΗPβCD was found to be cytotoxic at greater that 2.5% ΗPβCD, probably due to 
membrane disruption caused by the dissolution and removal of membrane components.  
This effect is likely to be reversible, depending on the capacity for the cells to replace 
lost membrane components following the removal of ΗPβCD.  The cytotoxicity of 
HPβCD has been investigated by a number of reporters (Yoshida et al., 1988; Irie et al., 
1992b; Shao et al., 1992). Shao et al., (1992) found HPβCD at 5% resulted in only 
minimal removal of epithelial membrane proteins, with no LDH activity, while Yoshida 
et al., (1988) observed cell haemolysis started at 0.5%, with an EC50 of approximately 
1.8%.  However both found the irritancy of HPβCD to be significantly lower than for α-
CD, β-CD and methylated CDs. Any variability in the results is most likely due to the 
degree of substitution of HPβCD, as haemolysis and complexing ability decrease with CHAPTER 4 
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increasing degree of substitution (Section 1.4) (Yoshida et al., 1988).  In addition, Irie et 
al., (1992b) found HPβCD preferentially solubilized cholesterol.  Therefore when 
evaluating drug/CD complexes in vitro, it is important to consider the CD concentration, 
as high concentrations can cause cell haemolysis.  However, the concentrations 
investigated here are considerably higher than would normally be reached when 
administering drugs as a complex.  While high ΗPβCD concentrations were found to be 
detrimental to HCT-8 cells, damage due to CDs observed in vitro is often not observed 
in vivo (Section 4.1.1).  In addition, due to the rapid equilibrium reached between CD 
and endogenous lipophiles, a rapid and full distribution of lipophiles into the accessible 
tissues and to lipoproteins is likely to occur.  Therefore HPβCD may function as a 
catalyst of lipid exchange within the organism (Irie et al., 1992b). 
 
4.4.3. ΗPβCD consumption  
 
The in vivo consumption of ΗPβCD solutions by rats was investigated to determine 
what concentration of ΗPβCD rats would drink for future in vivo drug/ΗPβCD 
experiments. ΗPβCD solutions of up to 5% ΗPβCD were found to be acceptable to rats, 
with fluid consumption comparable to or greater than that of control animals (given 
water).  Castro-Hermida et al., (2000) also observed suckling mice not to be adversely 
affected by a 2.5% β-CD suspension, with no noticeable effects on weight gain or 
suckling behaviour in treated verses control animals.  The decreased preference for 
ΗPβCD solutions of higher concentration was attributed to the higher viscosity and 
‘stickiness’ of the solutions.  The age of the animals was found to influence ΗPβCD 
consumption, with younger rats (3 w) having an increased preference for ΗPβCD 
solutions in comparison to the older rats (5-7 w).  This was possibly associated with the 
sweeter flavour of the ΗPβCD solution.  Therefore the results were not particularly 
surprising, as considerable evidence that a preference of sweet flavours in a number of 
juvenile mammals exists (Desore et al., 1973; Wurtman & Wurtman, 1979; Marlin, 
1983; Desore & Beauchamp, 1987; Graaf & Zandstra, 1999).   
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5.1. INTRODUCTION  
 
5.1.1. Giardia  
 
5.1.1.1. Lifecycle 
 
Giardia is a binucleate flagellated protozoan parasite that infects the small intestine of a 
number of vertebrate animals (Meyer, 1985; Adam, 1991; 2001).  It has a simple 
asexual life cycle, which includes a trophozoite and cyst form (Figure 5.1).  The 
trophozoite multiplies by binary fission and colonises the upper two thirds of the small 
intestine by attaching to the mucosa at the bases of the microvilli (Meyer, 1985; 
Ampofo et al., 1991). Encystment begins with the trophozoite rounding up to form an 
immature cyst.  Giardia has two nuclei that then undergo a single division, resulting in 
the cyst containing four nuclei.  While the initiation of encystation is unknown, it is 
thought to be due to either internal signals of the trophozoite, or external factors such as 
increased pH, increased bile concentration, or the intestinal contents leaving the 
jejunum and beginning to lose moisture (Owen, 1980; Acha & Szyfres, 1987; Farthing, 
1993; Eichinger, 2001; Jarroll et al., 2001).  The cyst is the dormant phase of the cycle, 
which is excreted in the faeces.  It is thought that the cyst requires a 3-7 day maturation 
period before becoming infective (Ampofo et al., 1991). After ingestion by another host 
it excysts after passage through the stomach as a tetranucleate trophozoite and 
undergoes cell division to release two trophozoites into the small intestine. Detailed 
reviews on Giardia can be found in Feely et al., (1990), Adam, (1991 and 2001), and 
Rabbini & Islam, (1994).   
 
5.1.1.2. Morphology 
 
Giardia is an extremely primitive or early diverging eukaryote, and lacks several 
prominent organelles, particularly the mitochondria, peroxisomes and the components 
for oxidative phosphorylation (Gillin et al., 1996; Adam, 2001; Eichinger, 2001).   
However Giardia has two anterior nuclei, and a number of highly evolved cytoskeletal 
structures such as four pair of flagellae, a ventral adhesive disc and two median bodies 
(Figure 5.2) (Levine, 1985; Adam, 2001).   CHAPTER 5 
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Figure 5.1: Giardia lifecycle (Meyer, 1974). 
 
 
 
 
 
 
 
 
 
Figure 5.2: Trophozoite and cyst morphology (Meyer, 1985). AF: anterior flagella, LF: 
lateral flagella, CF: caudal flagella, VF: ventral flagella, N: nucleus, AD: adhesive disc, 
MB: median bodies, CW: cell wall, SD: fragments of striated disk. 
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The general external morphology resembles a pear cut in half.  The dorsal surface is 
convex and may be either smooth or pitted, while the ventral surface is concave with a 
prominent anterior adhesive disk (Owen, 1980).  Internally, the cytoplasm contains both 
large and small granules, thought to be glycogen and ribosomes respectively.  The cell 
periphery however is filled with tubes and vesicles, which appear to form the digestive 
system for Giardia, and mainly occurs on the dorsal surface (Owen, 1980; Kattenbach 
et al., 1991).    
 
Giardia trophozoites attach to the intestinal epithelium by a rigid adhesive disk 
composed of microtubules, microribbons and cross bridges (Holberton, 1973; Holberton 
& Ward, 1981; Crossley & Holberton, 1983; Sousa et al., 2001).  It is not bilaterally 
symmetrical and has a vent in the posterior of the disk (Owen, 1980).  The mechanism 
of adhesion is unclear, but is thought maintained by reduced pressure beneath the disk 
due to disk contraction and flagella beating, with the lateral crest and ventrolateral 
flange important structures for attachment (Holberton, 1973; Feely et al., 1982; Sousa et 
al., 2001).  Giardia has four pairs of posteriorly directed flagellae (Figure 5.2).  They 
originate within the cytoplasm as axonemes (nine rows of double microtubules 
encircling two more microtubules), which pass through the cytoplasm and protrude 
from the body covered by a unit of membrane sheath (Owen, 1980).  The anterior 
flagellae originate between the cell edge and dorsal surface, while the lateral flagellae 
from a groove between the margin and dorsal surface. These flagellae provide motion 
for the trophozoite when detached, and stir the intestinal fluid when attached (Ghosh et 
al., 2001).  The ventral flagellae originate from the posterior vent of the adhesive disk 
and have fins extending along their entire length, which is thought to aid in expelling 
fluid from under the adhesive disk (Holberton, 1973; Owen, 1980).  The caudal 
flagellae extend from the tapered end and are involved in detachment and providing 
internal circulation of cytoplasmic fluids.  The median body is an oval aggregate of 
curved microtubules, which extend along the caudal flagellae axonemes, and is thought 
to reinforce vigorous movement of the caudal flagellae during cytoplasmic pumping and 
detachment (Owen, 1980).  This is found on the back of the disk and is the structure 
used for taxonomic identification (Acha & Szyfres, 1987; Adam, 2001).  
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The cyst has 2-4 nuclei, depending on the maturity of the cyst, and has a number of 
fibrillar remnants of trophozoite organelles (Levine, 1985).  The cysts are ovoid in 
shape, with cell dimensions generally 9 X 12 mm (Ampofo et al., 1991).  The cyst is the 
infective stage of the lifecycle and is very resistant to environmental factors and 
chlorinated disinfectants.   
 
5.1.1.3. Giardia species 
 
It was traditionally believed that Giardia was highly host specific, with different names 
given based on the host in which they were isolated from.  This resulted in numerous 
species being described that were morphologically similar. However morphological 
characteristics have since been used to divide the genus into three species, G. agilis, G. 
muris and G. duodenalis (Adam, 1991; 2001). G. duodenalis is the only one that can be 
cultured  in vitro, and hence the most widely studied (Faubert, 1988). Distinctions 
between the groups are based on cell dimensions and the morphology of the median 
body, although cell dimensions may reflect variation in the host diet and the intestinal 
environment, not evolutionary divergence (Owen, 1980; Bertram et al., 1984; Meyer, 
1985; Bemrick & Erlandsen, 1988).  Electron-microscopic studies have further divided 
the  G. duodenalis species, with identification of G. microti (rodent parasite), G. 
psittacae (parasite of the parakeet) and G. ardeae (parasite of the great blue heron).  
Identification of further species or sub-species is likely with the development of new 
techniques to distinguish between different strains of Giardia, such as antigenic 
differences, isoenzyme studies, serological tests (immunofluorescence) monoclonal 
antibody studies and DNA analysis (Meyer, 1985; Bemrick & Erlandsen, 1988; Adam, 
2001).   
 
5.1.2. Giardiasis 
 
5.1.2.1. Prevalence and transmission 
 
While G. duodenalis was once considered a commensal of the small intestine, it is now 
recognised as a potential hazard to the general population, children in day care centres 
and immunocompromised individuals (Farthing, 1993; Thompson, 2000; Linnane et al., CHAPTER 5 
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2001).  Recent observations indicate that G. duodenalis is the most prevalent intestinal 
parasite in the world, particularly among children of developing countries due to 
poverty and poor sanitation (McKerrow et al., 1993; Rabbini & Islam, 1994). The 
incidence of giardiasis is related to sanitation, with transmission mainly by faecal 
contamination.  Giardiasis is three times more common in children, as they are less 
likely to be concerned about sanitation. In addition, due to their limited exposure to the 
organism, they are less likely to have developed any resistance (Levine, 1985; Meyer, 
1985; Islam, 1990).  The existence of asymptomatic infected individuals, chronic 
individuals and the resistance of cysts to environmental conditions are important factors 
in the epidemiology (Acha & Szyfres, 1987).   
 
Although person to person contact is the major route of transmission, contaminated 
water may serve as a source of infection if it is collected from a wilderness situation 
(Bemrick & Erlandsen, 1988; Greig et al., 2001).  In addition, the lack of host 
specificity of Giardia results in cross transmissions between humans and animals, with 
infections confirmed in a great variety of domestic and wild mammals (Acha & Szyfres, 
1987; Enriquez et al., 2001). Animals that are commonly thought of as sources of 
Giardia are rodents, dogs, cats and hoofed animals (Bemrick & Erlandsen, 1988). 
Detailed reviews on G. duodenalis and giardiasis can be found in Smith & Wolfe, 
(1980), Pickering & Engelkirk, (1988), Islam, (1990), Wolfe, (1992), Rabbini & Islam, 
(1994) and Gillin et al., (1996). 
 
5.1.2.2. Disease and diagnosis 
 
The majority of infections are subclinical, with these infected individuals acting as 
carriers (Meyer, 1985).  Between 25-50% of people who ingest cysts develop diarrhoea, 
with the remainder asymptomatic, although some will pass cysts (Simmons, 1991; 
Centers for Disease Control and Prevention (CDC), 2001b).  Clinical manifestations 
range from mild transient intestinal complaints that resolve spontaneously, to severe 
long-standing disease with malabsorption and debilitation.  Symptoms of giardiasis are 
mainly diarrhoea, bloating, flatulence, nausea, abdominal pain and, less commonly, 
vomiting and fever.  The incubation period lasts 1-3 weeks after infection. The acute 
phase may last 3-4 days, but in the majority of cases it continues for weeks, where it is CHAPTER 5 
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then accompanied by malabsorption and weight loss (Wolfe, 1978; Acha & Szyfres, 
1987; Simmons, 1991; CDC, 2001b).   
 
In patients with acute diarrhoea, both the trophozoite and the cyst phase can be found in 
the faeces.  However in some patients the examination must be repeated, as cyst 
excretion can be variable.  Early techniques for the determination of Giardia infections 
included examination of duodenal fluid as well as biopsy at the duodenojejunal junction 
(Wolfe, 1978).  More recently, immunobiologic tests such as indirect 
immunofluorescence tests, blastic transformation, macrophage migration inhibition 
tests, counterimmunoelectrophoresis and enzyme-linked immunosorbent assays 
(ELISA) have been carried out (Acha & Szyfres, 1987; Wolfe, 1992; CDC, 2001b). 
 
5.1.2.3. Treatment and prevention   
 
Currently the most commonly used drugs in the treatment of Giardia infections are the 
nitroimidazoles metronidazole and tinidazole.  While therapy with these drugs is usually 
effective, they have a number of limitations with respect to palatability, systemic 
absorption, activity against normal intestinal flora, possible side effects, treatment 
failures and potential carcinogenicity (reviewed by Davidson, 1984, Wolfe, 1992, 
Gardner & Hill, 2001 and Harder et al., 2001).  These limitations are significant 
considerations, as drugs may need to be administered repeatedly due to re-infections.  
Attempts to improve the chemotherapy of giardiasis were originally hampered by the 
lack of in vitro and in vivo modelling systems, but this has since been overcome 
(Boreham et al., 1984; Meloni & Thompson, 1987; Reynoldson et al., 1991a).   
Subsequently a number of drugs have been evaluated for antigiardial activity in humans.  
These include alternative nitroimidazoles, benzimidazoles, tetracyclines and protein 
synthesis inhibitors (Boreham et al., 1985; Gordts et al., 1985; Crouch et al., 1986; 
Edlind, 1989a and b; Edlind et al., 1990; Morgan et al., 1990; Cedillo-Rivera & Muñoz, 
1992; Harris et al., 2001).  Of these the protein synthesis inhibitor, paromomycin, is 
frequently recommended for treatment of symptomatic giardiasis during pregnancy, due 
to its lack of intestinal absorption and the possible teratogenic effects of the other 
current antigiardial agents.  However, it is known to affect normal intestinal bacteria 
(Davidson, 1984; Edlind, 1989a; Adam, 1991; Gardner & Hill, 2001).  CHAPTER 5 
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As Giardia infections are often the result of ingesting viable cysts in contaminated food 
and water, methods to reduce food and water contamination, or to destroy or remove 
cysts from contaminated food and water, are necessary to prevent the spread of 
giardiasis. Therefore public water supplies must be protected from contamination by 
human and animal faeces.  Alternatively, the use of coagulation-sedimentation-filtration 
methods in water treatment plants are necessary to remove cysts and prevent waterborne 
giardiasis outbreaks (Wolfe, 1992). While chlorination will kill Giardia, variations in 
water temperature, clarity, pH and contact time affect efficacy, so that higher levels (4-
6mg dm) are required (Simmons, 1991).  In addition, sanitary elimination of faecal 
waste, instruction on personal hygiene in institutions for children, and the treatment of 
pets with giardiasis because of the close contact they may have with children are 
important measures in guarding against giardiasis (Acha & Szyfres, 1987; Enriquez et 
al., 2001).   
 
5.1.3. Benzimidazole action against Giardia  
 
The benzimidazoles ABZ, mebendazole and fenbendazole have exhibited either 
comparable or increased efficacy compared with the nitroimidazoles in vitro (Meloni & 
Thompson, 1987; Edlind et al., 1990; Cedillo-Rivera & Muñoz, 1992; Reynoldson et 
al., 1992). It is currently thought that the primary mode of action of the benzimidazoles 
against nematodes involves their ability to selectively bind to tubulin and hence prevent 
polymerisation (Section 2.1.2). Microtubules are major components of Giardia 
cytoskeletal structures, the adhesive disk, flagellae and median bodies, and thus have an 
integral role in maintaining morphology, motility and attachment.  Therefore the 
integral role of microtubules in the cytoskeleton of Giardia provides a potential drug 
target.  However it is possible that these drugs exert their effect on the giardins. 
Giardins are Giardia specific cytoskeletal proteins and are components of the 
microribbons, specific to the ventral disk (Holberton et al., 1988; Peattie et al., 1989; 
Peattie, 1990; Nohria et al., 1992).  Some support for this may be seen in 
benzimidazole-affected  Giardia isolates which retain flagella function, even though 
flagella rely on tubulin, and not giardins, for their integrity (Edlind et al., 1990; Meloni 
et al., 1990; Morgan et al., 1990; Oxberry et al., 1994).  Alternatively, the microtubules CHAPTER 5 
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of the axonemes may be less susceptible to benzimidazoles than disk microtubules, due 
to their lower accessibility or the presence of different tubulin isotypes with variable 
binding affinity (Oxberry et al., 1994; Oxberry et al., 2000).  Of the dinitroanilines, little 
is known of their effect on Giardia. 
 
5.1.4. Aim  
 
The purpose of this study was to investigate the in vitro and in vivo antigiardial activity 
of the antiparasitic agents ABZ, TF and OZ both alone and complexed.  In addition, the 
effect of ΗPβCD on Giardia, and the effect of ΗPβCD on drug efficacy, was 
investigated.  
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5.2. METHODS 
 
5.2.1. Maintenance of G. duodenalis in vivo and in vitro  
 
5.2.1.1. Cultivation of G. duodenalis in vitro 
 
5.2.1.1.1. Culture medium for G. duodenalis trophozoites 
The G. duodenalis isolate P1c10 (Portland 1: American Type Culture Collection No. 
30888, clone 10) was grown in axenic cultures in BI-S-33 medium, pH 6.7 (Meloni & 
Thompson, 1987) (Table 5.1).  
 
Table 5.1: BI-S-33 medium preparation for the cultivation of G. duodenalis in vitro. 
Ingredients  Amount in 1 L 
Biosate   30 g 
D-Glucose   10 g 
Sodium chloride   2.0 g 
Cysteine-hypochloride monohydrate   2.0 g 
Di-potassium hydrogen orthophosphate   1.0 g 
Potassium dihydrogen orthophosphate   0.6 g 
Ferric ammonium citrate   0.01 g 
Ascorbic acid   0.2 g 
Dehydrated bovine bile   0.5 g 
Antibiotics stock solution: Lincomycin (40 µg mL
-1) 
                                           Ampicillin (40 µg mL
-1)  
                                           Gentamycin (50 µg mL
-1)  
10 mL 
Make up to 900 mL in dH2O.  Adjust the pH to 6.7 and filter sterilise at 0.2 µm. 
NBCS (new born calf serum)   100 mL 
 
5.2.1.1.2. Removal of G. duodenalis trophozoites from cryopreservation  
Cryopreserved P1c10 was removed from liquid nitrogen and defrosted quickly at 37°C.  
Under sterile conditions approximately 500 µL of the cryopreserved stock was 
inoculated into 16 mL borosilicate culture tubes containing warm BI-S-33 medium. The 
culture tubes were then filled to capacity with medium to exclude air, inverted twice and 
incubated at 37°C at an angle of 10° until monolayer. A monolayer was characterised by 
a monolayer of trophozoites attached to the culture tube wall that occurs in the late log 
phase of growth (approximately 4 x 10
6 trophozoites ml
-1). Cultures were examined 
daily using an inverted microscope (Olympus). CHAPTER 5 
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5.2.1.1.3. Cultivation of G. duodenalis trophozoites 
For the in vitro cultivation of G. duodenalis, healthy cultures that had reached 
monolayer were selected for subculturing.  The cultures were left at room temperature 
for 10 min before rolling the tubes for 1 min to dislodge attached trophozoites. Under 
sterile conditions, approximately four drops of the culture was added to 16 mL 
borosilicate culture tubes containing warm BI-S-33 medium. The culture tubes were 
then inverted twice and incubated at 37°C at an angle of 10° until monolayer. Once the 
cultures have reached monolayer they were either subcultured (every 2-3 days), 
cryopreserved, or used in drug experiments. 
 
5.2.1.1.4. Cryopreservation of G. duodenalis trophozoites 
Healthy cultures that had just reached monolayer were selected for cryopreservation.  
The cultures were left on ice for 10 min before rolling the tubes for 1 min to dislodge 
attached trophozoites, after which the trophozoite concentration was determined using 
an improved Neubauer haemocytometer (B.S.748).  The trophozoites were then 
concentrated to approximately 1 x 10
7 cells mL
-1 by centrifugation (IEC Centra-4R 
centrifuge) at 2000 rpm for 10 min to sediment trophozoites, followed by removal of the 
supernatant before resuspending of trophozoites in an appropriate amount of phosphate 
buffered saline (PBS, below). An equal volume of sterile 15% dimethyl sulphoxide 
(DMSO) was then added so the final DMSO concentration was 7.5% (Lyman & 
Marchin, 1984).  1.5 mL aliquots were dispensed into sterile 2 mL cryogenic vials 
(Nalgene), which were placed into a cold Cryogenic 1˚C container (Nalgene) (the 
container containing isopropanol was placed in freezer for approximately 4 h prior to 
use) and put in –80˚C freezer for at least 4 h.  The cryopreservation vials were placed in 
liquid nitrogen containers once the freezing process was complete. 
 
PBS was prepared by dissolving 8.0 g NaCl, 1.21 g KH2PO4 and 0.34 g K2HPO4 in 1 L 
distilled water pH 7.0 and autoclave sterilised before storing at 4˚C. 
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5.2.1.2. Amplification of G. duodenalis in vivo 
 
5.2.1.2.1. Origin and housing of experimental animals 
Ten to twelve-day-old Mus musculus (Swiss Quackenbush strain) were used for the in 
vivo amplification of G. duodenalis. They were housed with mothers in standard mouse 
cages in an animal house maintained on a 12:12 h photoperiod at 21-24°C and were fed 
Rat and Mouse Cubes manufactured by Glen Forrest Stockfeeders, Western Australia.  
Both food and water were provided ad libitum. All animals were obtained from the 
Western Australian State Animal Resource Centre, Perth, Western Australia. The 
Murdoch University Animal Ethics Committee, in accordance with national animal 
welfare standards, approved the following experiments. 
 
5.2.1.2.2. Infection and amplification of G. duodenalis in vivo 
The G. duodenalis strain Rat 4 (isolated at Murdoch University) was used in all in vivo 
experiments.  This strain is specific for rats, with infections lasting approximately 3 
weeks.  This strain does not grow in vitro, and therefore needs to be amplified in vivo. 
Rat 4 was removed from cryopreservation as described for P1c10 (Section 5.2.1.1.2) 
and concentrated to 5 x 10
6 cells mL
-1 by centrifugation at 2000 rpm for 10 min 
followed by resuspension in an appropriate amount of PBS.  10-12 day old Swiss 
Quackenbush mice were infected orally by stomach intubation with approximately 5 x 
10
5 trophozoites in 0.1 mL PBS using a plastic tube (0.8 mm in diameter) attached to a 
blunted needle (23 G) on a 1 mL syringe. Ten days post-infection the mice were 
anaesthetised with 80% CO2: 20% O2 and then euthanased by cervical dislocation.  The 
small and large intestines were removed, cut longitudinally and placed in screw capped 
vials containing 5 mL cold PBS.  Vials were shaken vigorously for 1 min before the 
intestines were removed and the suspension washed through gauze to remove excess 
debris.  The trophozoite concentration was then determined using a haemocytometer 
and the sample prepared for cryopreservation or in vivo drug experiments. 
 
5.2.1.2.3. Cryopreservation of G. duodenalis trophozoites amplified in vivo 
Giardia trophozoites isolated in vivo (Section 5.2.1.2.2) were centrifuged (Spintron GT-
20) at 2000 rpm for 10 min to sediment the trophozoites followed by resuspension in 
PBS. The procedure was repeated twice more until the supernatant was reasonably clean CHAPTER 5 
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and to concentrate the cells to approximately 1 x 10
7 cells mL
-1. The trophozoites were 
then cryopreserved as described for in vitro cultivated trophozoites  (Section 5.2.1.1.4).   
 
5.2.2. Efficacy experiments against G. duodenalis in vitro 
 
5.2.2.1. Drug efficacy experiments 
 
Trophozoites in the late log phase of growth were exposed to a range of drug 
formulations (Section 5.2.2.2). Cultures grown to monolayer were left on ice for 10 min 
before rolling the tubes for 1 min to dislodge attached trophozoites. The trophozoite 
concentration was determined using a haemocytometer, and an appropriate volume of 
the trophozoite containing medium was then added directly to the total volume of 
medium required for the experiment, with an approximate final concentration between 1 
x 10
5 – 1.5 x 10
5 trophozoites ml
-1.  Five mL aliquots of the prepared trophozoites were 
then added to 5 mL borosilicate culture tubes, ready for the addition of drugs (Section 
5.2.2.2).  Once the drugs were added the cultures were incubated at 37°C at an angle of 
10°. After incubation for 24 h with constant exposure to drug or vehicle, the medium 
was aspirated and replaced with drug-free medium.  This needed to be done quickly to 
reduce trophozoite exposure to air, as live trophozoites remained attached to the culture 
vessel wall.  The cultures were incubated for a further 24 h in the manner described, 
after which a cell count was determined using an inverted microscope and the 
experiment terminated (Section 5.2.2.3). 
 
5.2.2.2. Administration of drugs 
 
ABZ, TF and OZ in two different formulations were tested against G. duodenalis 
(P1c10) in vitro.  The efficacy of these drugs dissolved in DMSO was compared to their 
efficacy when formulated in ΗPβCD.  In addition, the efficacy of ΗPβCD and a 
commercial form of ABZ (Valbazen®) were also investigated.  10 mM solutions of 
ABZ, TF and OZ were made up in 100% DMSO and then diluted with DMSO to create 
x1000 the concentrations required during the course of the experiment on the day of the 
experiment. ABZ (Valbazen®), ABZ/ΗPβCD, TF/ΗPβCD and OZ/ΗPβCD were 
diluted from stock solutions with dH2O and investigated over the same concentration 
range as the drugs dissolved in DMSO. Five µL aliquots of the drug solutions were CHAPTER 5 
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added to 5 mL borosilicate culture tubes containing trophozoites (Section 5.2.2.1). The 
final DMSO concentration in the cultures was 0.1%, with the control cultures containing 
drug vehicle or water as appropriate.  The efficacy of ΗPβCD was investigated by 
making stock solutions of ΗPβCD in media and adding 0.5 mL to 5 mL culture tubes 
containing trophozoites.   
 
5.2.2.3. Determination of in vitro drug efficacy - counting of trophozoites 
 
Trophozoite viability was determined by their adherence to the side of the glass tube in 
which they were grown, and the absence of morphological abnormalities compared with 
control cultures. A modification of the method of Meyer, (1970) was used to determine 
trophozoite number. Trophozoite number was determined by placing the culture tubes 
under an inverted microscope on the same side that they laid during incubation.  The 
number of viable trophozoites that could be seen in a field of view (diameter 1.72 mm) 
using 100 times magnification was counted and given a score (Table 5.2). 
 
Table 5.2: Scoring Method for the Assessment of Trophozoite Viability. 
Number of Trophozoites  Score 
0 0 
<1 1 
1-10 2 
10-25 3 
25-50 4 
50-100 5 
100-250 6 
250-500 7 
500-1000 8 
1000-2000 9 
monolayer 10 
 
The scores given to the cultures were used to determine the percentage inhibition of 
adherence, which was then used to generate a dose response curve (Section 5.2.4).   
Percentage inhibition was calculated using the following formula: 
% Inhibition of adherence  =
score of control culture- score of test culture
score of control culture
×100CHAPTER 5 
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5.2.3. Efficacy experiments against G. duodenalis in vivo 
 
5.2.3.1. Origin and housing of experimental animals 
 
Three-week-old albino male Rattus norvegicus (Sprague Dawley Strain) were used in 
all Giardia in vivo experiments.  They were housed in an animal house maintained on a 
12:12 h photoperiod at 21-24°C and were fed Rat and Mouse Cubes manufactured by 
Glen Forrest Stockfeeders, Western Australia. Rats were housed three animals per 
standard rat cage and both food and water were provided ad libitum.  All animals were 
obtained from the Western Australian State Animal Resource Centre, Perth, Western 
Australia. The Murdoch University Animal Ethics Committee, in accordance with 
national animal welfare standards, approved the following experiments. 
 
5.2.3.2. Efficacy of ABZ and ABZ/ΗPβCD against G. duodenalis in vivo 
 
The efficacy of drug formulations was determined using a modification of the method 
described by Reynoldson et al., (1991a).  The G. duodenalis strain Rat 4 was used in all 
in vivo experiments. Trophozoites that had been amplified in mice (Section 5.2.1.2.2) 
were used to infect rats orally by stomach intubation with approximately 5 x 10
5 
trophozoites in 0.1 mL PBS using a plastic tube (0.96 mm in diameter) attached to a 
blunted needle (21 G) and 1 mL syringe. Ten days post-infection the rats underwent 
drug treatment (below).  On the fourth day after commencement of treatment, rats were 
anaesthetised using 80% CO2: 20% O2 and then euthanased by cervical dislocation.  The 
small and large intestines were removed, cut longitudinally and placed in screw capped 
vials containing 5 mL and 12.5 mL cold PBS respectively.  Vials were shaken 
vigorously for 1 min before the intestines were removed and the suspension was washed 
through gauze to remove excess debris.  The trophozoites were then diluted 1:5 and the 
trophozoite concentration determined using a haemocytometer.  Cysts in faecal material 
were also counted. 
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5.2.3.3. ABZ drug regime 
 
A commercial formulation of ABZ, Valbazen®, was used to compare the efficacy of the 
ABZ/ΗPβCD formulation. Valbazen® was diluted with water to 2, 3.3, 6.6, 8, and 10 
mg mL
-1 and administered at 12 h intervals for three days.  Drugs were administered 
orally by stomach intubation at 0.1 mL 100 g
–1 body weight using a plastic tube (0.96 
mm in diameter) attached to a blunted needle (21 G) on a 1 mL syringe.  
 
5.2.3.4. ABZ/ΗPβCD drug regime 
 
The maximum oral dose of ABZ/ΗPβCD that could be achieved by conventional 
methods (above) to dose rats with was 6 mg kg
-1.  As the maximum dosage to be 
investigated was greater than this, animals were administered the ABZ/ΗPβCD 
formulation in their drinking water.  To determine if the rats would drink ABZ/ΗPβCD, 
the fluid consumption of rats given a range of ΗPβCD concentrations over three days 
was determined (Section 4.2.2). For drug experiments, the ABZ/ΗPβCD formulation 
was diluted as necessary based on the ΗPβCD consumption results (Section 4.3.2), with 
the  ΗPβCD concentration of the ABZ/ΗPβCD formulation not exceeding 5%.   
Approximate ABZ/ΗPβCD concentrations of 4, 6.6, 13.2, 16, and 20 mg kg
-1 ABZ were 
fed to animals, with the actual amount of drug and ΗPβCD consumed determined from 
the animals body weight and fluid consumption monitored over the three days. As 
Valbazen® was administered twice daily (above), the ABZ/ΗPβCD concentration was 
doubled so that the regimes were comparable.  
 
5.2.3.5. ΗPβCD regime 
 
To determine the effect of ΗPβCD on G. duodenalis in vivo, ΗPβCD was administered 
to Giardia infected rats in their drinking water at 2, 3.5 and 5% for three days. On the 
fourth day of the treatment regimes the rats were anaesthetised using 80% CO2: 20% O2 
and then euthanased by cervical dislocation.  Trophozoite number was then determined 
as described in section 5.2.3.2.  
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5.2.4. Statistical analysis 
 
The in vitro percentage inhibition of adherence for (mean ± SE) was determined across 
multiple experiments.  Non-linear sigmoidal curve fitting (GraphPad Prism) was used to 
generate dose response curves so that a number of drug sensitivity indicators could be 
measured. The 50% inhibitory concentration (IC50) measures the concentration of drug 
that produces 50% inhibition of adherence.  The minimum lethal concentration (MLC) 
is the lowest concentration at which 100% inhibition of parasites is observed, and the 
minimum inhibitory concentration (MIC) is the minimum concentration at which 
inhibition is observed.  These were calculated for each drug formulation against 
Giardia.  Comparisons between dose response curves were carried out using repeated 
measures ANOVA with Bonferonni’s post test (GraphPad Prism).  
 
Comparisons between in vivo doses and dosage regimes were carried out using t-tests 
and one way ANOVAs with Bonferonni’s post test as appropriate (GraphPad Prism). 
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5.3. RESULTS 
 
5.3.1. Efficacy experiments against G. duodenalis (P1c10) in vitro 
 
5.3.1.1. Effect of ΗPβCD on G. duodenalis in vitro 
 
The efficacy of ΗPβCD was tested against G. duodenalis (P1c10) in vitro (Section 
5.2.2.2). ΗPβCD was found to inhibit G. duodenalis, with an IC50 of 2.3%, MIC of 
1.1% and a MLC of 2.7% ΗPβCD (Figure 5.3). Inhibition of adherence to the culture 
vessel wall is used as an index of reduction in viability.  These results are similar to 
those reported in Chapter 4 on the cytotoxicity of ΗPβCD against the human ileocaecal 
adenocarcenoma cells (HCT-8 cells).  
 
 
 
Figure 5.3: Inhibitory effect of ΗPβCD on Giardia adherence to the culture vessel wall 
in vitro (mean ± SE, n=3-15).   
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5.3.1.2. ABZ efficacy against G. duodenalis in vitro 
 
The in vitro inhibition of G. duodenalis growth by ABZ in three different formulations 
was measured, and expressed as a percentage of the growth in untreated cultures.  The 
efficacy of ABZ when dissolved in DMSO, when formulated with ΗPβCD, and a 
commercial form of ABZ (Valbazen®) were investigated. All three formulations were 
found to be effective against G. duodenalis in vitro (Figure 5.4).  The dose response 
curves for the ABZ in DMSO and ABZ/ΗPβCD formulation were not significantly 
different (repeated measures ANOVA with Bonferonni’s post test p>0.05), with a mean 
IC50 of 118 nM, MIC of 50 nM and MLC of 800 nM (Table 5.3).  However, the 
commercial form of ABZ (Valbazen®) was found to be significantly different from 
both ABZ in DMSO and ABZ/ΗPβCD (repeated measures ANOVA and Bonferonni’s 
post test on sigmoidal dose response curves p<0.01), and was less effective with an IC50 
of 161 nM, MIC of <50 nM and MLC greater than 800 nM.  The dose response curve 
for this formulation was highly variable, with this variability and reduced efficacy likely 
due to the formulation precipitating out in culture, as it was observed to do in vials. 
 
 
Figure 5.4: In vitro efficacy of three ABZ formulations against Giardia adherence to 
the culture vessel wall (mean ± SE, n=3-21).   
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Table 5.3: The IC50, MIC and MLC of three ABZ formulations against G. duodenalis in 
vitro. 
Drug   IC50 (nM)  MIC (nM)  MLC (nM) 
ABZ in DMSO  119.3 50  800 
ABZ/ΗPβCD  116.5 50  800 
ABZ (Valbazen®)  161.3 <50 >800 
 
As previously observed, ΗPβCD is capable of inhibiting G. duodenalis growth.  The 
ΗPβCD concentration of the ABZ/ΗPβCD complex at the highest dose given (800 nM) 
was 0.005%.  This is considerably lower than the ΗPβCD concentration required to 
inhibit G. duodenalis growth (greater than 1.1%) (Section 5.3.1.1).  The effect of low 
concentrations of ΗPβCD on the efficacy of the ABZ/ΗPβCD complex against G. 
duodenalis in vitro was also investigated (Figure 5.5), and it was found that the efficacy 
of the ABZ/ΗPβCD complex declined with the addition of ΗPβCD.   
 
 
 
Figure 5.5: Effect of ΗPβCD on the efficacy of the ABZ/ΗPβCD complex against 
Giardia adherence to the culture vessel wall (mean ± SE, n=3-10).   
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5.3.1.3. Dinitroaniline efficacy against G. duodenalis in vitro 
 
The dinitroanilines OZ and TF were both ineffective against G. duodenalis in vitro 
either complexed or uncomplexed at the maximum concentrations achievable when 
complexed with ΗPβCD and the maximum media concentration of ΗPβCD was 1% 
(61.3 µM and 1.8 µM respectively).  They were therefore not tested in vivo. 
 
5.3.2. ABZ efficacy experiments against G. duodenalis (Rat 4) in vivo 
 
While both trophozoite and cyst numbers from the small intestine, large intestine and 
faeces were collected, the faecal cyst and large intestine results were not consistent 
within groups and did not reflect any effect from the drug regimes.  Therefore only the 
results of trophozoite counts from the small intestine and the total G. duodenalis results 
(trophozoite and cyst numbers from the small intestine, large intestine and faeces) are 
shown. 
 
5.3.2.1. Effect of ΗPβCD on G. duodenalis in vivo 
 
The in vivo efficacy of ΗPβCD alone against G. duodenalis was investigated. When rats 
were given ΗPβCD solutions at concentrations between 2% and 5% ΗPβCD, 
trophozoite number in the small intestine rapidly declined, with an IC50, MIC and MLC 
of 3.2%, 2% and >5% ΗPβCD respectively (Figure 5.6). ΗPβCD did not significantly 
affect total G. duodenalis numbers at less than 2% (t-test, p>0.05).  Again, these results 
are similar to those reported in Chapter 4 on the cytotoxicity of ΗPβCD against HCT-8 
cells, and are also comparable the in vitro  ΗPβCD results against G. duodenalis 
(Section 5.3.1.1). At 3.4 and 5% ΗPβCD, rats were observed to have very soft stool or 
diarrhoea.  As this was not observed in rats given similar ΗPβCD concentrations or 
higher in previous experiments (Section 4.3.2), this was therefore related to the effects 
of the G. duodenalis infection in combination with ΗPβCD administration. 
 
5.3.2.2. ABZ efficacy against G. duodenalis in vivo 
 
The in vivo efficacy of a six-dose regime of two ABZ formulations, ABZ/ΗPβCD and 
ABZ (Valbazen®), against G. duodenalis was investigated (Figures 5.7  and  5.8).CHAPTER 5 
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Figure 5.6: In vivo inhibitory effect of ΗPβCD on total Giardia number and Giardia 
trophozoites in the small intestine (mean ± SE, n=3). 
Figure 5.7: In vivo efficacy of ABZ (Valbazen®) and ABZ/ΗPβCD against trophozoite 
number in the small intestine of Giardia infected rats (mean ±SE, n=3). 
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Figure 5.8: In vivo efficacy of ABZ (Valbazen®) and ABZ/ΗPβCD against overall 
Giardia number in Giardia infected rats (mean ±SE, n=3). 
 
The two formulations were found to have similar efficacy against G. duodenalis, both 
formulations caused a dose related inhibition of parasite numbers, with doses of 6.4 mg 
kg
-1  ABZ/ΗPβCD or 10 mg kg
-1 ABZ (Valbazen®) completely eliminating G. 
duodenalis  infections.  Trophozoite numbers in the small intestine or total G. 
duodenalis numbers at all doses of both ABZ formulations (between 2-10 mg kg
-1) were 
significantly different to control parasite numbers (t-test, p<0.001). No significant 
difference was observed between the two formulations against G. duodenalis 
trophozoite numbers in the small intestine or total G. duodenalis numbers (one way 
AVOVA with Bonferonni’s post test, p>0.05).   
 
The ABZ/ΗPβCD formulation was administered in the rats’ drinking water, with the 
concentration required for a particular dose determined from the consumption of 
ΗPβCD solutions by three-week-old rats from previous experiments (Section 4.3.2).  In 
previous experiments, ΗPβCD solutions of 5% ΗPβCD and less were consumed in 
greater amounts than water by control animals.  Here however, the ABZ/ΗPβCD 
formulation was consumed in amounts comparable to water. This may reflect a possible 
change in flavour of ΗPβCD solutions in the presence of complexed ABZ. 
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5.4. DISCUSSION 
 
5.4.1. Effect of ΗPβCD on G. duodenalis 
 
5.4.1.1. In vitro 
 
At concentrations of ΗPβCD alone greater than 1.1%, G. duodenalis growth was 
inhibited in vitro.  These results were similar to that of the cytotoxicity assay in section 
4.4.2.  Thus the effect of ΗPβCD on G. duodenalis trophozoites is probably as 
described for HCT-8 cells, and results from membrane disruption caused by the 
dissolution and removal of membrane components.  This is likely of be reversible, 
depending on the capacity for Giardia to repair membrane damage. ΗPβCD was 
observed to effect HCT-8 cells at a minimum concentration of 2.5% ΗPβCD, which is 
higher than the MIC observed against G. duodenalis trophozoites (1.1%).  This may 
indicate that G. duodenalis trophozoites membranes are slightly more susceptible to the 
effects of ΗPβCD.  HPβCD preferentially solubilizes membrane cholesterol (Irie et al., 
1992b).  Therefore the effect of other CDs, such as methylated CDs, α-CD and β-CD, 
and HPβCD of different degrees of substitution would be worth investigating, as G. 
duodenalis trophozoites may have differential susceptibility to these CDs.  In addition, 
when evaluating drug/CD complexes against G. duodenalis in vitro, it was important to 
consider the actual CD concentration, as concentrations greater than 1% inhibit 
trophozoite growth.   
 
5.4.1.2. In vivo 
 
ΗPβCD was found to decrease parasite number in Giardia infected rats when 
administered as a solution at greater than 2% ΗPβCD.  These results are similar to that 
observed in the cytotoxicity assay and G. duodenalis trophozoites in vitro, and therefore 
also likely to result from trophozoite membrane disruption.  In addition, at 3.4 and 5% 
ΗPβCD, Giardia infected rats were observed to have very soft stool or diarrhoea, which 
was not observed in uninfected rats given similar or higher ΗPβCD concentrations in 
previous experiments (Section 4.3.2).  As ΗPβCD was effective at eliminating G. CHAPTER 5 
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duodenalis  infections at these concentrations, the occurrence of diarrhoea may be 
related to the death and subsequent removal of large amounts of Giardia debris from the 
gastrointestinal tract.  Alternatively, the capacity for ΗPβCD to complex endogenous 
compounds from the gastrointestinal tract, including Giardia components, may be 
involved. 
 
5.4.2. Drug efficacy 
 
5.4.2.1. In vitro 
 
ABZ exhibited high efficacy against G. duodenalis in vitro, with an IC50 of 119 nM, and 
these results were consistent with other reports (Edlind et al., 1990; Meloni et al., 1990; 
Morgan et al., 1990; Cedillo-Rivera & Muñoz, 1992; Katiyar et al., 1994; Oxberry et 
al., 1994).  While some variability between the IC50s of different studies exists (IC50s 
ranging from 38 nM – 4 µM), these differences are due to the different Giardia strains 
used, the different methods for assessing drug efficacy, and the use of DMSO to 
dissolve drugs.  ABZ appears to act irreversibly against Giardia (Meloni et al., 1990; 
Morgan et al., 1990).  However, research by Oxberry et al., 2000 suggests that Giardia 
may be capable of metabolising ABZ to its sulfoxide and sulphone.  ABZ is thought to 
affect Giardia adherence more so than flagella activity (Edlind et al., 1990; Meloni et 
al., 1990; Morgan et al., 1990; Oxberry et al., 1994), with the primary effect of ABZ 
against Giardia considered due to its binding to cytoskeletal proteins (tubulin and/or 
giardins), particularly of the ventral disk (Edlind, 1989b; Oxberry et al., 1994) (Section 
5.1.3). Thus adherence of trophozoites to the culture vessel wall is often used in the 
assessment of Giardia viability (Seow et al., 1985; Meloni et al., 1990; Morgan et al., 
1990). HCT-8 cells were also observed to lose their ability to adhere to the culture 
vessel wall when cultured in the presence of ABZ (Section 4.4.1.1), indicating a similar 
mode of action.  However ABZ was not cytotoxic to HCT-8 cells at these 
concentrations, indicating that, unlike G. duodenalis, the loss of adherence in these cells 
did not interfere with cell survival. 
 
The ABZ/ΗPβCD complex proved to be as effective against G. duodenalis as ABZ 
dissolved in DMSO, with an IC50 of 116 nM.  The two formulations of ABZ, ABZ in CHAPTER 5 
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DMSO and the ABZ/ΗPβCD complex, have different characteristics in solution.  In the 
ABZ in DMSO cultures, the DMSO concentration was consistent, and sufficient to 
ensure all administered ABZ remained in solution in the free form.  In addition, DMSO 
has been reported to stabilise microtubules, which could interfere with the action of 
ABZ (Lacey, 1988; 1990).  In comparison, the ABZ/ΗPβCD complex presents 
dissolved ABZ in two forms, in the free form and as a complex.  The identical dose 
response curves and IC50s indicated that the complex readily dissociated to make 
comparable amounts of ABZ available to inhibit trophozoite growth (in the free form), 
similar to the ABZ in DMSO formulation.  The efficacy of the ABZ/ΗPβCD complex 
may be improved if alternative derivatised CDs were used. For example, the methylated 
CDs, particularly DMβCD, may increase drug absorption by increasing cell 
permeability (Section 4.1.2). In addition, investigations into alternative derivatised CDs 
may reveal CDs that specifically target Giardia trophozoites, by forming weak, non-
destructive interactions (i.e. hydrogen bonding) between the derivatised groups of CDs 
and ionophoric groups on the trophozoite cell membrane (Section 4.1.1).  CDs with 
higher affinity to particular cells could potentially result in the targeting of complexed 
drugs to these cells. 
 
The commercial formulation of ABZ had reduced efficacy compared to ABZ dissolved 
in DMSO and the ABZ/ΗPβCD complex.  However the commercial formulation is 
designed for in vivo administered as an oral drench, and therefore unsuitable for in vitro 
experimentation.  This was reflected in the highly variable results that were observed, 
which resulted from the sedimentation of the formulation when administered into in 
vitro cultures.  In spite of this, the formulation still attained a very high efficacy against 
G. duodenalis trophozoites in vitro. 
 
The addition of low concentrations of ΗPβCD to ABZ/ΗPβCD treated cultures resulted 
in decreased efficacy of ABZ against G. duodenalis trophozoites in vitro.  This effect 
has been described in sections 3.1.1 and 4.1.2.  The decrease in drug action is attributed 
a decrease in the effective drug concentration through inclusion complex formation 
rather than an interaction between ΗPβCD and the cell membrane (Uekama et al., 1981; 
1983).  A drug/CD complex in liquid medium is governed by an equilibrium reaction 
between host and guest molecules, i.e.: dissolved complex ↔ free CD + free drug CHAPTER 5 
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(Duchêne & Wouessidjewe, 1990a).  As the drug can only exert its affect when it is 
dissolved in solution as free drug, the concentration of dissolved free drug determines 
drug efficacy.  The administration of low CD concentrations together with the drug/CD 
complex results in the dissociation equilibria being shifted toward a higher ratio of 
complexed drug in solution (Habon et al., 1984). The extent of this effect correlates 
with the stability constants of the drug/CD complexes (Uekama et al., 1983).  When the 
stability constant is high, which it is for ABZ, then complex dissociation is weak, and 
even though the solubility of the drug complex is high, the bioavailability of the drug 
remains low, as there are few free drug molecules available for action (Habon et al., 
1984).  Therefore excess ΗPβCD effectively 'mops up' free ABZ, decreasing the uptake 
of ABZ into G. duodenalis trophozoites.   
 
The dinitroanilines OZ and TF were both ineffective against G. duodenalis in vitro 
either complexed or uncomplexed at 61.3 µM and 1.8 µM respectively.  These were the 
maximum culture concentrations of OZ/ΗPβCD and TF/ΗPβCD that could be achieved 
with ΗPβCD concentrations of 1%.  Therefore no change in efficacy was observed in 
these drugs when complexed with ΗPβCD.  Previous experiments at Murdoch 
University have also found the dinitroanilines to have limited efficacy against G. 
duodenalis in vitro, with IC50s in the mM range (Armson, A. unpublished data). 
 
5.4.2.2. In vivo 
 
Meloni et al., (1988) and Reynoldson et al., (1991b) developed a mouse model to 
determine the in vivo effectiveness of ABZ against Giardia infected mice. Reynoldson 
et al., (1991a), using this model, found a four-dose regime of ABZ was able to clear 
Giardia infections at doses greater than 100 mg kg
-1. This model was adapted to 
investigate the in vivo effectiveness of ABZ and the ABZ/ΗPβCD complex against 
Giardia infected rats.  This model was successful, with a six-dose regime of the 
commercial formulation of ABZ, Valbazen®, able to clear Giardia infections at doses 
greater than 10 mg kg
-1.  However, unlike Reynoldson et al., (1991a), faecal cyst 
numbers in rats did not exhibit a dose related decrease, and were therefore not a reliable 
method of determining drug efficacy.  The considerably lower doses required to 
eliminate Giardia infections in the rat model as apposed to the mouse model is thought CHAPTER 5 
__________________________________________________________________________________________________________ 
  172
to be due to a slower transit time of the drug through the gastrointestinal tract of the rat 
in comparison to the mouse, thus increasing the time the parasite was exposed to the 
drug (Reynoldson et al., 1991a). 
 
The ABZ/ΗPβCD complex proved to be as effective against Giardia in vivo as the 
commercial form of ABZ (Valbazen®).  In Chapter 3, the pharmacokinetics of these 
two formulations was investigated, and found that administration of the ABZ/ΗPβCD 
complex resulted in higher plasma concentrations of ABZ metabolites than for the 
commercial form of ABZ.  If ABZ was being absorbed to a greater extent systemically, 
this could possibly decrease the amount of ABZ available to inhibit Giardia, resulting 
in decreased efficacy.  However this was not observed. Craft et al., (1987) found oral 
antibiotic therapy to be compromised by decreased absorption in the presence of 
giardiasis. As Giardia can attach in very high numbers (Feely et al., 1990), they may act 
as a physical barrier to drug systemic absorption.  In addition, Giardia infections are 
known to cause intestinal malabsorption.  Some proposed mechanisms for 
malabsorption include mucosal damage, increased enterocyte turnover, mucosal 
inflammation, bacterial overgrowth, inhibition of lipolysis, or consumption of 
conjugated bile salts (reviewed by Farthing, 1986 and Katelaris & Farthing, 1992).  
Therefore the Giardia infections may have reduced systemic absorption of the ABZ 
from the ABZ/ΗPβCD formulation, with the extent of systemic absorption relative to 
the impact of the Giardia infection.  In addition, the two formulations were 
administered by completely different techniques.  Because the ABZ/ΗPβCD 
formulation was administered in the drinking water, the ABZ concentration would have 
been more consistent over the experimental time frame in comparison to Valbazen®.  
Alternatively, if the ABZ/ΗPβCD formulation uncomplexed (and thus precipitated) in 
the gut, it would need to redissolve to exert its effect, with dissolution being the rate-
determining step as it is for the commercial preparation.  Therefore the mode of 
administration would have also impacted on drug efficacy.  
 
Clinical trials have reported ABZ to be effective against Giardia in humans (Zhong et 
al., 1986; Hall & Nahar, 1993; Reynoldson et al., 1998), although there have been 
conflicting results (Kollaritsch et al., 1993).  MBZ, another benzimidazole effective 
against  Giardia in vitro, also demonstrated variable success (Al-Waili et al., 1988; CHAPTER 5 
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Gascon et al., 1989).  The variable success of these drugs against Giardia may reflect 
the formulations used to administer the drugs, as the success of the benzimidazoles is 
often attributed to their poor gastrointestinal absorption, therefore resulting in higher 
concentrations in the gastrointestinal tract. In addition, the results here indicated that 
cyst counts from Giardia infected rats were not a reliable indicator of treatment 
effectiveness, as animals with high infections in the gastrointestinal tract could exhibit 
variable faecal cyst numbers.  Intermittent and variable cyst quantities from Giardia 
infected mammals have also been previously reported (Wolfe, 1978; Craft, 1982; Buret 
et al., 1991). 
 
5.4.3.Conclusion 
 
The ABZ/ΗPβCD formulation was observed to have equal efficacy against Giardia as 
conventional ABZ formulations in vitro and in vivo.  Alternative formulations, such as 
pH modified ABZ/ΗPβCD formulations (Section 2.3.1.2), may result in increased 
efficacy (more ABZ in solution for longer period of time; Section 3.4.3), equal efficacy, 
or decreased efficacy (increased systemic absorption).  Such formulations cannot be 
investigated in vitro due to precipitation of ABZ, an undesirable effect in vitro, although 
an appropriate (and expected) effect in vivo. ΗPβCD was also found to reduce ABZ 
efficacy.  This is attributed a decrease in the effective drug concentration through 
inclusion complex formation.  In addition, at significantly higher concentrations, 
ΗPβCD alone was also effective against Giardia in vitro and in vivo, possibly due to the 
extraction of membrane components.   CHAPTER 6 
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6.1. INTRODUCTION 
 
6.1.1. Cryptosporidium 
 
6.1.1.1. Lifecycle 
 
Cryptosporidium is a zoonotic protozoan parasite that infects a wide range of vertebrate 
hosts worldwide. The life cycle of C. parvum is monoxenous and begins with ingestion 
of the oocyst, the resistant stage found in the environment (Figure 6.1). Upon 
excystation, sporozoites are released into the gastrointestinal tract where they penetrate 
individual epithelial cells. The endogenous developmental stages are intracellular, but 
extracytoplasmic, and located at the luminal surface of the host cell (Petersen, 1993).  
The parasite develops a feeder organelle at the interface between the parasite and the 
host cell cytoplasm, which is thought to be involved in the exchange of material 
between the host and parasite (O'Donoghue, 1995). The organism then undergoes 
complex asexual and sexual stages which ultimately result in the release of more 
infectious oocysts into the environment (see text for Figure 6.1).  The two autoinfective 
cycles, the type I meronts and thin-walled oocysts, allows persistent chronic infections 
without further exposure to exogenous oocysts.  While infections predominantly occur 
in the small intestine, infections have also been found in other organs and tissues 
(O'Donoghue, 1995). Detailed reviews of Cryptosporidium and cryptosporidiosis may 
be found in Current & Garcia, (1991) and O'Donoghue, (1995).   
 
6.1.1.2. Cryptosporidium species 
 
Initially it was assumed that Cryptosporidium was host specific, with species named on 
the basis of host occurrence.  However, Cryptosporidium was later found to be readily 
transmissible between different host species, with some degree of host specificity at the 
vertebrate class level.  Subsequent studies revealed multiple Cryptosporidium species 
within the same vertebrate class and even the same host species, with six species now 
considered valid on the basis of differences in host specificity, oocyst morphology and 
site of infection.  These are C. muris, C. parvum and C. wrairi in mammals, C. 
meleagridis and C. baileyi in birds, C. serpentis in reptiles and C. nasorum in fish CHAPTER 6 
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Figure 6.1: Diagrammatic representation of the proposed lifecycle of C. parvum as it 
occurs in the mucosal epithelium of an infected mammalian host.  After excysting from 
oocysts in the lumen of the intestine (a), sporozoites (b) penetrate the host cell and 
develop into trophozoites (= uninucleate meronts) (c) within parasitophorous vacuoles 
confined to the microvillous region of the mucosal epithelium.  Trophozoites undergo 
asexual division (merogony) (d and e) to form merozoites.  After being released from 
type I meronts, the invasive merozoites enter adjacent host cells to form additional type 
I meronts, or to form type II meronts (f).  Type II meronts do not recycle but enter host 
cells to form the sexual stages, microgamonts (g) and macrogamonts (h).  Most 
(approximately 80%) of the zygotes (i) formed after fertilization of the macrogamont by 
the microgametes (released from microgamont) develop into environmentally resistant, 
thick-walled oocysts (j) that undergo sporogony to form sporulated oocysts (k) 
containing four sporozoites.  Sporulated oocysts released in faeces are the 
environmentally resistant life cycle forms that transmit the infection from one host to 
another.  A smaller percentage of the zygotes (approximately 20%) do not form a thick, 
two-layered oocyst wall: they only have a unit membrane surrounding the four 
sporozoites.  These thin-walled oocysts (l) represent auto infective life cycle forms that 
can maintain the parasite within the host without repeated oral exposure to the thick-
walled oocysts present in the environment (Text and figure from Current & Blagburn, 
1990, cited in Current & Garcia, 1991). 
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(Levine, 1984; O'Donoghue, 1995).  Of the mammalian species, C. parvum appears to 
be the most widespread, and is the zoonotic species responsible for the majority of 
infections in humans and livestock (Upton & Current, 1985; Dubey et al., 1990; 
O'Donoghue, 1995).  However further species differentiation is necessary, and likely 
with the development of new molecular techniques to distinguish between different 
strains of Cryptosporidium.   
 
6.1.2. Human cryptosporidiosis 
 
6.1.2.1. Prevalence and transmission 
 
In industrialised nations it is thought that between 0.4% - 4.5% of the population may 
be passing oocysts at any one time, with up to 50% of the population having antibodies 
to C. parvum (O'Donoghue, 1995; Upton, 2001).   In third world countries however, 
prevalence rates are thought to be between 3-20%, and sero-prevalence may be as high 
as 85% (Current & Garcia, 1991; Upton, 2001).  C. parvum is predominantly a parasite 
of neonate animals, and is widespread in both domestic and wild animal populations 
(O'Donoghue, 1995).  In comparison, humans are susceptible to infection throughout 
their lives, with only previous exposure resulting in either partial or full immunity to the 
parasite (Upton, 2001).  However infections are most common in young children and 
the immunocompromised.  Peaks in human infection are usually seen in the spring, and 
associated with increased runoff and high numbers of neonate animals which amplify 
oocyst numbers (Simmons, 1991; Upton, 2001).  
 
Ingestion of drinking water contaminated with oocysts is the major mode of 
transmission, with contamination of water supplies occurring via animal excreta.   
Person to person transmission is also common, especially in childcare settings.   
Infections may also develop from direct contact with infected animals or ingestion of 
contaminated foods (Simmons, 1991).  In addition, infections may develop from 
inhalation of oocysts (O'Donoghue, 1995).  The higher prevalence of infections in less 
developed countries is thought to be due to poor sanitation, contaminated water 
supplies, overcrowding, and greater contact with potential reservoir hosts (Current & 
Garcia, 1991). CHAPTER 6 
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6.1.2.2. Disease and diagnosis 
 
Clinical signs of the disease can vary depending on the host species, its immune and 
nutritional status, the site and severity of infection, and the parasite species involved.  
The incubation period is approximately one week before the onset of symptoms that 
may persist for one to three weeks, although asymptomatic infections are possible 
(O'Donoghue, 1995).  The main symptom is profuse offensive watery diarrhoea, which 
may be accompanied by abdominal pain, vomiting, fever and headache, and may lead to 
significant weight loss and dehydration (Ungar, 1990).  Most infections are self-
limiting, with the immune system able to stop the infection (Simmons, 1991; 
O'Donoghue, 1995). Many factors affect the longevity of infections, with the most 
important relating to the immunocompetency of the host and the parasite species 
involved (O'Donoghue, 1995).  However in some individuals, specifically young 
children, the elderly and the immunocompromised, infections may be associated with 
severe, chronic disease that can become life threatening (Simmons, 1991; O'Donoghue, 
1995).    
 
Diagnosis is primarily by microscopic demonstration of oocysts in the faeces, or by 
direct detection of parasite life stages within host tissues (Simmons, 1991; O'Donoghue, 
1995).  While immunofluorescence microscopy is most commonly used in the detection 
of oocysts, several immunolabelling techniques have been developed and are now 
commercially available (O'Donoghue, 1995; CDC, 2001a).  In addition, 
immunoserological tests are being developed for the detection of specific host 
antibodies against Cryptosporidium antigens.  While several molecular diagnostic 
methods have been developed, they are mainly used as research tools (CDC, 2001a). 
 
6.1.2.3. Treatment and prevention 
 
The majority of treatments for cryptosporidiosis deal with the symptoms of the disease, 
and are aimed at adequate fluid and electrolyte replacement.  This is because, at present, 
there is no specific chemotherapeutic treatment for eliminating C. parvum (CDC, 
2001a).  Because of the severity of infections in the young and immunocompromised, CHAPTER 6 
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the development of effective therapy is vital to treat cryptosporidiosis in these 
populations.  While hundreds of compounds have been tested against C. parvum, none 
have been shown to be particularly effective (Fayer & Fetterer, 1995; O'Donoghue, 
1995). In immunocompromised individuals, immunological intervention to restore or 
enhance the host immune function can sometimes provide passive immunity 
(O'Donoghue, 1995).  In addition, paromomycin and nitazoxanide have also had some 
effect on the parasite, and can occasionally eliminate the disease (Upton, 2001). For a 
review on the drugs tested, see O'Donoghue, (1995).   
 
The genes of the microtubule proteins α-tubulin and β-tubulin of C. parvum have been 
cloned and sequenced, and thus provide information on potential targets for 
chemotherapeutic agents against cryptosporidiosis (Petersen, 1993). The dinitroanilines 
are thought to target tubulin (Section 2.1.3.1), and have recently been found to have 
some effect against C. parvum in vitro (Arrowood et al., 1996; Benbow et al., 1998; 
Armson et al., 1999a; 1999b; MacDonald et al., 2002) and in vivo (Armson et al., 
1999b; 2002).  However further investigations are required to assess their potential 
against human cryptosporidiosis. 
 
Cryptosporidium oocysts are highly resistant to a range of environmental conditions and 
to chemical disinfectants, in particular chlorination at concentrations used to treat 
drinking water (Tzipori, 1983; Robinson et al., 1992).  Therefore to reduce the risk of 
infection they must be removed by effective flocculation and filtration (Simmons, 
1991). However, due to its ability to pass through the majority of filtration systems, it is 
far better to prevent contamination of water supplies than to rely on water treatment 
techniques.  Therefore the best preventative measures are frequent water testing, and 
converting to well maintained public water supplies.  In addition, high standards of 
hygiene should be observed to reduce transmission between humans, from animals, and 
from contaminated food (Dubey et al., 1990). 
 
6.1.3. Development of in vitro drug assays for C. parvum 
 
C. parvum has earned a worldwide reputation as a serious threat to public health, 
particularly to neonates and the immunocompromised.  The search for curative CHAPTER 6 
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treatments has been severely hampered by the absence of reliable in vitro drug assays 
for the assessment of potential anticryptosporidial agents. While a number of techniques 
have been developed for the detection and quantitation of C. parvum in vitro (Upton et 
al., 1995; Woods et al., 1995; Arrowood et al., 1996; You et al., 1996; Walker et al., 
1998; Armson et al., 1999a), they are often subjective and time consuming, and lack 
sensitivity and reproducibility.  More recently, PCR methods have been developed to 
overcome these disadvantages (Jenkins et al., 1998; Walker et al., 1998; MacDonald et 
al., 2002).   
 
A reliable quantitative-PCR (Q-PCR) method for the quantitation of in vitro drug assays 
for C. parvum has been developed by MacDonald et al., (2002).  In brief, Q-PCR uses a 
molecular fluorescent probe that is specific for a particular DNA sequence, which 
generates a fluorescent signal that is proportional to the initial amount of template DNA.  
The fluorescent probe consists of an oligonucleotide probe with a fluorescent reporter 
dye attached linked to the 5’ end, and a quencher dye attached to the 3’ end, with the 
close proximity of the quencher dye to the reporter dye greatly reducing reporter 
fluorescence due to Forster resonance energy transfer (Livak et al., 1995).  During PCR 
the fluorescent probe anneals to the target DNA (of C. parvum), which is downstream 
from one of the primers, and during extension of the primer the 5’ nuclease activity of 
Taq DNA polymerase cleaves the probe.  This results in the separation of the reporter 
dye from the quencher dye, and thus an increase in the fluorescence signal from the 
reporter.  With each cycle of the PCR, additional fluorescent probes are cleaved, 
resulting in an increase in fluorescence that is proportional to the initial amount of target 
DNA.  The fluorescence values are then plotted against the cycle number, and the 
reactions characterised by the cycle number when the PCR product is first detected (Ct 
value). The method developed by MacDonald et al., (2002) offers not only higher 
sensitivity and specificity in comparison to other, labour intensive methods, but also 
allows the rapid assessment of a wide range of potential anticryptosporidial agents.  In 
addition, it has the potential to be used in a variety of in vivo systems (i.e. parasite 
burdens in clinical samples to in vivo drug trials) as well as for genotyping and 
quantification of oocysts in environmental samples. 
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6.1.4. Aim 
 
The purpose of this study was to investigate the in vitro anticryptosporidial activity of 
the antiparasitic agents ABZ and OZ both alone and complexed with ΗPβCD.  Due to 
the unusual cellular location of Cryptosporidium, it was thought that the action of 
ΗPβCD as a drug carrier (Chapter 1) and its ability to increase membrane permeability 
(Chapter 4) might improve the activity of these drugs when complexed with ΗPβCD. CHAPTER 6 
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6.2. METHODS 
 
6.2.1. Maintenance of C. parvum in vivo and in vitro 
 
The C. parvum isolate used in both in vivo and in vitro experiments was originally 
obtained from a calf in Millicent, South Australia in 1993 (Meloni & Thompson, 1996). 
The methodology for the in vivo and in vitro cultivation of C. parvum was as described 
by Meloni & Thompson, (1996). 
 
6.2.1.1. Cultivation of C. parvum in vivo 
 
6.2.1.1.1. Origin and housing of experimental animals 
Six to seven day old Mus musculus (ARC strain) were used in the in vivo amplification 
of C. parvum. They were housed with mothers in standard mouse cages in an isolated 
animal house maintained on a 12:12 h photoperiod at 21-24°C and were fed Rat and 
Mouse Cubes manufactured by Glen Forrest Stockfeeders, Western Australia.  Both 
food and water were provided ad libitum. All animals were obtained from the Western 
Australian State Animal Resource Centre, Perth, Western Australia. The Murdoch 
University Animal Ethics Committee, in accordance with national animal welfare 
standards, approved the following experiments. 
 
6.2.1.1.2. Infection and collection of C. parvum oocysts in vivo 
Six to seven day old ARC mice were infected orally by stomach intubation with 
approximately 1 x 10
5 oocysts (obtained from previously infected mice) in 0.1 mL PBS 
using a plastic tube (0.8 mm in diameter) attached to a blunted 23 G needle on a 1 mL 
syringe. Seven days post-infection the mice were anaesthetised with 80% CO2: 20% O2 
and then euthanased by cervical dislocation.  The jejunum, ileum, caecum, colon and 
rectum were removed, chopped finely and pooled with approximately 4 mL cold sterile 
PBS containing tween-20 (0.02%) and suptasol (5 mg mL
-1) per mouse intestine.  The 
suspension was homogenised at 4˚C followed by rotation on a rotary mixer (Ratex 
Instruments) for 90-120 min before it was centrifuged (Spintron GT-20) at 3000 rpm for 
10 min. The supernatant was removed to within 1 mL of the pellet and an ether 
extraction was performed by resuspending the oocyst-containing pellet in PBS/Tween-CHAPTER 6 
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20 and ether (20% final volume).  The homogenate was then mixed vigorously (30 sec) 
and centrifuged at 3000 rpm for 8 min.  This was repeated twice to wash the suspension.  
After the second spin, the plug and supernatant were removed and the pellet checked for 
oocysts.  Additional oocysts were recovered by remixing the supernatant layers from the 
ether extraction and re-centrifuging as described above to pellet and wash the oocysts.  
The pellet was then resuspended in 4 mL PBS and cold ficoll gradients (Section 
6.2.1.1.3) were used to further purify the oocysts by layering 2 mL of suspension on top 
of each gradient.  The gradients were centrifuged at 2500 rpm for 30 min before 
removing the interface into a sterile tube and diluting to 1 x 10
6 mL
-1 oocysts with 
sterile PBS and antibiotics (ampicillin and streptomycin).  The oocysts were then stored 
at 4˚C until ready for reinfection of mice or in vitro cultivation.  
 
6.2.1.1.3. Ficoll gradients 
Ficoll gradients are used to purify C. parvum oocysts from intestinal and faecal samples.  
Four solutions consisting of 0.5, 1, 2 and 4% ficoll in 16% sodium diatrizoate in sterile 
PBS were made up.  One mL aliquots of each solution are layered upon each other, 
starting with the 4% layer on the bottom and finishing with the 0.5% layer on top.  The 
gradients were then centrifuged at 3500 rpm for 5 min to separate the layers, after which 
they were stored in the refrigerator at 4ºC. 
 
6.2.1.2. Cultivation of C. parvum in vitro 
 
For the in vitro cultivation of C. parvum oocysts obtained as described in section 
6.2.1.1.2, the oocysts needed to undergo excystation before they could infect the 
continuous cell line, human ileocaecal adenocarcenoma cells (HCT-8 cells) in vitro.   
 
6.2.1.2.1. Culture medium for the cultivation of HCT-8 cells 
HCT-8 cells were maintained in 25-mm
2 tissue culture flasks with filter caps in RPMI 
1640 medium supplemented with 25 mM HEPES, 25 mM sodium hydrogen carbonate, 
2 mM glutamine, 10% foetal bovine serum (FBS), antibiotics, and incubated in an 
incubator (Forma Scientific) at 37°C in 5% CO2 (Table 6.1). 
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Table 6.1: Medium preparation for the cultivation of HCT-8 cells. 
Ingredients  Concentration  Amount to prepare 1 L 
RPMI 1640  -  10.4 g 
HEPES 25  mM  5.97  g 
Sodium hydrogen carbonate  25 mM  2.1 g 
Glutamine 2  mM  0.3  g 
Stock solution antibiotics: 
Lincomycin (40 µg mL
-1) 
Ampicillin (40 µg mL
-1) 
Gentamycin (50 µg mL
-1) 
 
4 µg mL
-1 
4 µg mL
-1 
5 µg mL
-1 
10 mL 
Make up to 900 mL with dH2O.  Adjust the pH to 7.4 and filter sterilise at 0.2 µm. 
FBS 10%  100  mL 
 
6.2.1.2.2. Removal of HCT-8 cells from cryopreservation 
Cryopreserved HCT-8 cells were removed from liquid nitrogen and defrosted quickly at 
37°C.  Under sterile conditions approximately 500 µL HCT-8 cells were added to 
25mm
2 flasks containing 5 mL of culture medium (Section 6.2.1.2.1) and incubated at 
37°C in 5% CO2. 
 
6.2.1.2.3. Cultivation of HCT-8 cells 
For the cultivation of HCT-8 cells, healthy cultures that had reached confluence were 
selected. The medium was removed and the cells were rinsed twice with PBS, followed 
by the addition of 700 µL trypsin for 20 min to lift the cells from the culture vessel wall. 
Ten mL of warm media was added and mixed to separate the cells, of which 5 mL 
aliquots were then dispensed into 25mm
2 flasks and incubated at 37°C in 5% CO2. 
HCT-8 cells that were to be maintained at confluence were grown in 1% FBS, with the 
above media made up to 990 mL before the addition of FBS. 
 
6.2.1.2.4. Cryopreservation of HCT-8 cells 
For the cryopreservation of HCT-8 cells, healthy cultures that had reached confluence 
were selected. The media was removed and the cells rinsed twice with PBS.  700 µL 
trypsin were added for 10 min to lift the cells from the culture vessel wall. Two mL of 
warm media were added and mixed to separate the cells followed by centrifugation at 
1500 rpm for 5 min and the supernatant discarded.  The cells were resuspended in FBS 
(90%) and DMSO (10%) in a volume of 2 mL. One mL aliquots were dispensed into 
sterile 2 mL cryogenic vials, which were then placed into a cold Cryogenic 1˚C CHAPTER 6 
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container and put in –80˚C freezer for at least 4 h.  The cryopreservation vials were 
placed in liquid nitrogen containers once the freezing process was complete. 
 
6.2.1.2.5. Excystation of C. parvum oocysts for in vitro cultivation 
The  in vitro cultivation of C. parvum was as described by Hajjawi et al., (2001).   
Excystation was carried out by exposing 0.1-1 mL aliquots of purified oocysts (Section 
6.2.1.1.2) (approximately 5000 oocysts per flask to be infected) to 9 mL warm sterile 
excystation media (0.5% trypsin in dH2O, pH 2.5) at 37˚C for 20 min, with mixing 
every 5 min.  The oocysts were then centrifuged at 3500 rpm for 4 min before the pellet 
was resuspended in an appropriate amount of RPMI-1640 basal medium (Table 6.2). 
 
Table 6.2: Medium preparation for the cultivation of C. parvum in vitro. 
Ingredients  Amount to prepare 1 L 
RPMI 1640  10.4 g 
HEPES 5.97  g 
Sodium hydrogen carbonate  2.1 g 
Glutamine     0.3 g 
Dehydrated bovine bile  0.2 g 
D-Glucose 1.0  g 
Folic acid  0.25 mg 
4-aminobenzoic acid  1.0 mg 
Calcium pantothenate  0.5 mg 
Ascorbic acid  8.75 mg 
Make up to 990 mL with dH2O.  Adjust the pH to 7.4 and filter sterilise at 0.2 µm. 
FBS 10  mL 
 
6.2.1.2.6. Cultivation of C. parvum in vitro 
HCT-8 cells that had been grown to confluence were used for the cultivation of C. 
parvum. The medium of the HCT-8 cells was removed and RPMI-1640 basal medium 
containing the excysted oocysts (Section 6.2.1.2.5) added.  The oocysts were then 
incubated for 60-120 min at 37˚C in a candle jar after which the infected medium was 
replaced with fresh RPMI-1640 basal medium and the cultures incubated in a candle jar 
for a further 72-120 h at 37˚C.  The cultures were examined daily using an inverted 
microscope (Olympus) at magnifications ranging from x150 to x600. 
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6.2.2. Efficacy experiments against C. parvum in vitro  
 
6.2.2.1. Drug efficacy experiments  
 
Cultivated HCT-8 cells were prepared for growth in 24 microwell plates as described in 
section 6.2.1.2.3.  The cells were then suspended in 12.5 mL of warm medium and 500 
µL aliquots per well were dispensed into 24 microwell plates and incubated at 37°C in 
5% CO2. Once the cell layers were confluent (approximately 24 h) they were 
maintained in 1% FBS and infected with 5000 oocysts per well (Section 6.2.1.2.6) 
followed by incubation for 120 min.  Following removal of infected medium and 
addition of test medium (Section 6.2.2.2), the cells were incubated for 48 h with 
constant exposure to the drugs or drug vehicle.  Upon completion of the experiment, the 
media was removed, the cell monolayer washed twice with PBS, and 200 µL ATL 
buffer (Qiagen, Hilden, Germany) added before the cultures were frozen.  Parasite 
growth was quantified as per section 6.2.3. 
 
6.2.2.2. Administration of drugs  
 
ABZ and OZ in two different formulations were tested against C. parvum in vitro.  The 
efficacy of these drugs dissolved in DMSO was compared to when these drugs were 
formulated in ΗPβCD.  10 mM solutions of ABZ and OZ were made up in 100% 
DMSO and then diluted with DMSO to create x1000 the concentrations required during 
the course of the experiment on the day of the experiment. ABZ/ΗPβCD and 
OZ/ΗPβCD were diluted from stock solutions with dH2O and investigated over the 
same concentration range as the drugs dissolved in DMSO. 2.5 µL of each drug 
concentration were added to 2.5 mL culture medium, with 0.5 mL then added per 
parasitised microwell in quadruplicate. The control cultures contained either drug 
vehicle or dH2O as appropriate.  The final DMSO concentration in the cultures 
containing DMSO was 0.1%.  The assay also required 2 additional controls, which were 
included in quadruplicate on each microwell plate.  These were: 
 
5.  HCT-8 cells only (negative controls) 
6.  Untreated parasitised HCT-8 cells (positive controls) CHAPTER 6 
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6.2.3. Quantification of in vitro parasite growth  
 
Quantification of parasite growth following in vitro drug efficacy experiments against 
C. parvum was as described by MacDonald et al., (2002). 
 
6.2.3.1. DNA extraction 
 
The procedure for extracting total DNA from drug treated cultures was a modification 
of the method by Morgan et al., (1995).  Previously frozen cultures containing 200 µL 
ATL buffer (Section 6.2.2.1) were thawed, incubated at 37°C for 30 min, and the cell 
lysate removed to a fresh eppindorff tube. The microwells were then rinsed with an 
additional 200 µL ATL buffer and pooled with the cell lysate, giving a total of 400 µL.  
The pooled lysate was incubated at 95°C for 10 min, centrifuged at 14 000 rpm for 30 
sec, and the supernatant added to another eppindorff tube containing 200 µL AL buffer 
(Qiagen) and 10 µL glass milk (Bio-rad, Richmond, Calif).  The sample was then 
vortexed, incubated at 72°C for 15 min with gentle mixing every 5 min, and then 
centrifuged at 14 000 rpm for 2 min, after which the supernatant was discarded. The 
pellet was washed twice with 600 µL AW buffer (Qiagen) and vacuum dried for 10 min 
before elution of the DNA in 50 µL AE elution buffer (Qiagen) at 37°C for 30 min. 
After centrifugation at 14 000 rpm for 5 min the supernatant was removed to a fresh 
eppindorff tube and stored at 20°C until required. 
 
6.2.3.2. PCR 
 
The primers and fluorescent probe were designed by MacDonald et al., (2002) based on 
a diagnostic sequence previously described by Morgan et al., (1996).  Primer specificity, 
QT-PCR sensitivity and QT-PCR reproducibility was evaluated by MacDonald et al., 
(2002).  The forward primer 5’ AAGAAGGCCGTGTTGGCTTA 3’ and reverse primer 
5’ GGGATTCAGCCCACCAGAAT 3’ amplified an 85bp product, with the probe, 5’ 
(FAM) TGTACCACAAACTGCACAAGAAAGCTCAGAA (TAMARA) 3’ designed 
to the complementary strand.  Amplifications were carried out in an Applied 
Biosystems ABI 7700 sequence detector using the software Sequence Detection 
Systems Version 1.7 (ABI Prism, Perkin Elmer). Amplifications were in 25 µL CHAPTER 6 
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reactions consisting of 6.25 pmoles of forward and reverse primers (Life Technologies, 
Mulgrave, VIC) and probe (Applied Biosystems) (2.5 µL each), 12.5 µL Taqman 
Universal Master Mix, 2.5 µL sterile dH20, and 2.5 µL sample DNA.  The thermal 
cycling consisted of 1 cycle of 50°C for 2 min, 1 cycle 95°C for 10 min, and 40 cycles 
of 95°C for 15 sec, 60°C for 1 min.   
 
6.2.4. Statistical analysis 
 
While the method developed by MacDonald et al., (2002) was quantitative, here the 
method was used to determine relative amounts of Cryptosporidium DNA in treated 
cultures compared to control cultures.  Standards were prepared for each microwell 
plate using DNA from untreated parasitised controls (neat), with the neat sample taken 
as 100% DNA, the maximum amount of parasite DNA produced under specified 
conditions without drug treatment.  The neat sample was then serially diluted to provide 
50%, 25%, 12.5% and 6.25% of neat DNA, and a Ct value was determined for each 
sample (Section 6.1.3).  A standard curve plotting the Ct value vs the log of the dilution 
factor was then generated by the software (r > 0.92, n=3), which was used to determine 
the percentage inhibition of the drug treated samples on that microwell plate. The % 
DNA reduction of drug treated samples was then pooled across microwell plates and the 
IC50, MLC and MIC for each drug formulation against C. parvum determined.  Where 
possible, dose response curves using non-linear sigmoidal curve fitting were generated 
(GraphPad Prism). Comparisons between dose response curves were carried out using 
repeated measures ANOVA with Bonferonni’s post test or t-tests where appropriate 
(GraphPad Prism).  CHAPTER 6 
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6.3. RESULTS 
 
6.3.1. Efficacy of albendazole formulations against C. parvum in vitro 
 
The in vitro efficacy of ABZ when dissolved in DMSO and when formulated with 
ΗPβCD was evaluated against C. parvum, and expressed as a percentage DNA 
reduction in comparison to untreated controls (Figure 6.2).  The dose response curves 
for ABZ in DMSO and ABZ/ΗPβCD were not significantly different (repeated 
measures ANOVA with Bonferonni’s post test  p>0.05). However the results at the 
lowest concentration tested (1 µM) were significantly different (t-test, p<0.001).  The 
IC50, MIC and MLC for ABZ was <1 µM, <1 µM and >100 µM, and for ABZ/ΗPβCD 
were 4.3 µM, 1 µM and >100 µM respectively  (Table 6.3).  OF the two formulations, 
ABZ dissolved in DMSO appeared to be more effective, as its IC50 was less than 1 µM. 
 
 
Figure 6.2: In vitro efficacy of ABZ and ABZ/ΗPβCD against C. parvum  (mean ± SE, 
n=4). 
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Table 6.3: The IC50, MIC and MLC of two ABZ formulations against C. parvum in 
vitro. 
Drug   IC50 (µM)  MIC (µM)  MLC (µM) 
ABZ in DMSO  <1 <1  >100 
ABZ/ΗPβCD  4.3 1  >100 
 
As previously observed, CD is capable of inhibiting a number of cell types (Chapters 4 
and 5).  Castro-Hermida et al., (2000) and Castro-Hermida et al., (2001) investigated the 
in vitro and in vivo efficacy of β-CD against C. parvum and found β-CD as a 2.5% 
suspension to be effective against C. parvum oocysts both in vitro and in vivo. The 
ΗPβCD concentration of the ABZ/ΗPβCD complex at the highest dose given (100 µM) 
was 0.661%.  Therefore the ΗPβCD concentration was lower than that required to 
inhibit G. duodenalis, HCT-8 cells and C. parvum oocysts.  It is therefore it is unlikely 
to have affected either the HCT-8 cells on which C. parvum was cultured, or any of the 
C. parvum life stages. 
 
6.3.2. Efficacy of oryzalin formulations against C. parvum in vitro 
 
The in vitro efficacy of OZ in two different formulations against C. parvum was also 
investigated, and found that OZ when dissolved in DMSO and when formulated with 
ΗPβCD were equally effective against C. parvum  in vitro (Figure 6.4).  The dose 
response curves for the two formulations were not significantly different (repeated 
measures ANOVA with Bonferonni’s post test p>0.05) with a mean IC50 of 0.86 µM, 
MIC of <0.1  µM and MLC of >10 µM (Table 6.2).   
 
Table 6.4: The IC50, MIC and MLC of two OZ formulations against C. parvum in vitro. 
Drug   IC50 (µM)  MIC (µM)  MLC (µM) 
OZ in DMSO  0.9 <0.1 >10 
OZ/ΗPβCD  0.81 <0.1 >10 
 
The ΗPβCD concentration of the OZ/ΗPβCD complex at the highest dose given (10 
µM) was 0.094%, which was considerably lower than the ΗPβCD concentration 
required to inhibit G. duodenalis, HCT-8 cells and C. parvum oocysts.  Therefore it is CHAPTER 6 
__________________________________________________________________________________________________________ 
  191
unlikely to have affected either the HCT-8 cells on which C. parvum was cultured, or 
any of the C. parvum life stages. 
 
 
Figure 6.3: In vitro efficacy of OZ and OZ/ΗPβCD against C. parvum (mean ± SE, 
n=8). 
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6.4. DISCUSSION 
 
6.4.1. Albendazole 
 
ABZ was predicted to have minimal efficacy against C. parvum based on β-tubulin 
sequences (Edlind et al., 1994; Katiyar et al., 1994; Cacciò et al., 1997), which has been 
reflected in vitro (Armson, Murdoch University, unpublished data) and in vivo (Fayer & 
Fetterer, 1995).  While some efficacy has been observed, high drug concentrations are 
required.  Here both ABZ dissolved in DMSO and the ABZ/ΗPβCD complex showed in 
vitro efficacy against C. parvum at lower concentrations than that observed in previous 
research (10-30 µM versus 4.3 µM).  This is likely to be a reflection of the alternative 
assessment method employed here.  As ABZ affects the HCT-8 cell layer at these 
concentrations by causing the cells to lift from the culture flask (Sections 4.3.1.1 and 
4.4.1.1), microscopic evaluation of parasite growth becomes impossible.  However, as 
the suspended cells were still viable, it is unclear whether C. parvum growth has really 
been affected.  It is therefore impossible to determine if ABZ efficacy is related to its 
effect on the cell layer or against C. parvum itself.  While the results here do indicate 
that ABZ affect C. parvum, it is unclear whether the efficacy of ABZ is related to a 
decreased ability of the parasite to infect suspended cells, or a direct effect against C. 
parvum itself.   
 
Differential efficacy between ABZ dissolved in DMSO and the ABZ/ΗPβCD complex 
was observed, with the ABZ/ΗPβCD appearing to have lower efficacy.  As there are 
two potential targets of ABZ, the HCT-8 cell layer and C. parvum, the decreased 
efficacy may be related to a differential effect of the ABZ/ΗPβCD complex on one or 
both of these processes. This may be reflected in both formulations having similar MLC 
but different IC50’s.  As the ABZ/ΗPβCD complex had a high stability constant (Section 
2.4.1.1), and a high stability constant can reduce the concentration of free drug (Section 
3.1.1 and 4.1.2), ΗPβCD may have decreased the amount of free ABZ through inclusion 
complex formation and therefore decreasing its ability to interact with either of these 
processes.  However, it is unusual that this process occurred here against C. parvum but 
did not occur against G. duodenalis unless excess ΗPβCD was added (Section 5.4.2.1).  
Even though the proportion of ABZ to ΗPβCD was the same against both parasites, CHAPTER 6 
__________________________________________________________________________________________________________ 
  193
ΗPβCD appeared to decrease the efficacy of the complex against C. parvum.  Therefore 
the differential effect may instead relate to the different locations of the two parasites in 
culture,  G. duodenalis on the culture wall and C. parvum within a host cell.  For 
example, ΗPβCD may have partially protected the HCT-8 cell membrane against the 
effects of ABZ (Section 1.2.3.2 and 4.1.1), but could not protect the parasite due to its 
location within the cell.  This implies that the effect of ABZ against HCT-8 cells occurs 
at much lower concentrations than the effect of ABZ against C. parvum.  However this 
would need to be evaluated in more detail.  Alternatively, the ABZ/ΗPβCD complex 
may have had differential efficacy against different stages in the lifecycle of C. parvum. 
However these results may simply be a reflection of the method used to evaluate drug 
efficacy against C. parvum, discussed in more detail below (Section 6.4.3).  
 
6.4.2. Oryzalin 
 
Previous research has found C. parvum to be susceptible to OZ both in vitro (Benbow et 
al., 1998; Armson et al., 1999b; MacDonald et al., 2002) and in vivo (Armson et al., 
1999b; 2002). OZ exhibited relatively high efficacy against C. parvum in vitro both 
alone and complexed, with an average IC50 of 0.86 µM.  These results were comparable 
to that observed in previous research.  The similar efficacy of the two formulations 
indicated that complexation with ΗPβCD did not interfere with drug action as it did 
with the ABZ/ΗPβCD complex.  This may be due to the fact that OZ does not interfere 
with the cell layer, as did ABZ, or that OZ inhibited a different stage of the lifecycle to 
ABZ.  Alternatively, the lower stability constant of the OZ/ΗPβCD complex resulted in 
the complex readily dissociating to allow free OZ to inhibit C. parvum growth.   
 
6.4.3. Conclusion 
 
The ABZ/ΗPβCD complex showed decreased efficacy against C. parvum compared to 
ABZ dissolved in DMSO in vitro, although the reasons for this were unclear.  In 
comparison the OZ/ΗPβCD complex exhibited equal efficacy against C. parvum 
compared to OZ dissolved in DMSO. The PCR method developed by MacDonald et al., 
(2002) is a convenient and efficient method for in vitro drug screening.  However, the 
quality of data vastly improved when 8 samples rather than 4 samples were assessed, as CHAPTER 6 
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sample variability was high.  In addition, as the method requires fresh oocysts, in vivo 
oocyst amplification must be carried out immediately prior to in vitro experiments, 
which increases the time taken to perform experiments.  The effect of ΗPβCD on C. 
parvum was not evaluated here as it was previously found to extract membrane 
components from HCT-8 cells on which C. parvum is cultivated.  In addition, Castro-
Hermida et al., (2000) reported that a 2.5% suspension of β-CD reduced oocyst viability 
in vitro, and had both preventative and curative effects against C. parvum  in vivo.  
However, oocysts exposed to β-CD before administration to animals were still infective, 
with reduced intensity of infection. These results were attributed to β-CD modifying the 
oocyst wall permeability.  As HPβCD has a reduced tendency to extract membrane 
components, it may be less effective against C. parvum.  However, the in vivo efficacy 
of β-CD against C. parvum appears promising, and may add to the in vivo efficacy of 
drug/CD complexes. As neither formulation resulted in increased drug efficacy when 
formulated with ΗPβCD, in vivo drug efficacy was not investigated.   CHAPTER 7 
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7.1. INTRODUCTION 
 
7.1.1. Plasmodium 
 
7.1.1.1. Lifecycle of malaria 
 
Malaria is a mosquito-borne infection caused by the protozoan parasite Plasmodium. 
The life cycle of Plasmodium involves two hosts, with the vector a female mosquito.  
There are at least 60 species of Anopheles mosquito, the principal vector, and for lizard 
and bird malaria, culicine mosquitos and sandflies are vectors (Katz et al., 1982).  When 
the vector takes a blood meal, sporozoites present in the salivary glands of the mosquito, 
the infective stage of plasmodia, are injected into the vertebrate host (Figure 7.1).  The 
sporozoites infect liver cells and there undergo asexual multiplication to produce 
merozoites in a process called exoerythrocytic schizogony.   After a period of time 
thousands of merozoites are released into the blood stream.  The latent period after 
initial infection depends on the infecting species of Plasmodium, and some species of 
Plasmodium have two exoerythrocytic forms.  The second form is the hypnozoite, 
which is capable of remaining dormant in liver cells for extended periods of time.  At 
some future time, which may by weeks or even years after initial infection, the 
hypnozoites activate, undergo exoerythrocytic schizogony, and subsequently release 
merozoites into the blood stream.   
 
Once the merozoites enter the bloodstream they invade red blood cells (RBC), initiating 
erythrocytic schizogony.  Here the parasite continues asexual multiplication in the RBC, 
with the ensuing release of merozoites being responsible for the clinical manifestations 
of the disease.  In a number of Plasmodium species erythrocytic schizogony becomes 
synchronised, with the simultaneous rupture of large numbers of RBC and the liberation 
of large numbers of merozoites and metabolic waste products into the blood stream 
resulting in the paroxysms of malaria (Garcia & Bruckner, 1988).  The length of this 
development cycle, and hence periodicity of clinical manifestation, also varies 
depending on the infecting Plasmodium species.   
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Figure 7.1: Plasmodium (P. vivax) lifecycle (Fujioka & Aikawa, 1999). 
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Some of the merozoites in the RBC then differentiate into the sexual stages called the 
gametocytes, consisting of female macrogametocytes and male microgametocytes.  A 
vector ingests the gametocytes during a blood meal, where they mature in the 
mosquito's stomach. After fertilisation the zygote develops into a motile ookinete that 
migrates to the lining of the midgut and develops into an oocyst.  The oocyst grows, 
ruptures, and releases sporozoites, which invade the entire mosquito, including the 
salivary glands.  The vector phase of the lifecycle is called sporogony, and can take 
between 8-35 days, depending on the infecting Plasmodium species and environmental 
conditions.  Inoculation of the sporozoites into a new vertebrate host perpetuates the 
malaria life cycle.  Detailed reviews on Plasmodium can be found in Noble & Noble, 
(1979), James & Gilles, (1985) and Garcia & Bruckner, (1988), and online by Navy 
Environmental Health Center, (2001) and CDC, (2001c). 
 
7.1.1.2. Human Plasmodium  
 
There are approximately 156 named species of Plasmodium that infect various species 
of vertebrates and four are known to infect humans: P. falciparum, P. vivax, P. ovale 
and P. malariae.  These are distinguished by the type, severity and frequency of the 
clinical symptoms, and by the morphology of the parasites in stained blood smears 
during microscopic analysis (James & Gilles, 1985).  Some simian Plasmodium species, 
such as P. knowlesi and P. cynomolgi, are also capable of infecting humans, causing 
relatively mild disease (Katz et al., 1982). 
 
7.1.2. Malaria 
 
7.1.2.1. Prevalence 
 
Malaria is one of the most serious protozoan diseases affecting humans, and is 
widespread in more than 100 countries. Malaria generally occurs in tropical and 
subtropical areas, where environmental conditions allow parasite multiplication to occur 
in the vector (CDC, 2001c; Navy Environmental Health Center, 2001).   The WHO 
estimates that 300-500 million cases of malaria occur yearly, with more than 1 million 
people a year worldwide dying of the disease (WHO, 2000a; CDC, 2001c).  The CHAPTER 7 
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majority of infections occur in children under the age of five years, with most 
developing partial immunity that protects them from severe disease (Winstanley, 2000). 
Despite extensive control programs to eradicate it, malaria is still a major health 
problem in many developing countries, and also poses a significant economic burden to 
these countries (WHO, 2000b).  Difficulties in the eradication of malaria have arisen 
due to increasing populations in high risk areas, increased population movement, 
increasing drug resistance in both the vector and parasite, and the spread of malaria via 
human impact on the environment into areas previously transmission-free (Olliaro et al., 
1996; Martens & Hall, 2000; Persidis, 2000; WHO, 2000c).   
 
7.1.2.2. Clinical disease  
 
The symptoms of uncomplicated malaria can be rather non-specific, and develop 10 
days to 4 weeks after infection, depending on the infecting species of Plasmodium.  The 
initial symptoms of malaria may be mild and include fever, malaise and flu-like 
symptoms, with or without other symptoms such as headache, muscle aches and 
weakness, shaking chills, nausea, vomiting, diarrhoea and cough (Garcia & Bruckner, 
1988).  Anaemia and jaundice may also develop due to the loss of red blood cells 
(WHO, 2001; CDC, 2001c).  The clinical presentation can vary substantially depending 
on the infecting species, the level of parasitemia, and the immune status of the patient.   
A characteristic response to the synchronised erythrocytic cycle is the paroxysm, which 
begins with chills and a gradually mounting fever, followed by the patient feeling 
intensely hot, after which perspiration starts until the fever subsides (Noble & Noble, 
1979).  If left untreated, all forms of malaria tend to become chronic, with the 
development of immunity eventually leading to its spontaneous cure (Katz et al., 1982).  
Infection with P. falciparum can also develop into more severe forms of the disease, 
involving the central nervous system and/or other organs.  If not promptly treated, 
severe malaria can result in rapid deterioration into stupor, seizures, coma and usually 
death (CDC, 2001c).   
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7.1.2.3. Treatment and prevention 
 
Even with the development of a number of antimalarial drugs in the last 20 years, only a 
relatively small number of antimalarial drugs are available today (Persidis, 2000).   
Current control measures are becoming less effective due to drug resistance, and as yet 
no highly effective vaccine exists (Persidis, 2000; Winstanley, 2000). Therefore, 
affordable new drugs as well as improved formulations of existing drugs are needed.  
While malaria can be cured with prescription drugs, the type of drugs and length of 
treatment is dependent on the kind of malaria diagnosed, where the patient was infected, 
the age of the patient, and how severely ill the patient was at start of treatment (CDC, 
2001c). Commonly used antimalarial drugs include chloroquine (CHQ), quinine, 
artemisinin and its derivatives, pyrimethamine combinations and primaquine, and the 
more expensive mefloquine and halofantrine. CHQ has been a cheap, safe and practical 
antimalarial drug for decades, but with the extensive development of resistance it can no 
longer be relied upon to produce clinical improvement in patients infected with P. 
falciparum  (Winstanley, 2000).  CHQ has been largely replaced by quinine in the 
treatment of P. falciparum, and while resistance has developed, it is largely confined to 
Southeast Asia (Winstanley, 2000).  For a review of the currently used antimalarials, see 
White, (1996) and Winstanley, (2000).  As microtubules have been identified in nearly 
all stages of the Plasmodium lifecycle, antimicrotubule drugs have also been 
investigated as potential antimalarial agents (see reviews by Bell, 1998 and Hommel & 
Schrével, 1998).  A number of classes of microtubule inhibitors have been investigated 
against malaria, such as colchicine-site binders (including some benzimidazoles), 
vinblastine-site binders, vinca alkaloids and taxoids, as well as the microtubule 
inhibitors tubulozole and trifluralin.  While a number are potent against various stages 
of  Plasmodium, many also exhibit mammalian cell toxicity.  Therefore further 
investigation into antimicrotubules that have a weaker effect on mammalian cells may 
prove worthwhile.  However, detailed analysis of malarial microtubule proteins is 
hampered due to the technical difficulty in obtaining material for biochemical studies 
(Section 7.1.3).   
 
Current malaria intervention programs utilise a number of avenues to reduce malaria-
induced morbidity and mortality, such as vector control and avoidance, vaccine CHAPTER 7 
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development, chemoprophylaxis, drug treatment/management, and basic education 
programs for populations at risk (Persidis, 2000; WHO, 2000c).  For travellers to 
Africa, prevention of malaria can be achieved by using insect repellents and indoor 
residual spraying between dusk and dawn, and insecticide-treated mosquito nets where 
necessary, in combination with the regular use of the correct antimalarial drugs for 
prophylaxis (WHO, 2001). WHO recommends weekly mefloquine prophylaxis, which 
should be started 2-3 weeks before travel.  Alternatively, daily doxycycline treatment 
started the day before travel.  Both drugs should be continued during the stay and for 4 
weeks after leaving the endemic area (WHO, 2001).  
  
7.1.3. Preclinical assessment of antimalarials  
 
The present day methodology for the assessment of antimalarials involves a number of 
techniques, including the initial selection and screening of compounds for antimalarial 
activity against P. falciparum in vitro.  P. falciparum can be cultivated in continuous 
culture in vitro, and procedures for the assessment of blood schizontocidal action of 
drugs have been developed (James & Gilles, 1985).  Further drug screening is then 
carried out using non-human Plasmodium species in vivo.  There are many animal 
models for non-human Plasmodium species. As a number of murine plasmodia have 
been adapted to certain laboratory rodents, and can be transmitted through species of 
laboratory-reared mosquitoes, these have become the most practical models for the 
experimental study of mammalian malaria (Carter & Diggs, 1977).  However, one of the 
disadvantages in early drug screening is that data obtained from in vitro screens against 
P. falciparum and in vivo screens against rodent malarias are not directly comparable.  
While in vitro drug screening methods against rodent malaria have been developed, the 
in vitro cultivation of the rodent malarias in continuous culture has been more difficult 
(Coombs & Gutteridge, 1975; McNally et al., 1992; Sohal & Arnot, 1993).  The 
development of in vitro rodent malaria models offers a number of advantages. The 
rodent malarias are more accessible and relatively inexpensive in comparison to the 
primate malarias (McNally et al., 1992), they are easy and safe to handle and 
manipulate in the laboratory (Janse & Waters, 1995), they are not infective to humans, 
and they allow direct comparison to in vivo drug trials (Mons & Sinden, 1990).  In 
addition, this will allow the mass cultivation of parasite material for molecular studies CHAPTER 7 
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as well as investigations into the relationship between the parasite and the host’s 
immune system (Mons & Sinden, 1990; Janse & Waters, 1995).  The basic biology of 
P. berghei, the most commonly studied rodent malaria, closely resembles other 
mammalian malaria parasites, and hence exhibits similarities in drug susceptibility and 
mechanisms of drug resistance (Janse & Waters, 1995; Mons & Sinden, 1990). While 
recent advances have allowed the cultivation of P. berghei in vitro (Mons & Sinden, 
1990; Janse & Waters, 1995; Dow, 2000), its cultivation is still problematic, and its 
preference for reticulocytes makes it less comparable to P. falciparum (Mons & Sinden, 
1990).  Therefore research into the in vitro cultivation of other rodent plasmodia needs 
to be continued, particularly those that are similar to P. falciparum, such as P. chabaudi 
(Mons & Sinden, 1990).   
 
7.1.4. Aim 
 
The purpose of this study was to investigate the in vitro and in vivo antimalarial activity 
of the antiparasitic agents ABZ and OZ both alone and complexed.  In addition, the 
effect of ΗPβCD on P. chabaudi, and the effect of ΗPβCD on drug efficacy, was 
investigated. 
 CHAPTER 7 
__________________________________________________________________________________________________________ 
  203
7.2. METHODS 
 
7.2.1. P. chabaudi 
 
The rodent malaria P. chabaudi used in in vitro and in vivo experiments was obtained 
from Professor David Walliker at the University of Edinburgh.  All procedures were 
carried out under sterile conditions using a biohazard hood. The cultivation of P. 
chabaudi in vitro and in vivo was modified from Dow, (2000). 
 
7.2.2. In vivo parasite amplification for in vitro and in vivo drug studies 
 
7.2.2.1. Origin and housing of experimental animals 
 
Six-week-old male Mus musculus (ARC Swiss strain) were used to passage P. chabaudi 
in vivo, and five-week-old male Rattus norvegicus (Wistar strain) were used as donor 
rats to amplify parasite number for in vitro and in vivo experiments.  They were housed 
in an isolated animal house maintained on a 12:12 h photoperiod at 21-24°C and were 
fed Rat and Mouse Cubes manufactured by Glen Forrest Stockfeeders, Western 
Australia.  Mice were housed 3 animals per standard mouse cage and rats housed 3 
animals per standard rat cage, and both food and water were provided ad libitum.  All 
animals were obtained from the Western Australian State Animal Resource Centre, 
Perth, Western Australia. The Murdoch University Animal Ethics Committee, in 
accordance with national animal welfare standards, approved the following 
experiments. 
 
7.2.2.2. Passage of P. chabaudi through mice 
 
P. chabaudi was maintained in vivo by serial passage through mice. P. chabaudi was 
obtained from either cryopreserved stock (Section 7.2.2.4) or from previously infected 
mice. Blood was collected from infected mice by snipping the tip of the animal’s tail 
with sharp scissors (less than 1.0mm of tail was removed each time a blood sample was 
taken), and two to three drops of tail vein blood collected.  A thin smear of the blood 
was used to determine parasitaemia (Section 7.2.2.5).  The blood of the infected mouse CHAPTER 7 
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was then diluted in 10 mL glucose citrate solution (GC - below) of which 300 µL were 
injected i.p. into a recipient mouse using a 26G needle under halothane anesthesia 
(Section 7.2.2.6).  After 6-8 days, asexual stages became visible on peripheral blood 
smears and the parasite was passaged again.  
 
GC was prepared by dissolving 15 g tri-sodium citrate and 2.5 g D-glucose in 500 mL 
warm deionised water and filter sterilised (0.2µm) before storing at 4˚C. 
 
7.2.2.3. Infection and harvesting of P. chabaudi from donor rats for drug studies  
 
P. chabaudi was maintained in vivo by serial passage through mice (Section 7.2.2.2).  
To amplify parasite number for drug experiments, blood from an infected mouse with 
parasitaemia in excess of 20% (eight to nine days post infection) was used to infect 
donor rats. 1-2 drops of infected mouse blood (obtained by cardiac puncture, section 
7.2.2.6) were diluted in 300 µL GC solution and injected i.p. into recipient rats using a 
26G needle under halothane anaesthesia (Section 7.2.2.6). Six to eight days after 
infection the rats had rising parasitaemias of >5% and were used as donor animals for 
drug experiments.  Blood was taken via cardiac puncture (Section 7.2.2.6) and diluted in 
5.0 mL prewarmed GC solution. The parasite titre (Section 7.2.2.5) was calculated 
before the parasites were diluted to the appropriate concentration for drug experiments 
with GC solution. 
 
7.2.2.4. Cryopreservation of P. chabaudi 
 
P. chabaudi was cryopreserved by mixing a drop of blood obtained from an infected 
mouse (Section 7.2.2.2) with 150µL Alsevier’s solution (AS - below) in sterile 2 mL 
cryogenic vials (Nalgene).  The vials were then submerged in liquid nitrogen for 
storage. Cryopreserved P. chabaudi was removed from liquid nitrogen and defrosted 
quickly at 37°C. The vial contents were then immediately injected i.p. into recipient 
mice using a 26G needle (as described in section 7.2.2.2). 
 
AS was prepared by dissolving 0.52 g NaCl, 1 g tri-sodium citrate, 2.33 g D-glucose 
and 9.5 mL glycerol in 100 mL warm deionised water and filter sterilised (0.2µm) 
before storing at 4˚C.  CHAPTER 7 
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7.2.2.5. Determination of parasitaemia and parasite titre 
 
The parasitaemia is defined as the percentage of red blood cells (RBC) parasitised by P. 
chabaudi, and was determined using Diff-Quik (Perth Scientific Equipment, Australia) 
stained thin smears prepared from tail blood from infected rodents.  A thin blood smear 
was allowed to dry before ten one-second dips in methanol followed by rinsing with 
five one-second dips in water, with this procedure repeated for each of the dyes.  At 
least 2000 erythrocytes (five to ten fields of view) per smear were viewed under oil at 
1000x magnification, with the total number of erythrocytes and number of infected 
erythrocytes determined. The parasitaemia was then determined using the formula: 
 
Parasite titre is the concentration of infected erythrocytes and was determined from the 
RBC titre (RBC mL
-1) and parasitaemia (above) of the infected animal. The RBC titre 
was determined using a haemocytometer and used to calculate the parasite titre 
according to the following formula: 
 
7.2.2.6. Anaesthesia and euthanasia  
 
Animals to be infected with P. chabaudi were anaesthetised for parasite administration 
i.p.  They were anaesthetised with halothane in a special delivery chamber of clear 
perspex (40x20x20 cm) with an inlet hose from an in-line vaporiser (Ohio Medical 
Products, USA) using oxygen as the carrier for 0.5-1% halothane. An outlet hose from 
the chamber was connected to a rat mask, the rat was placed within the chamber until 
anaesthetised after which it was removed and the snout placed into the mask to maintain 
halothane anaesthesia during parasite administration. 
 
For the collection of blood by cardiac puncture, animals were anaesthetised as above. 
Blood was then collected via cardiac puncture using 21G needles into 1 mL (mice) or 5 
mL (rats) syringes containing 0.1 mL of 200 U mL
-1 porcine heparin in PBS to prevent 
Parasitaemia (%) =
number infected erythrocytes
total number erythrocytes
×100
) mL   (RBC    titre RBC  x  100
ia Parasitaem
  =   ) mL   RBC   ed (parasitis    titre Parasite 1 -
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blood clotting. After blood collection the animals were euthanased by halothane 
overdose and cervical dislocation.  
 
7.2.3. In vitro drug studies 
 
7.2.3.1. Culture medium for in vitro drug studies 
 
The culture medium for in vitro drugs experiments against P. chabaudi was RPMI 1640 
medium supplemented with 2 mM L-glutamine, 25 mM HEPES, 21 mM sodium 
hydrogen carbonate, antibiotics and 20% FBS (Table 7.1).  
 
Table 7.1: Medium used in drug experiments against P. chabaudi in vitro. 
Ingredients  Concentration  Amount to prepare 1 L 
RPMI 1640   -  10.4 g 
L-glutamine  2  mM  0.3 g 
HEPES  25  mM  5.95 g 
Sodium hydrogen carbonate  21 mM  1.75 g 
Gentamycin (50 µg mL
-1) 15  ng  mL
-1 0.3  mL 
Made up to 800 mL in dH2O.  Adjust to pH 7.2 and filter sterilise at 0.2 µm. 
FBS 20%  200  mL 
 
7.2.3.2. Preparation of drugs 
 
The in vitro efficacy against P. chabaudi of ABZ and OZ when dissolved in DMSO was 
compared to their formulation in ΗPβCD.  The efficacy of CHQ, the ABZ metabolites 
ABSO and ABSO2, and the effect of ΗPβCD were also investigated.  Appropriate 
concentrations of ABZ, ABSO, ABSO2 and OZ were made up in 100% DMSO and then 
diluted with DMSO to create 200 times the concentrations required during the course of 
the experiment on the day of the experiment. The drug solutions were then diluted 1:100 
with media (above), so that they were twice the concentration required in the 
experiment (in 1% DMSO). CHQ was similarly prepared, except that it was dissolved in 
PBS before dilution with media. ABZ/ΗPβCD (Section 2.3.1.1) and OZ/ΗPβCD 
(Section  2.3.3.1) were diluted from stock solutions with media to the same 
concentration range as the drugs dissolved in DMSO. The drug solutions were then 
added to equal volumes of parasitised blood (Section 7.2.2.3), so that the parasitised CHAPTER 7 
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blood volume diluted the drugs to the appropriate concentrations.  The final DMSO 
concentration in the cultures containing DMSO was 0.5%.  Control cultures contained 
DMSO, PBS or dH2O as appropriate.   
 
7.2.3.3. In vitro drug efficacy studies 
 
Drug efficacy experiments against P. chabaudi were performed using 96 well plates. 
100µL aliquots of drug (Section 7.2.3.2), and 100µL of P. chabaudi-parasitised 
erythrocytes at a parasitaemia of 11.6% (Section 7.2.2.3) were added to each well (final 
parasitaemia 5.8%).  Each drug concentration was investigated in quadruplicate.  The 
cultures were mixed gently and then incubated in 5% CO2 and 10% O2 in nitrogen for 
24 h before evaluation of drug efficacy. 
 
7.2.3.4. Determination of in vitro drug efficacy 
 
Drug efficacy against P. chabaudi in vitro was determination as described by Dow, 
(2000).  After incubation of the parasites in the presence of the drugs for 24 h, a drop of 
the culture was used to prepare a thin film.  The parasitaemia of the cultures was then 
determined as described in section 7.2.2.5, and drug efficacy assessed using the 
following formula: 
 
The average inhibition was then determined for each drug concentration and non-linear 
sigmoidal curve fitting (Prism™) was used to generate dose response curves and to 
determine IC50 values.   
 
7.2.4. In vivo drug studies 
 
7.2.4.1. Mass infection of rats for in vivo drug studies 
 
Five-week-old male Rattus norvegicus (Wistar strain) were used in in vivo drug 
experiments.  They were housed, caged and fed as described in section 7.2.2.1.  P. 
% Inhibition  =
control parasitaemia-test parasitaemia
control parasitaemia
×100CHAPTER 7 
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chabaudi-parasitised erythrocytes derived from donor rats (Section 7.2.2.3) were diluted 
to a concentration of 6.67 x 10
6 parasitised RBC mL
-1 (parasite titre, section 7.2.2.5) 
with GC solution (Section 7.2.2.2).  Recipient rats were inoculated i.p. with 300 µL of 
diluted parasites, or a final inoculum of two million parasitised RBC.  This inoculum 
protocol was broadly based on a review of published methods Ager, (1984). 
 
7.2.4.2. Drug formulations 
 
The  in vivo efficacy of ABZ (suspension, section 3.2.2.1.2, Table 3.1) against P. 
chabaudi  was compared to that of the ABZ/ΗPβCD complex at pH 2.1 (Section 
2.3.1.2).  As the ABZ/ΗPβCD formulation was at a specific pH and ΗPβCD 
concentration to ensure all ABZ was dissolved, the volume of the ABZ/ΗPβCD 
formulation was adjusted as appropriate to administer 7.5, 15, 30 or 60 mg kg
-1 day
-1 
ABZ.  This was done to avoid premature precipitation of the ABZ.  A similar dosing 
regime was applied to the ABZ suspension.  The efficacy of 18 mg kg
-1 day
-1 CHQ 
dissolved in PBS was also evaluated.  The controls were the suspension and ΗPβCD 
only (at pH 2.1) administered at 1.2 g kg
-1 (same ΗPβCD concentration and volume as 
the largest ABZ/ΗPβCD dose).  
 
7.2.4.3. In vivo drug efficacy studies 
 
Wistar rats inoculated with P. chabaudi (Section 7.2.4.1) were administered ABZ, 
ABZ/ΗPβCD, chloroquine or control solutions PO (Section 7.2.4.2) at 12 h intervals on 
days 5, 6 and 7 post inoculation. The maximum ΗPβCD concentration was 1.2 g kg
-1.  
Rats were lightly anaesthetised before drugs were administered by stomach intubation 
of up to 0.2 mL 100 g
–1 rat using a plastic tube (0.96 mm in diameter) attached to a 
blunted needle (21 G) on a 1 mL syringe. Animals were assessed by twice daily 
examinations, and parasitaemias determined on days 4, 5, 6, 7, 8 and 10 post-
inoculation (Section 7.2.2.5), and hematocrits determined on days 4, 6, 8 and 10 post-
inoculation (Section 7.2.4.4).  Upon completion of the experiment (10 days post 
inoculation), animals were euthanased by halothane overdose and cervical dislocation as 
described in section 7.2.2.6. 
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7.2.4.4. Determination of haematocrit values 
 
Haematocrit values were determined to assess whether animals were anaemic.  Tail vein 
blood samples were collected (Section 7.2.2.2) into heparinised capillary tubes (Chase 
Scientific Glass, USA), which were then plugged and centrifuged for six minutes in a 
haematocrit centrifuge (Clements).  The respective lengths of the red cell and plasma 
columns were recorded and used to determine haematocrit values in the formula: 
 
 
 
7.2.4.5. Determination of in vivo drug efficacy 
 
In all chemotherapy experiments the drug efficacy of each drug regime was evaluated 
using repeated measures ANOVA with Bonferonni’s post test (GraphPad Prism).   
Comparisons of the percentage change in mean body weight between days 4 and 10 post 
inoculation, and haematocrit on day 10 post-inoculation, were carried out for each drug 
using t-tests (GraphPad Prism).  The percentage change in body weight between days 4 
and 10 post inoculation was determined by the following formula: 
 
 
 
 
 
 
fraction   plasma   of length  + fraction    cell   red   of length 
fraction   cell   red   of length 
= t  Haematocri
% Change in body weight  =
x weight on day 10-x weight on day 4
x weight on day 4
×100CHAPTER 7 
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7.3. RESULTS 
 
7.3.1. Effect of ΗPβCD on P. chabaudi in vitro 
 
Short term in vitro cultures (24h) were used to assess the efficacy of a range of 
compounds against P. chabaudi.  The parasitaemia declined during culture, with the 
parasitaemia of control cultures dropping from 5.8% at the commencement of the 
experiment to an average of 2.7% at the completion of the experiment.   
 
The effect of ΗPβCD on P. chabaudi was investigated in vitro, and was found to 
improve culture conditions.  Approximately 2% ΗPβCD maintained the initial 
parasitaemia, and concentrations greater than 2% resulted in increased parasite growth 
over the initial parasitaemia (Figure 7.2).   
 
 
 
Figure 7.2: In vitro effect of ΗPβCD on P. chabaudi parasitaemia over 24 h (mean ± 
SE, n=4). 
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7.3.2. In vitro drug studies 
 
7.3.2.1. In vitro efficacy of CHQ, ABZ and OZ against P. chabaudi  
 
The efficacy of CHQ, ABZ, ABSO, ABSO2 and OZ were investigated against P. 
chabaudi in vitro.  CHQ, ABZ and OZ exhibited IC50‘s of 0.98 µM, 63.7 µM, and 5.4 
µM respectively (Table 7.2).  However, ABZ preparations at high concentrations 
(≥100µM) formed a precipitate.  The ABZ metabolites ABSO and ABSO2 both were 
found to be ineffective against P. chabaudi in vitro at below 1000 µM.  
 
Table 7.2: Drug IC50s against P. chabaudi in vitro. 
Drug CHQ  ABZ  ABSO  ABSO2  OZ 
IC50 against P. chabaudi (µM)  0.98 63.7  >1000  >1000 5.4 
 
7.3.2.2. In vitro efficacy of drug/ΗPβCD complexes against P. chabaudi 
 
The efficacy of the ABZ/ΗPβCD and OZ/ΗPβCD complexes were also investigated 
against P. chabaudi in vitro.  Both drug formulations resulted in improved parasite 
growth (Figure 7.3), with improved growth associated with the ΗPβCD concentration of 
the formulations.  The improved growth due to the ΗPβCD concentration of the 
formulations correlate with the results of section 7.3.1. 
 
7.3.3. In vivo drug studies 
 
P. chabaudi infection in Wistar rats resulted in relatively high parasitaemias (up to 
35%), no mortality or neurological symptoms, and did not cause severe anaemia or 
weight loss (control animals, Table 7.3).  At a dose of rate of 18 mg kg
-1day
-1, CHQ 
significantly reduced P. chabaudi infection, causing 100% suppression of parasitaemia 
by day 10 post-inoculation (repeated measures ANOVA and Bonferonni’s post test, 
p<0.05) (Figure 7.4).   CHAPTER 7 
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Figure 7.3: In vitro effect of ABZ/ΗPβCD and OZ/ΗPβCD on P. chabaudi 
parasitaemia over 24 h (mean ± SE, n=4).  The ΗPβCD concentration of the 
formulations (when greater than 0.5%) is shown in brackets. 
 
Figure 7.4: Course of infection in P. chabaudi infected rats, and when treated orally 
with 18 mg kg
-1day
-1 CHQ on days 5-7 post-innoculation (mean ± SE, n=8). 
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ABZ did not exhibit significant efficacy when administered at up to 60 mg kg
-1 day
-1 
(repeated measures ANOVA and Bonferonni’s post test, p>0.05).  Investigation into the 
therapeutic effects of ABZ found that ABZ treatment resulted in increased anaemia 
(significant at 60 mg kg
-1day
-1, t test, p<0.05) (Table 7.3). The in vivo efficacy of the 
ABZ/ΗPβCD complex (pH 2.1) against P. chabaudi was also investigated, and found to 
exhibit no significant efficacy at up to 60 mg kg
-1day
-1 (repeated measures ANOVA and 
Bonferonni’s post test, p>0.05).  In addition, the ABZ/ΗPβCD formulation resulted in a 
dose related depression of weight gain (significant at 60 mg kg
-1day
-1, t test, p<0.05) 
and increased anaemia (significant at 60 mg kg
-1day
-1, t test, p<0.05), which appeared to 
be greater than that observed for the ABZ formulation (Table 7.3). 
 
Table 7.3: Therapeutic effects of oral ABZ and ABZ/ΗPβCD treatment in P. chabaudi 
infected rats. 
ABZ
 a  ABZ/ΗPβCD 
b  Drug 
treatment 
(mg kg
-1day
-1) 
% Change in 
body weight ± 
SE
 c 
Post treatment 
haematocrit ± 
SE 
d 
% Change in 
body weight ± 
SE
 c 
Post treatment 
haematocrit ± 
SE 
d 
Control   +18.8 ± 2.8  0.32 ± 0.018  +17 ± 2.8  0.33 ± 0.02 
7.5  +20.1 ± 4.0  0.32 ± 0.01  +18.9 ± 3.1  0.36 ± 0.014 
15  +19.7 ± 3.5  0.3 ± 0.019  +14.6 ± 2.1  0.36 ± 0.008 
30  +19.5 ± 2.5  0.29 ± 0.011  +13.8 ± 2.5  0.27 ± 0.031 
60  +12.4 ± 3.1  0.24 ± 0.017*  +1.9 ± 5.1*  0.21 ± 0.042* 
a. ABZ and control (drug vehicle) were administered orally at 12 h intervals on days 5, 6 and 7 post 
inoculation. b. ABZ and control (ΗPβCD) were administered orally at 12 h intervals on days 5, 6 and 7 
post inoculation. c. Percentage change in mean body weight between days 4 and 10 post inoculation.  
d. Haematocrit on day 10 post-inoculation. Haematocrit values greater than 0.39 are normal in rats (Dow, 
2000). * Significantly different from control group (t test, p<0.05). 
 
 
The OZ/ΗPβCD complex was formulated in 60% ΗPβCD at pH of 11.  I.p. 
administration of this formulation at 0.1 mL kg
-1 appeared to cause no adverse effects. 
However larger or multiple doses of this formulation resulted in chemical peritonitis and 
metabolic alkalosis (Section 3.4.4). Therefore the in vivo antimalarial activity of OZ or 
OZ/ΗPβCD complex was not investigated further.   
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7.4. DISCUSSION 
 
7.4.1. Effect of ΗPβCD in vitro 
 
The parasitaemia of short term P. chabaudi cultures declined during culture, with the 
parasitaemia of control cultures dropping from 5.8% to 2.7% over 24 h.  Similar results 
were observed in P. chabaudi chabaudi by Sohal & Arnot, (1993), P. vinckei chabaudi 
by Coombs & Gutteridge, (1975) and in P. berghei by Dow, (2000) and Kamiyama & 
Matsubara, (1992).  These researchers reported the decrease in parasitaemia due to 
reduced reinvasion by merozoites under in vitro culture conditions, and therefore this 
was probably the case here. ΗPβCD was found to improve P. chabaudi growth in in 
vitro cultures.  CD has also been found to improve microbial growth in a number of in 
vitro systems (Bar, 1990; Sawada et al., 1990; Ramirez et al., 1993; Morshed et al., 
1994; Kátó et al., 1993; 1994; Frohlich et al., 1996; Gorfien et al., 2000; Testerman et 
al., 2001), although the mechanism for improved growth was not always clear.   
Proposed mechanisms for increased microbial growth have been:  
 
1.  CD as a carbon source (Schlosser et al., 1993), as described in section 1.2.2. 
 
2.  Increased solubilization of a substrate or product due to complexation (Sawada et al., 
1990; Singer et al., 1991; Greenberg-Ofrath et al., 1993; Jadoun & Bar, 1993a; 
Ramirez et al., 1993; Kátó et al., 1993; 1994; Gorfien et al., 2000), as described in 
section 1.3.1.  
 
3.  Increased stability of a substrate (Kátó et al., 1994), as described in section 1.3.2. 
 
4.  Modification of the cell membrane/wall (Sawada et al., 1990; Frohlich et al., 1996), 
as described in section 4.1.1 and 4.1.2.  
 
5.  CD involved in a microbial process by interacting with the cell membrane (Singer et 
al., 1991; Jadoun & Bar, 1993a), as described in section 4.1.1. 
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6.  Decreased inhibition by an inhibitory or toxic compound due to complexation (by 
decreasing the concentration of the uncomplexed compound) (Sawada et al., 1990; 
Singer et al., 1991; Kátó et al., 1993; 1994; Morshed et al., 1994; Frohlich et al., 1996; 
Gorfien et al., 2000; Testerman et al., 2001), as described in section 3.1.1 and 4.1.2. 
 
7.   CD stressed the microorganism in a particular manner that resulted in a specific 
response, which lead to improved survival/growth (Siundiukova et al., 1999). 
 
Several of these mechanisms can lead to either decreased or increased microbe growth.  
In addition, in in vitro culturing systems where the exact media components are not 
known, several of these processes may be occurring, as CDs are capable of complexing 
a wide range of components.  Therefore it is necessary to determine which is the critical 
process, i.e. the one that leads to increased microbial growth.  As the decreased 
parasitaemia in in vitro cultures of P. chabaudi was associated with reduced reinvasion 
by merozoites, it is possible that increases in parasitaemia observed with the addition of 
ΗPβCD may have been associated with the improved reinvasion of RBC by merozoites.  
However the mechanism for such an improvement is unclear.  It is also quite possible 
that improved P. chabaudi growth in the presence of ΗPβCD resulted from ΗPβCD 
acting as a food source. Intracellular plasmodia ingest the contents of the host cell, 
which is mainly haemoglobin or haemoglobin precursors, depending on the age of the 
cell. In comparison, exoerythrocytic plasmodia obtain their nutrients mainly by simple 
diffusion, with the main source of energy being glucose (Carter & Diggs, 1977; Noble 
& Noble, 1979).  As the malaria media contained excess glucose (11.1 mM from 
RPMI), and to use ΗPβCD as a food source, the parasite would need 
cyclomaltodextrinases to breakdown the ΗPβCD (Section 1.2.2), it is unlikely that 
ΗPβCD was acting as a food source.  Alternatively, ΗPβCD may interact with, or 
induce modifications to the merozoite or RBC membrane that facilitate reinvasion or 
improve the survival of the free merozoite.  However increases in ΗPβCD concentration 
greater than 4% did not lead to additional increases in parasite growth. Therefore 
improved growth more likely resulted from the increased solubilization, and hence 
bioavailability of a necessary component, or the complexation and removal of an 
inhibitory compound. 
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During erythrocytic schizogony, the parasite invades and multiplies in the RBC.   
Therefore the susceptibility of RBC to CD is also very important.  Garay et al., (1994) 
investigated the haemolytic effects of CDs on human RBC, and found the presence of 
plasma strongly reduced the haemolytic potency of HPβCD and the methylated CDs.  In 
particular, HPβCD exhibited a hemolysis ED50 of 57 mM (approximately 8%) in saline 
media, whereas no hemolysis was observed in plasma. This would explain the absence 
of RBC hemolysis due to HPβCD in the P. chabaudi  in vitro experiments, as the 
cultures contained 50% whole blood.  The presence of whole blood resulted in a larger 
competitive binding capacity exerted by the larger amounts of complexable components 
in the medium.  
 
Complexation of ABZ and OZ with ΗPβCD did not improve the antimalarial efficacy 
of these drugs.  Instead, the parasitaemia of the test cultures increased in correlation 
with their ΗPβCD concentration.  While ΗPβCD may be acting to decrease the efficacy 
of the drugs, it is more likely that the improved growth due to ΗPβCD was greater that 
the detrimental effect of the drugs.  CDs have been introduced as carriers of essential 
lipids, cholesterol and long-chain fatty acids into a number of microbial in vitro 
cultures, as an alternative to serum and BSA (Greenberg-Ofrath et al., 1993).  However 
the results of these experiments indicate that the use of CDs as a part of the cultivation 
medium may modify the behaviour and therefore efficacy of administered drugs in in 
vitro drug studies. Therefore after optimisation of cultures with CD, the effect of CD on 
the efficacy of these drugs would need to be investigated. 
 
7.4.2. In vitro drug studies 
 
The control compound, CHQ, exhibited an IC50 of 0.984 µM against P. chabaudi in 
vitro, which is higher than that previously reported for this parasite (Sohal & Arnot, 
1993), and for the malaria parasites P. falciparum and P. berghei (Dow, 2000) (Table 
7.5). This is most likely a consequence of the different culture and assay conditions.   
 
ABZ exhibited an IC50 of 63.7 µM against P. chabaudi in vitro, which is comparable to 
that previously reported for P. falciparum (Dieckmann-Schuppert & Franklin, 1990; 
Skinner-Adams et al., 1997; review by Bell, 1998), but lower than that for P. berghei, CHAPTER 7 
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which was >1000 µM (Dow, 2000) (Table 7.5).  In addition, both ABSO and ABSO2 
were found to be ineffective against P. chabaudi in vitro. As previously observed by 
Dow, (2000), ABZ preparations at high concentrations (>100µM) formed a precipitate.  
Dow, (2000) therefore suggested that the level of antimalarial potency of ABZ observed 
in published reports may be underestimated.  The wide range in ABZ efficacy over a 
narrow pH range observed by Skinner-Adams et al., (1997)  supports this, as ABZ 
solubility increases with decreasing pH (Section 2.3.1.2).  
 
OZ exhibited an IC50 of 5.424 µM against P. chabaudi in vitro, which is comparable to 
that previously reported for P. berghei (Dow, 2000) (Table 7.5).  The effects of the 
dinitroaniline trifluralin against P. falciparum have been investigated, and found to 
cause microtubule depolymerisation (Kaidoh et al., 1995).  This is therefore the likely 
explanation for the effect of OZ against P. chabaudi and P. berghei, given their similar 
structural characteristics.   
 
Table 7.4: Drug IC50s against P. falciparum, P. berghei and P. chabaudi in vitro. 
Drug IC50 against  
P. falciparum (µM) 
IC50 against  
P. berghei (µM)
 b 
IC50 against  
P. chabaudi (µM) 
c 
ABZ  2->100 
a >1000
  63.7 
ABSO  200
 a >1000  >1000 
ABSO2  >100
 a >1000 >1000 
OZ  - 4.3  5.424 
CHQ  0.015
 b 0.096  0.984 
a. Data from Dieckmann-Schuppert & Franklin, (1990), Skinner-Adams et al., (1997) and Bell, (1998).   
b. Data from Dow, (2000). c. Present experiments. 
 
7.4.3. In vivo drug studies 
 
While the rat malaria model did not result in malaria infections comparable in severity 
and mortality to conventional mouse malaria models (Carter & Diggs, 1977; Dow, 
2000; Dow et al., 1998), in vivo drug efficacy was easily assessable as seen from the 
CHQ data.  The efficacy of CHQ (18 mg kg
-1day
-1) against P. chabaudi was similar to 
that previously reported for P. berghei (Dow, 2000), causing 100% suppression of 
parasitaemia in the rat malaria model. However ABZ (up to 60 mg kg
-1day
-1) either 
alone or complexed was ineffective against P. chabaudi infections, as the highest dose CHAPTER 7 
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tested did not result in significant parasite inhibition.  These results correlate with the 
pharmacokinetics of ABZ (Chapter 3) and the in vitro antimalarial efficacy of ABZ, 
ABSO and ABSO2 (Section 7.4.2). In pharmacokinetic studies, orally administered 
ABZ achieved only low plasma concentrations, and was rapidly metabolised to ABSO 
and ABSO2, which had no efficacy against P. chabaudi in vitro at less than 1000 µM. 
Therefore the plasma concentrations achieved by these compounds in vivo were 
considerably lower than those required to cause 50% inhibition of parasite growth.   
 
P. chabaudi infected Wistar rats did not exhibit the characteristic anaemia or 
suppression in body weight gain as was described for P. berghei infected LEW/SSN rats 
by Dow et al., (1999).  Dow et al., (2000) observed orally administered ABZ to 
exacerbate these symptoms in a dose related fashion. Here high doses of ABZ resulted 
in suppression in weight gain, and high doses of the ABZ/ΗPβCD complex resulted in 
anaemia and suppression in weight gain.   ABZ has been found to induce pancytopenia 
in a dog, cat (Stokol et al., 1997) and an elderly woman with hepatic hydatids 
(Fernández et al., 1996).  Leucopaenia in rats (Dow, 2000), resulting from bone marrow 
toxicosis has also been observed. The toxic effect was thought to be directed against 
proliferating committed hematopoietic precursors, probably caused by inhibition of 
mitosis resulting from the antitubulin action of ABZ (Stokol et al., 1997).  This theory is 
supported by the results of Whittaker & Faustman, (1991), who found ABZ to be a 
potent inhibitor of cell growth and differentiation, causing an accumulation of cells in 
the mitotic phase of the cell cycle in rat embryonic cells (See section 4.4.1.1).  
Manifestations of the antimitotic activity of a number of benzimidazole analogues 
include cell-cycle arrest, cytoskeletal disruption, random chromosomal dispersion and 
micronucleus formation (Holden et al., 1980, reviewed by Delatour & Parish, 1986 and 
Whittaker & Faustman, 1991).  The occurrence of anaemia and suppression in weight 
gain in rats treated with high doses of ABZ/ΗPβCD is therefore likely the result of ABZ 
induced bone marrow injury, with increased bone marrow injury in rats administered 
the ABZ/ΗPβCD complex associated with the higher systemic concentrations that can 
be achieved following oral administration (Section 3.4.1.4). 
 
Dow et al., (2000) found ABZ to inhibit P. berghei in vivo.  However, as P. berghei 
preferentially parasitises reticulocytes and other young RBC (McNally et al., 1992), it is CHAPTER 7 
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likely that the antimalarial effects of ABZ against P. berghei are mediated via depletion 
of red cell precursors, as opposed to a direct effect against the parasite itself (Dow et al., 
2000).  While not observed in vivo, P. chabaudi has also been found to preferentially 
parasitise reticulocytes in vitro, but to a lesser extent than P. berghei (McNally et al., 
1992).  This therefore explains the absence of any indirect effect of ABZ against P. 
chabaudi in vivo. 
 
7.4.4. Conclusion 
 
P. chabaudi is difficult to cultivate in vitro, predominately due to the reduced reinvasion 
of erythrocytes by merozoites.  The use of CDs therefore offers a potential solution to 
this problem.  As whole blood or plasma reduces the haemolytic effect of HPβCD by 
providing a source of complexable compounds, it effectively reduces the free 
concentration of HPβCD.  Therefore more research would be required to determine 
appropriate concentrations of CD and plasma for the in vitro cultivation of the rodent 
malarias.  CD solubility, its toxicity to the cell, its ability to complex lipids, and the 
extent of complexation (strong binding decreases the concentration of the uncomplexed 
compound) are important factors that must be considered when choosing a CD.  In 
general the methylated CDs are the most potent solubilizing agents (Szente, 1994), but 
their effect on cell membranes would need to be closely monitored. If the increase in P. 
chabaudi growth is the result of complexation of either water insoluble or inhibitory 
compounds, the methylated CDs may offer improved in vitro cultivation systems.   
Alternatively, HPβCD may offer a compromise between increased lipid solubilization 
and decreased membrane interference.  However, a possible disadvantage of the use of 
CD to enhance P. chabaudi growth for drug studies is the potential sequestration of 
drug by CD following drug addition to the cultures. 
 
Due to the occurrence of bone marrow injury after oral administration of high doses of 
ABZ, the necessity for high doses of ABZ to exhibit antimalarial efficacy in vitro, and 
the rapid metabolism of ABZ in vivo, ABZ is unlikely to be an effective antimalarial 
agent.  The dinitroanilines appear to be more promising antimalarials than the 
benzimidazoles.  In particular, Dow, (2000) found pendimethalin and TF to be the most 
effective dinitroanilines against malaria in vitro.  However, due to the low plasma levels CHAPTER 7 
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of TF achieved in in vivo experiments, it was found to be ineffective against P. berghei 
in vivo.  OZ also achieved only low plasma concentrations for short periods of time in 
pharmacokinetic experiments (Chapter 3).  Therefore, while these plasma 
concentrations were in excess of the IC50 for OZ against P. chabaudi in vitro, the results 
of the OZ pharmacokinetic study did not indicate that the OZ/ΗPβCD complex would 
result in improved bioavailability of OZ for the treatment of systemic parasites.   
Therefore alternative means to improve systemic concentrations of the dinitroanilines 
still need to be investigated. 
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8.1. DRUG SOLUBILITY AND CD COMPLEXATION 
 
CDs have the ability to form noncovalent bonded inclusion complexes with 
hydrophobic drugs, increasing various physicochemical properties such as drug aqueous 
solubility, stability and dissolution rate (Duchêne et al., 1987; Szejtli, 1991a; Loftsson 
& Brewster, 1996).  This allows the creation of formulations for water insoluble drugs 
that are difficult to deliver with more traditional formulations.  Extensive examples of 
the role of CD complexation of poorly water-soluble drugs to improve their aqueous 
solubility and stability, to provide improved dissolution characteristics over other 
formulations of the drug, and hence improved bioavailability, exist in the literature.  
Here the antiparasitic agents ABZ, TF and OZ were investigated with a view of 
improving their water solubility and in vivo bioavailability through CD complexation.  
All three antiparasitic agents exhibited improved solubility with ΗPβCD complexation.  
However, complexation alone was not enough to produce formulations of sufficient 
concentration for in vivo experiments.  In general the complexation efficiency of CDs is 
rather low, and thus large amounts of CD are required to complex small amounts or 
drug (Loftsson et al., 1999).  Increased complexation efficiency can be achieved by 
increasing either the aqueous solubility of the drug (SO) or the stability constant of the 
complex (KC).  The use of temperature and pH were used to increase the water 
solubility of the drugs, with ABZ solubility increasing with increasing temperature and 
decreasing pH, and OZ solubility increasing with increasing temperature and increasing 
pH.  Subsequently, additional increases in ABZ and OZ solubility were achieved 
through the manipulation of temperature and pH in combination with increased ΗPβCD 
concentrations.  Of particular interest is the improved pharmacokinetics of the 
ABZ/ΗPβCD complex when formulated at a low pH. In addition, complexation of OZ 
with ΗPβCD was also improved with increasing pH, with ionisation of OZ favouring 
complex formation (increasing KC) (Section 2.4.3.3).  The investigations into potential 
CD formulations here were by no means exhaustive.  Alternative techniques that may be 
investigated to enhance of the drug solubilizing capacity of CD include the addition of 
components such as polymers, organic acids, pluronics, nanoparticles, or hydroxypropyl 
methylcellulose to aid complexation (Section 1.3.1), the complexation of prodrugs, or 
by altering the ionic strength (Zia et al., 2001).  In addition, improved solubilization 
over that achieved by HPβCD may potentially be observed with a number of other CDs CHAPTER 8 
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and derivatised CDs, particularly the methylated CDs (Castillo et al., 1999).  However, 
the mode of drug administration would need to be considered, as alternative CDs can 
have drawbacks in relation to their own biological activity (Section 1.4.2 and 1.7.1).  
More recently, SBE7M-β-CD has been found to have stronger complexation ability over 
HPβCD (Zia et al., 2001), and as it has comparable parenteral safety to that of HPβCD 
(Stella, 1996), it may provide a feasible alternative.   
 
Various methods can be applied to enhance the complexation efficiency of CDs, and it 
is frequently possible to enhance the efficiency even further by applying several 
methods simultaneously (Loftsson et al., 1999).  Several methods to increase ABZ 
solubility and bioavailability have been investigated.  These include various additives or 
formulations (Lanusse & Prichard, 1991; Yang & Fung, 1991; del Estal et al., 1993; 
Wen et al., 1994; 1996a and b; Rodrigues et al., 1995; Torrado et al., 1996a and b; 
1997; Sarciron et al., 1997), as well as altered diet and dosing regimes (Kwan et al., 
1988; Lange et al., 1988; Barger et al., 1992; Hussar, 1997; New et al., 1994).   
Combinations of these methods in conjunction with CD formulation, temperature 
adjustment and pH modifications could therefore enhance ABZ solubility and 
bioavailability considerably. In addition, DMβCD (Castillo et al., 1999) and SBE7M-β-
CD (Piel et al., 1999) have been observed to improve ABZ solubilization over that 
achieved by HPβCD, though the biological activity of these cyclodextrins via various 
routes of administration needs to be considered. However, by using appropriate CDs 
and enhancing complexation efficiency, less CD is needed to solubilize a given amount 
of drug, thus reducing its potential impact on biological systems. 
 
Ionic cyclodextrin derivatives may enhance the solubility and stability of ionic guest 
molecules by establishing ionic interactions with them (Szejtli, 1991a; Másson et al., 
1996) (Section 1.4.2.5). Compared to the neutral CDs, enhanced complexation is 
frequently observed when the drug and CD have opposite charge (Másson et al., 1996; 
1998).  The mode of interaction is presumed to be the hydrophobic interaction with the 
cavity interior, with additional electrostatic interactions between the oppositely charged 
guest and host (Zia et al., 2001).  As previously discussed (Section 2.4.1.3), increased 
drug solubility due to its ionisation is generally associated with a decrease in 
complexation (Yalkowsky, 1999).  However, while the location/arrangement of the CHAPTER 8 
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guest within the CD cavity may be modified to allow for ionic interactions, the presence 
of this charge attraction between the ionised drug and the ionic CD derivative seems to 
counterbalance the adverse effect of the increased guest hydrophilicity, thus maintaining 
their binding potential (Másson et al., 1998; Zia et al., 2001).  Therefore particular ionic 
CDs may be more effective at solubilizing ionic ABZ and OZ.  Given that ionised OZ 
exhibited improved complexation with HPβCD, additional improvements may also by 
observed with oppositely charged ionic CDs.  This would also allow investigations into 
the increased complexation of OZ observed when in its ionised form, and potentially 
allow less extreme pHs to be tested.  
  
Further research should also include the preparation of solid inclusion complexes for 
more specific investigations into stoichiometry, dissolution studies and clinical drug 
trials.  While the stoichiometry of the ABZ/CD complex has been investigated by a 
number of researchers (Kata & Scheuer, 1991; Piel et al., 1999; Castillo et al., 1999), 
more detailed studies are needed, as well as investigations into the stoichiometry of the 
OZ/ΗPβCD complex.  Further studies are also required to investigate the effect of 
different buffers on drug solubility enhancement.  A number of different buffers have 
been used in combination with ABZ/CD complexation with the view of modifying the 
pH and thus enhancing ABZ solubility  (Chun & Park, 1993; Evrard et al., 1998; 
Castillo et al., 1999; Piel et al., 1999).  In the present study a differential solubilizing 
ability between phosphate buffer and citric acid buffer was observed, with the 
phosphate buffer more effective.  The reason for this requires further investigation, as 
well as investigations into alternative buffering systems that may result in additional 
increases in ABZ solubility.  In addition, OZ was observed to have unusual 
solubilization curves with varying pH values and ΗPβCD concentration (Section 
2.3.3.2), which also requires further investigation.  
 
8.2. ALBENDAZOLE CD COMPLEXATION 
 
ABZ is a benzimidazole carbamate with a broad anti-parasitic spectrum (Theodorides et 
al., 1976; de Silva et al., 1997; Parfitt, 1999).  Initially ABZ was predominantly used as 
an anthelmintic, but over recent years it has also been used as an antiprotozoal agent 
(Morgan et al., 1990; Reynoldson et al., 1992; Harris et al., 2001). As absorption of CHAPTER 8 
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ABZ from the gastrointestinal tract is poor, orally administered ABZ has been of most 
value against intestinal parasites.  ABZ is principally metabolised in the gut, with ABZ 
that is absorbed from the gastrointestinal tract rapidly metabolised in the liver to ABSO 
and ABSO2. ABSO is considered the active compound against helminths, whereas ABZ 
is the active compound against protozoa (Bogan & Marriner, 1984; Marriner et al., 
1986; Hussar, 1997).  Therefore the purpose of the present study was to evaluate the 
potential usefulness of ABZ when complexed with ΗPβCD against a range of protozoan 
parasites.  This approach involved investigations into the pharmacokinetics, 
cytotoxicity, in vitro efficacy against Giardia, Cryptosporidium and malaria, and the in 
vivo efficacy against Giardia and malaria of both ABZ and the ABZ/ΗPβCD complex. 
 
Through the use of ΗPβCD complexation ABZ solubility was increased sufficiently for 
in vitro drug efficacy studies, and in combination with pH modification and temperature 
manipulation, ABZ solubility was sufficient for in vivo drug efficacy studies (Chapter 
2).  The cytotoxicity experiments carried out here supported the findings of Whittaker & 
Faustman, (1991), where the cytotoxic affects of ABZ were only relevant to cells 
undergoing rapid cellular growth or differentiation, or those that were unable to detoxify 
ABZ. It was also determined that ΗPβCD complexation did not affect ABZ cytotoxicity 
(Chapter  4).  Therefore the effect of ABZ and its metabolites on both rapidly 
proliferating and differentiating cells must be considered when evaluating treatment 
regimes for parasitic infections, particularly when high concentrations are used over 
extended periods of time.  In the ABZ pharmacokinetic experiments investigated here, 
single oral doses of up to 30 mg kg
-1 were administered. Complexation of ABZ with 
ΗPβCD improved drug bioavailability systemically, indicating a potential for improved 
efficacy of ABZ against systemic parasites over conventional ABZ formulations.  ABZ 
was rapidly metabolised to ABSO and ABSO2, with plasma concentrations <100 µM 
(maximum concentration investigated in cytotoxicity experiments), and the majority of 
ABZ metabolites eliminated from the body within 12 hours (Chapter 3).  Therefore 
ABZ and its metabolites would have resulted in minimal overall cytotoxicity. However, 
their effect on rapidly proliferating and differentiating cells within the body would be 
relative to the ability of the cells to metabolise ABZ and the length of toxicant exposure 
(Whittaker & Faustman, 1992). The treatment of malaria infected rats with ABZ 
required high doses of ABZ to be administered over an extended time frame, resulting CHAPTER 8 
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in dose related anaemia and suppression in weight gain, which was amplified in rats 
administered the ABZ/ΗPβCD complex (Chapter 7).   The occurrence of anaemia and 
suppression in weight gain is likely the result of ABZ induced bone marrow injury, 
resulting from the anti-tubulin action of ABZ (Stokol et al., 1997; Dow, 2000). 
Therefore under these conditions the cytotoxic effects of ABZ were evident.  In 
addition, the increased bone marrow injury in rats administered the ABZ/ΗPβCD 
complex was associated with the higher systemic concentrations of ABSO that can be 
achieved following the oral administration of ABZ. 
 
The efficacy of ABZ was investigated against three protozoan parasites that infect 
different compartments within the body.  Both Giardia and Cryptosporidium infect the 
gastrointestinal tract, with Giardia attaching to the mucosa at the bases of the microvilla 
(Meyer, 1985; Ampofo et al., 1991), and Cryptosporidium predominately an 
intracellular parasite located at the luminal surface of the host epithelial cell 
(O'Donoghue, 1995; Petersen, 1993).  Malaria on the other hand causes systemic 
infections, invading the liver and RBCs (James & Gilles, 1985; Garcia & Bruckner, 
1988; CDC, 2001c; Navy Environmental Health Center, 2001).  ABZ was a potent 
inhibitor of Giardia in vitro, with the MIC, IC50 and MLC all in the nM range.  In 
addition, ABZ was effective against Giardia in vivo.  The primary effect of ABZ against 
Giardia appears to be due to its binding to cytoskeletal proteins (tubulin and/or 
giardins), thus effecting Giardia attachment and possibly feeding (Seow et al., 1985; 
Edlind, 1989b; Meloni et al., 1990; Morgan et al., 1990; Oxberry et al., 1994).   
Therefore the location of the parasite within the body makes it susceptible to orally 
administered antigiardial agents (Chapter 5).  ABZ was also effective against 
Cryptosporidium in vitro, although less so than against Giardia, with the MIC, IC50 and 
MLC in the low µM range.  The lower efficacy of ABZ against Cryptosporidium was 
attributed the lower susceptibility of Cryptosporidium tubulin (Edlind et al., 1994; 
Katiyar et al., 1994; Fayer & Fetterer, 1995; Cacciò et al., 1997) (Chapter 6).  In 
comparison, ABZ was effective against malaria in vitro in the low µM range, but was 
not effective against malaria in vivo.  While malaria tubulin has been found to be 
susceptible to a number of tubulin antagonists (Bell, 1998; Hommel & Schrével, 1998; 
Dow, 2000), the absence of ABZ in vivo efficacy in comparison to its in vitro efficacy CHAPTER 8 
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was due to the low plasma concentrations of ABZ following its oral administration 
(Chapter 7). 
 
Complexation of ABZ with ΗPβCD modified the behaviour of ABZ in a number of 
systems.  As discussed above, the complex did not affect ABZ cytotoxicity, but did 
improve the pharmacokinetics of ABZ.  Against the protozoan parasites, the 
ABZ/ΗPβCD formulation was observed to have equal efficacy against Giardia both in 
vitro  and in vivo, but decreased efficacy against C. parvum  in vitro compared to 
conventional ABZ formulations.  This was attributed to the different locations of the 
two parasites, G. duodenalis on the culture wall in vitro or attached to epithelial cells in 
vivo, and C. parvum enclosed within a host cell.  In addition, excess ΗPβCD was also 
found to reduce ABZ efficacy against Giardia in vitro, due to a decrease in the effective 
drug concentration through competitive inclusion complex formation. ΗPβCD 
complexation also decreased the efficacy of ABZ against malaria in vitro.  However, 
this is more likely the result of improved cultivation of the parasite as opposed to any 
effect on ABZ efficacy.  However, further investigations would be required to verify 
this.  In comparison, the ABZ/ΗPβCD formulation did not affect ABZ efficacy against 
malaria  in vivo, despite the improved dissolution and absorption of ABZ, as the 
systemic concentrations of ABZ would have still been insufficient to inhibit parasite 
growth. 
 
Albendazole is highly effective in the treatment of a majority of intestinal helminth 
infections and, with high, prolonged doses, against systemic helminth infections 
(Section 2.1.2.3).  Many attempts to increase ABZ solubility and dissolution have been 
carried out with the view of increasing the systemic bioavailability of ABSO for the 
treatment of a number of systemic infections such as hydatid disease and 
neurocysticercosis (Section 2.1.4.1).  As high and prolonged doses of ABZ are required 
against such infections, methods that improve ABSO bioavailability can result in a 
decrease in the dose and duration of albendazole treatment, and possibly, reduce its 
adverse effects.  Recently the efficacy of an ABZ/HPβCD complex was investigated 
against the tissue nematode Trichinella spiralis, and compared to ABZ prepared in 0.5% 
sodium-carboxymethylcellulose (García-Rodriguez et al., 2001).  Complexation was 
found to improve both the pharmacokinetics (AUC and Cmax) and anthelmintic effects CHAPTER 8 
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of the complex against all stages of the Trichinella lifecycle, particularly the intestinal 
and muscular stages.  In comparison, the pharmacokinetic profile of the ABZ/HPβCD 
complex (pH 2.1) used here were greater that that achieved by García-Rodriguez et al., 
(2001), and thus may also prove effective against systemic helminth infections.  In 
addition, previously used methods to increase ABZ or ABSO bioavailability could be 
used in conjunction with CD complexation.  One such method is the co-administration 
of the dipeptide methyl ester (Phe-Phe-OMe), which has been found to damage the 
laminated layer of the cyst of E. multilocularis (Sarciron et al., 1997).  The laminated 
layer is a non-cellular membrane that represents an important barrier to the penetration 
of drugs.  Another alternative is the co-administration of cimetidine, a cytochrome p-
450 inhibitor that has been found to enhance ABSO concentrations, particularly in the 
liver and biliary system (Wen et al., 1994; 1996a).   
 
Ultimately, the formulation of ABZ with ΗPβCD did not improve ABZ efficacy against 
the protozoan parasites Giardia, Cryptosporidium or malaria.  Drugs with low solubility 
have an advantage in the treatment of intestinal parasites, as a larger portion of the drug 
remains in the gastrointestinal tract, and hence, in contact with the parasites.  Therefore 
the main advantage of the ABZ/ΗPβCD complex, i.e. the improved dissolution and 
absorption of ABZ, is unlikely to present any real improvements over current 
formulations against Giardia and Cryptosporidium.  The oral administration of the 
ABZ/ΗPβCD complex would therefore be more beneficial in the treatment of systemic 
parasites, as the ABZ/ΗPβCD complex results in higher systemic concentrations of the 
ABZ and its metabolite ABSO over conventional formulations.  In addition, further 
evaluation of the role of enantiomeric ABSO may also reveal interesting results.   
However, as protozoan parasites are predominantly affected by ABZ and not ABSO, the 
high systemic concentration of ABSO achieved is of little consequence against malaria. 
Therefore the future use of ABZ/ΗPβCD complexes has potential against susceptible 
systemic parasites, and with further investigation may also show potential against a 
range of intestinal parasites or even multiple infections.  
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8.3. CD COMPLEXATION OF THE DINITROANILINES 
 
The dinitroanilines exhibit both fungicidal and herbicidal activity, and have recently 
been found to exhibit activity against certain parasites (Probst et al., 1975). Following 
oral administration the dinitroanilines OZ and TF display low tissue residues and 
plasma concentrations, which is attributed to poor drug absorption and their extensive 
metabolism in the gut.  Parenteral administration also results in low plasma 
concentrations, as they are strongly tissue bound (Weber & Monaco, 1972) (Section 
2.1.3).  Therefore the purpose of the present study was to evaluate the potential 
usefulness of the dinitroanilines TF and OZ when complexed with CD against a range 
of protozoan parasites.  While the solubility of TF did improve with ΗPβCD 
complexation, the final TF/ΗPβCD concentrations were insufficient for in vitro or in 
vivo  drug efficacy studies. However OZ did exhibit increases in solubility when 
complexed with ΗPβCD that were sufficient for drug efficacy studies, and hence its 
antiparasitic activity was investigated.  This involved investigations into the 
pharmacokinetics, cytotoxicity, and in vitro efficacy against Giardia, Cryptosporidium 
and malaria of both OZ and the OZ/ΗPβCD complex. 
 
Through the use of ΗPβCD complexation OZ solubility was increased sufficiently for in 
vitro drug efficacy studies, and in combination with pH modification and temperature 
manipulation, OZ solubility was increased sufficiently for in vivo drug efficacy studies.  
Previously published results found OZ to inhibit a variety of tumour cells in culture, 
with IC50s in the range of 2-25 µM (Dvorakova et al., 1997; Powis et al., 1997).   
However the present cytotoxicity studies did not reveal any cytotoxic effects of OZ 
(Chapter 4). This was thought due to the different assessment techniques employed, and 
attributed to OZ being selective for proliferating or differentiating cells, similar to ABZ. 
These results are not surprising, as both drugs affect the microtubule system (Anthony 
& Hussey, 1999) (Section 2.1.1).   Therefore the effect of OZ on both rapidly 
proliferating and differentiating cells must be considered when evaluating treatment 
regimes for parasitic infections, particularly when high concentrations are used over 
extended periods of time.  In the OZ pharmacokinetic experiments carried out here, 
single i.p. doses of up to 25 mg kg
-1 were administered, with the complexation of OZ 
with  ΗPβCD not significantly improving the bioavailability of OZ (Chapter 3).   CHAPTER 8 
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However, OZ plasma concentrations following OZ/ΗPβCD administration peaked 
earlier and higher than after OZ administration, and OZ was eliminated from the plasma 
sooner. While plasma OZ concentrations in these experiments did reach sufficient 
concentrations to effect proliferating or differentiating cells based on the findings of 
Dvorakova et al., (1997) and Powis et al., (1997), they were not sufficient to affect cells 
in the stationary phase based on the cytotoxicity experiments carried out here. Therefore 
the administration of larger doses over extended time frames would need to be carefully 
evaluated.  Given the strong binding capacity of OZ and its extensive metabolism in 
vivo, lower toxicity than expected may be observed.  Alternatively, CD complexation, 
while not affecting the pharmacokinetic profile of OZ, may improve OZ stability and 
increase renal clearance, thus reducing its toxicity.  As the dinitroanilines are 
susceptible to photodecomposition and readily adsorb to glass and proteinaceous 
substances, the capacity for CD complexation to influence the photodecomposition and 
binding capacity of the dinitroanilines also requires further investigation.   
 
 The  in vitro efficacy of OZ was investigated against the three protozoan parasites 
Giardia, Cryptosporidium and malaria.  OZ was found to be ineffective against Giardia 
at the concentrations tested, with IC50’s in the mM range (Chapter 5).  In comparison, 
OZ was effective against Cryptosporidium and malaria in vitro, with IC50’s of 0.9 nM 
and 5.4 µM respectively (Chapters 6 and 7).  Following complexation with ΗPβCD, OZ 
efficacy did not improve against Giardia or Cryptosporidium, and in the presence of 
ΗPβCD, OZ efficacy against malaria decreased in vitro.  The OZ/ΗPβCD complex had 
a lower stability constant than the ABZ/ΗPβCD complex (Chapter 2).  While this would 
have resulted in the increased solubility and potentially improved dissolution of OZ, it 
would have not exhibited the extent of altered drug behaviour that was observed for the 
ABZ/ΗPβCD complex (i.e. its decreased efficacy against Giardia in the presence of 
excess ΗPβCD, and its decreased efficacy against Cryptosporidium).  As the efficacy of 
the OZ/ΗPβCD complex did not improve against Giardia or Cryptosporidium in vitro, 
the  in vivo efficacy of both OZ and the OZ/ΗPβCD complex were not evaluated.   
However, this does not mean that improved efficacy could not be observed in vivo.  
Improved efficacy may be observed against Cryptosporidium due to the improved 
dissolution and/or stability of OZ in the gastrointestinal tract, and particularly as CD 
itself also exhibits anticryptosporidial activity.  While the OZ plasma concentrations CHAPTER 8 
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were in excess of the IC50 for OZ against P. chabaudi in vitro, the in vivo efficacy of the 
OZ/ΗPβCD complex was also not evaluated against malaria, as the pH-modified 
OZ/ΗPβCD formulation was not suitable for high, multiple i.p. doses.  
 
Ultimately the OZ/ΗPβCD complex did not improve the bioavailability of OZ, or its 
efficacy against the protozoan parasites Giardia, Cryptosporidium or malaria. Therefore 
alternative means to improve TF and OZ bioavailability still need to be investigated.  
Given their poor absorption and rapid metabolism within the gastrointestinal tract, it is 
likely that such a formulation would need to be administered parenterally.  In addition, 
the alternative formulation would need to be able to compensate for the fact that the 
dinitroanilines are strongly tissue bound.  Such methods may involve the formation and 
formulation of prodrugs, or even the use of liposomes to modify drug absorption or 
metabolism, and to specifically direct large quantities of drug to the sites of parasitic 
infection.  
 
8.4. THE ROLE OF CYCLODEXTRINS 
  
In biological systems CDs exhibit a lack of selectivity and may rapidly exchange guest 
molecules (Pitha, 1990), thus making it necessary to evaluate the impact CD has on 
tissue components.  HPβCD was found to be cytotoxic to human carcinoma cells at 
greater than 2.5% (Chapter 4), and to inhibit Giardia both in vitro and in vivo at greater 
than 1% and 2% respectively (Chapter 5).  In addition, a 2.5 % suspension of β-CD 
reduced oocyst viability in vitro, and had both preventative and curative effects against 
C. parvum in vivo (Castro-Hermida et al., 2000) (Chapter 6).  The effect of HPβCD in 
these systems is most probably due to membrane disruption caused by the dissolution 
and removal of membrane components (Irie et al., 1982; Ohtani et al., 1989; Bar, 1994; 
Irwin et al., 1994).  This effect is likely to be reversible, depending on the capacity for 
the cells to replace lost membrane components following the removal of CD (Pitha, 
1992).  Thus, when evaluating drug/CD complexes in vitro, it is important to consider 
the CD concentration, as high concentrations can cause cell damage and even 
haemolysis.   
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Following oral administration of CD the viability of both Giardia (Chapter 5) and C. 
parvum were effected in vivo (Castro-Hermida et al., 2000; 2001; 2002). This most 
likely resulted from the high concentration of CD in the gastrointestinal tract, leading to 
the extraction of membrane components as observed in in vitro systems.  Under normal 
conditions the oral consumption of up to 5% ΗPβCD solutions by rats had minimal 
impact on the animals (Section 4.3.2), but similar doses in Giardia infected animals 
resulted in very soft stool or diarrhoea (Section 5.4.1.2). Previous research has found 
that the removal of mucin from the surface of the intestine enhances the effects of CD 
on the mucosal membrane (Nakanishu et al., 1990; 1994).  Mucin adheres to the luminal 
surface of the gastrointestinal tract as a gel or high viscosity solution, thus disturbing the 
direct interaction of CD with membrane lipids of the mucosal membrane. Therefore 
under normal conditions, CD has a limited impact on gastrointestinal cells due to the 
mucin layer.  Both Giardia and C. parvum infect the gastrointestinal tract of the host, 
resulting in a broad spectrum of intestinal abnormalities that ultimately disturbs the 
intestinal absorptive function and compromises the nutritional status of the host 
(Farthing, 1986; Katelaris & Farthing, 1992; Armson et al., 2002).  Thus parasitic 
infections are likely to disturb this protective mucin layer, allowing a direct interaction 
between CD and the mucosal membrane.  Therefore under parasitised conditions the 
detrimental effect of CD on mucosal cells would be more pronounced (i.e. the diarrhoea 
observed in Giardia infected animals). 
 
Unlike  Giardia and C. parvum,  in vitro cultivated P. chabaudi grew better in the 
presence of ΗPβCD, with no detrimental effect observed at up to 8% ΗPβCD.  The 
improved growth was thought to result from the increased solubilization, and hence 
bioavailability of a necessary component, or the complexation and removal of an 
inhibitory compound from the cultivation medium.  However, given the affect of 
ΗPβCD on human carcinoma cells, Giardia and C. parvum, it was surprising to find 
that even high concentrations of ΗPβCD had no detrimental effects on the parasite.  
This was attributed to the presence of whole blood in the cultivation medium, as plasma 
reduces the haemolytic effect of HPβCD by providing a source of complexable 
compounds (Garay et al., 1994).  This resulted in greater competition for the cavity of 
HPβCD, therefore reducing its impact on membrane components.  In comparison, orally 
administered CD would have limited impact on systemic parasites, as minimal amounts CHAPTER 8 
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of orally administered CD are absorbed intact (Gerlóczy et al., 1990; Frijlink et al., 
1990; Monbaliu et al., 1990).  Parenterally administered CD would also have limited 
impact on systemic parasitic infections due to decreased CD concentration (unless 
administered directly to site of infection), to the rapid equilibrium reached between CD 
and endogenous lipophils (Pitha, 1992; Garay et al., 1994), and to the rapid elimination 
of CD from the blood stream (Anderson et al., 1990; Frijlink et al., 1990; Monbaliu et 
al., 1990) (Section 3.4.2.2). 
 
Given the antigiardial and anticryptosporidial effects of CD both in vitro and in vivo, 
CD could potentially play a role in the treatment of these parasites.  In addition, CD 
complexation of antiparasitic drugs and additions of excess CD may result in a 
synergistic increase in efficacy.  This may result from the increased drug dissolution of 
the drug/CD complex, the excess CD limiting drug absorption from the gastrointestinal 
tract, and the antiparasitic activity of CD itself.  However further studies would need to 
be carried out to investigate the effect CD against a greater range of cells as well as 
determining whether CD is static or cidal against these parasites.  CD has been used to 
improve the cultivation of a number of organisms in vitro (Section 7.4.1).  CD was also 
found to improve the cultivation of P. chabaudi, although more research would be 
required to determine the exact effects of CD as well as formulating an ideal culture 
medium.  Therefore these results may help in the development of in vitro rodent malaria 
models, thus complimenting the current in vivo rodent malaria models.  In addition, 
these results open the door to alternative cultivation techniques for the vast array of 
parasites that cannot currently be cultivated in vitro. 
 
8.5. CONCLUSION 
 
While CDs have a wide range of applications, in the pharmaceutical industry they have 
predominantly been used to increase the aqueous solubility of poorly water-soluble 
drugs, with the view of improving drug dissolution and hence systemic bioavailability 
(Section  1.7.2). In the present study the tubulin inhibitors ABZ, TF and OZ were 
complexed with ΗPβCD, and their potential usefulness against the protozoan parasites 
Giardia, Cryptosporidium and Plasmodium was evaluated.  Complexation did not affect 
drug cytotoxicity, and in pharmacokinetic studies complexation improved ABZ (and CHAPTER 8 
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metabolites) bioavailability, but had no significant affect on OZ bioavailability.  In 
addition, the antiprotozoal activity of the tubulin inhibitors was not improved following 
complexation with ΗPβCD.  However, this does not mean that the complexation of 
these compounds with CD will not increase their efficacy against other parasitic 
organisms.  Here improved bioavailability of ABZ and its metabolites was observed 
following oral administration of the ABZ/ΗPβCD complex.  Therefore, while it is 
unlikely that ABZ efficacy would be improved against intestinal protozoan parasites, 
the improved bioavailability indicates potential against susceptible systemic parasitic 
infections.  This has recently been demonstrated, with CD complexation improving the 
anthelmintic activity of ABZ against T. spiralis (García-Rodriguez et al., 2001).  In 
comparison, complexation of OZ with CD is unlikely to be of any benefit against 
systemic infections, as it did not improve OZ bioavailability.  CD complexation has also 
been used to increase drug stability and decrease drug degradation (Section 1.3.2).  
Therefore, as OZ is rapidly metabolised within the gut, its efficacy against intestinal 
parasites may be improved if complexation with CD reduces its gastrointestinal 
degradation.  However, further research into the degradation of the OZ/ΗPβCD 
complex is required. 
 
Orally administered CD was found to inhibit both Giardia (Chapter 5) and 
Cryptosporidium (Castro-Hermida et al., 2000; 2001; 2002) in vivo.  This was attributed 
to parasite membrane disruption caused by the dissolution and removal of membrane 
components when exposed to high concentrations of CD within the gastrointestinal 
tract. Therefore the antiparasitic activity of CD alone should be investigated further, 
particularly against intestinal infections.  However, these investigations also need to 
assess the effect of high CD concentrations on intestinal epithelial cells.  In comparison, 
ΗPβCD alone improved the in vitro growth of malaria.  This was attributed to either the 
increased solubilization of a necessary media component, or the complexation and 
removal of an inhibitory compound from the cultivation medium.  While in vitro drug 
screening methods against rodent malaria have been developed, the in vitro cultivation 
of the rodent malarias in continuous culture has been more difficult (Section 7.1.3).  
Therefore the improved in vitro cultivation of P. chabaudi in the presence of CD 
presents a promising approach to its potential long-term cultivation.  Given the results 
of the current study, it is unlikely that either ABZ or OZ in their current formulations CHAPTER 8 
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(either alone or complexed) will ever be used as clinical antimalarials.  However, this 
should not preclude further investigations into other microtubule antagonists.  One 
significant advantage of an in vitro rodent malaria model would be the mass cultivation 
of parasite material for molecular studies, particularly detailed analysis of malarial 
microtubule proteins.  Such studies would allow the characterisation of drug binding 
sites on malaria tubulin, thus facilitating the development of microtubule antagonists as 
antimalarials. 
 
One major limitation of the current research was the requirement for large amounts of 
CD to solubilize small amounts of drug.  Therefore the impact of high in vivo doses of 
CD needed to be carefully monitored.  This also limits the choice of CDs available, 
particularly with different modes of administration.  In addition, ΗPβCD alone was not 
sufficient to achieve adequate drug concentrations, so temperature and pH were also 
manipulated in order to increase drug concentrations.  However, these manipulations 
limited the flexibility of the formulations, with small changes in temperature and pH 
resulting in precipitation of the drug, particularly for the OZ/ΗPβCD complex.  In 
addition, the necessity for extreme pH values meant that the OZ/ΗPβCD formulation 
could not be administered parenterally.  Therefore future work in this area should 
include investigations into the feasibility of alternative CDs as well as alternative 
techniques to increase drug solubility in combination with CD (discussed above).   CHAPTER 9 
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10.1. BIOCHEMICALS 
 
ABZ, ABSO, ABSO2 and Valbazen (drench, 19 mg kg
-1) were from SmithKline 
Beecham, TF and OZ were from Alltech. BAB was from Curtin University, Perth, WA. 
HPβCD was from Wacker-Chemie, (Germany) with a molar substitution of 0.71 and an 
average molecular mass of 1423.26.  All solvents were analytical and chromatographic 
grade. 
 
Product Supplier 
Acetonitrile  EM Science and Burdick and Jackson 
Aerosil  Western Stock Distributors 
4-aminobenzoic acid   ICN Biochemicals 
Amphotericin   Trace Biosciences 
Ampicillin   Commonwealth Serum Laboratories 
Ascorbic acid   Sigma Chemical Company 
Calcium pantothenate  ICN Biochemicals 
Citric acid   APS Chemicals 
Chromic acid (glassware cleaning)  APS Chemicals 
Cysteine-hypochloride monohydrate   Calbiochem 
CytoTox 96®   Promega 
Biosate   Baltimore Biological Laboratory 
Dehydrated bovine bile   Sigma Chemical Company 
Dichloromethane Row  Scientific 
DMSO (Dimethyl sulfoxide)  Ajax Chemicals 
Di-potassium hydrogen orthophosphate   Ajax Chemicals 
di-sodium hydrogen orthophosphate  Ajax Chemicals 
Ethanol Biolab  Scientific 
Ferric ammonium citrate   British Drug House Chemicals 
FBS (foetal bovine serum)   Life Technologies 
Ficoll   Pharmica Biotech AB 
Folic acid   ICN Biochemicals 
formaldehyde Western  Stock Distributors 
Formic Acid  Ajax Chemicals 
Gentamycin   Sigma Chemical Company 
Glycerol   Ramprie Laboratories 
D-Glucose   Ajax Chemicals 
Glutamine Sigma  Chemical  Company 
Halothane  Laser Animal Health, Australia 
HBSS (Hank’s balanced salt solution)   Flow Laboratories 
Heparin   DBL Laboratories 
HEPES   BDH Laboratory Supplies 
HEPES (1M)  Sigma R-6504 CHAPTER 10 
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Hydrogen chloride   APS Chemicals 
Ispropanol Biolab  Scientific 
Keltrol F  Western Stock Distributors 
Lincomycin   Commonwealth Serum Laboratories 
ß-mercaptoethanol   Sigma Chemical Company 
Methanol Biolab  Scientific 
MYRJ 52  Western Stock Distributors 
NBCS (new born calf serum)   Flow Laboratories 
PEG 6000 (polyethylene glycol)  Western Stock Distributors 
Potassium dihydrogen orthophosphate   Ajax Chemicals 
Potassium sorbate  Western Stock Distributors 
RPMI 1640   Trace Biosciences 
Sodium chloride   Ajax Chemicals 
Sodium citrate  Western Stock Distributors 
Sodium diatrizoate   Sigma Chemical Company 
Sodium hydrogen carbonate   BDH Laboratory Supplies 
Sorbitol   Sigma Chemical Company 
Sputasol   Oxoid 
Streptomycin Sigma  Chemical  Company 
Tetrahydrofluran  Burdick and Jackson 
Trimethylpentane Ajax  Chemicals 
Tri-sodium citrate  Ajax Chemicals (analytical grade) 
Trypsin   Sigma Chemical Company 
Tween-20   BDH Laboratory Supplies 
Tween-80   BDH Laboratory Supplies 
 
 
 
 
 